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ABSTRACT 
 
 
1. The literature relating to peripheral mechanisms of inflammatory pain is 
reviewed. 
 
2. To investigate the role of the transient receptor potential vanilloid type 1 
(TRPV1) ion channel in spinal nociceptive processing after burn injury, the 
candidate studied scalding-type burn injury-induced activation of extracellular 
signal-regulated kinase 1/2 (ERK1/2) in the spinal dorsal horn of wild-type 
(WT) and TRPV1 knock-out (KO) mice.  Activation of ERK1/2 in the spinal 
dorsal horn is a recognised marker for spinal nociceptive processing. At 5 
minutes after severe scalding injury to WT mouse hind-paw, a substantial 
number of phosphorylated ERK1/2 (pERK1/2) immunopositive neurons were 
found in the ipsilateral dorsal horn. At 1 hour post-injury, the number of 
pERK1/2-labelled neurons remained substantially the same. However, at 3 
hours post-injury, a further increase in the number of labelled neurons was 
found on the ipsilateral side, while a remarkable increase in the number of 
labelled neurons on the contralateral side resulted in there being no significant 
difference between the extent of the labelling on both sides. By 6 hours post-
injury, the number of labelled neurons was reduced on both sides without 
there being significant difference between the two sides. A similar pattern of 
severe scalding injury-induced activation of ERK1/2 in spinal dorsal horn 
neurons over the same time-course was found in TRPV1 KO mice, except that 
the extent to which ERK1/2 was activated in the ipsilateral dorsal horn at 5 
minutes post-injury was significantly greater in WT animals when compared 
to TRPV1 null animals. This difference in activation of ERK1/2 in spinal 
dorsal horn neurons was abolished within 1 hour after injury, demonstrating 
for the first time that TRPV1 is not essential for the maintenance of ongoing 
spinal nociceptive processing in inflammatory pain conditions in mouse 
resulting from at least certain types of severe burn injury.  The facts that 
neuronal staining for activated ERK1/2 not only persisted, but also that the 
number of neurons expressing activated ERK1/2 increased with the passage of 
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time are significant novel findings of this study which have important 
implications.  After an acute noxious stimulus (provided by hind-paw injection 
of capsaicin), ERK1/2 activation reaches a peak within 2-5 min and then 
quickly subsides, such that it is barely detectable or absent by 2 hours after the 
stimulus (Ji et al., 1999).  The findings of this study that activated ERK1/2 is: 
(i) still present in neurons at the 3 hour and 6 hour time-points post-burn 
injury; and (ii) that it is found in even more neurons at those later time-points 
than at the earlier time-points measured, strongly suggest that the ERK1/2 
activation found at 3 hours and 6 hours post-injury, respectively, is not merely 
residual from the initial noxious heat stimulus, but rather that it has been 
caused by the ongoing inflammatory process itself.  This is a key novel finding 
of this study.  The data obtained contain evidence of a dissociation within the 
physiological process of the burn injury of these two distinct "noxious insults" 
comprising: first, the initial external heat stimulus of the burn injury, which 
causes direct damage to the tissue accompanied by heat-induced activation of 
heat-sensitive receptors which result in excitation of nociceptive primary 
afferents; and, second, the burn injury-induced massive inflammatory response 
whereby inflammatory mediators occasion an ongoing activation of their 
receptors on those nociceptors to maintain, and, indeed, increase, nociceptive 
signaling in those neurons.  The further finding that, at 3 hours after scalding-
type burn injury, in both TRPV1-null and wild-type mice, the contralateral 
side of the spinal cord now exhibited a substantial number of pERK1/2-
immunopositive neurons remains intriguing, notwithstanding that the 
phenomenon of hyperalgesia developing in the hind-paw contralateral to a 
heat injury has long been noted (Coderre and Melzack, 1991; Polgar et al., 
1998). One may speculate that this labelling is caused, or contributed to, by an 
action of descending fibres on these contralateral dorsal horn neurons since the 
concept of supraspinal pronociceptive modulation of pain is now well 
recognised (Lima et al., 2002; Tavares and Lima, 2007). In addition, or in the 
alternative, this labelling may result from cross-communication between 
opposite dorsal horn neurons (Coderre and Melzack, 1991; Shenker et al., 
2003). In any event, the activation of ERK1/2 on both sides of the dorsal horn 
discloses a process in which spinal neurons are driving inflammatory 
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nociceptive activity after the excitatory effect of peripheral inflammagens has 
abated in primary sensory afferents. 
 
3. Xenon provides effective analgesia in several pain states at sub-anaesthetic 
doses. The aim of this second study was to examine whether xenon may 
mediate its analgesic effect, in part, through reducing the activity of TRPV1, a 
receptor known to be involved in certain inflammatory pain conditions.  The 
candidate studied the effect of xenon on capsaicin-evoked cobalt uptake in rat 
cultured primary sensory neurons and in human TRPV1 (hTRPV1)-expressing 
human embryonic kidney 293 (HEK293) cells. He also examined xenon's 
effect on the phosphorylation of extracellular signal-regulated kinase 1/2 
(ERK1/2) in the rat spinal dorsal horn evoked by hind-paw injection of 
capsaicin.  Xenon (75%) reduced the number of primary sensory neurons 
responding to the TRPV1 agonist, capsaicin (100 nM-1 µM) by ~25% to 
~50%. Xenon reduced the number of heterologously-expressed hTRPV1 
activated by 300 nM capsaicin by ~50%. Xenon (80%) reduced by ~40% the 
number of phosphorylated ERK1/2-expressing neurons in rat spinal dorsal 
horn resulting from hind-paw capsaicin injection. The key original finding is 
that xenon substantially reduces the activity of TRPV1 in response to noxious 
stimulation by the specific TRPV1 agonist, capsaicin, suggesting a possible 
role for xenon as an adjunct analgesic where hTRPV1 is an active contributor 
to the excitation of primary afferents which initiates the pain sensation.   Next, 
to investigate whether the xenon-induced inhibition of TRPV1 in rat DRG 
neurons reduces nociceptive processing, the effect of xenon in reducing the 
release of calcitonin gene-related peptide (CGRP) from those neurons was 
examined.  Exposure to xenon failed to effect a reduction of capsaicin-evoked 
CGRP release from cultured primary sensory neurons when stimulated by 
capsaicin.  This latter novel finding suggests that xenon acts on several 
molecular targets on nociceptive primary sensory neurons, and that xenon’s 
action on one, or more, of those targets serves to offset the inhibitory, pro-
analgesic, effect of xenon on TRPV1.  It is concluded that xenon may not 
produce any analgesic effect through peripheral nociceptors. 
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4. Clinically relevant concentrations of isoflurane or sevoflurane sensitize 
TRPV1 to several of its activators, including capsaicin. It has, moreover, been 
suggested these volatile general anaesthetics may augment nociceptive 
signalling arising from surgical procedures and thereby contribute to post-
operative pain. To investigate this suggestion, the candidate studied 
intraplantar capsaicin injection-induced phosphorylation of extracellular 
signal-regulated kinase 1/2 (pERK1/2) in spinal dorsal horn neurons (which is 
a recognised marker of spinal nociceptive processing) in rat during isoflurane 
or sevoflurane anaesthesia after 60 min under anaesthesia. Control animals 
were anaesthetised with pentobarbital (which of itself does not activate 
ERK1/2 in spinal dorsal horn neurons). Unilateral intraplantar capsaicin 
injection in control animals evoked pERK1/2 in a group of neurons in lamina I 
and lamina II of the ipsilateral spinal dorsal horn in a somatotopically 
appropriate area. In contrast, both anaesthetic gases (given for 60 min and 
without subsequent capsaicin injection) induced ERK1/2 activation in a 
different group of mainly lamina I neurons bilaterally. The total number of 
spinal dorsal horn neurons labelled on the ipsilateral side following capsaicin 
injection into the isoflurane-, or sevoflurane-, anaesthetised animals was 
significantly less than that produced by capsaicin alone. Further, capsaicin 
injection into isoflurane-, or sevoflurane-, anaesthetised animals reduced 
pERK1/2 induced by the gases alone on both sides. These key original 
findings are inconsistent with the suggestion that isoflurane-, or sevoflurane-, 
induced sensitisation of TRPV1 by capsaicin, or other agonist, is translated 
into induction of spinal nociceptive processing and consequential pain 
sensation. 
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PREFACE 
 
       This work has been prepared while reading for the Degree of Doctor of 
Philosophy of Imperial College London in the Department of Academic Anaesthetics, 
at Chelsea & Westminster Hospital.   Its subject is one which is profoundly important.  
Pain is the almost inevitable accompaniment of serious injury and disease.   It may 
also constitute an independent disease state.  The  reality of pain may be utterly 
destructive.  Pain is that which terrifies every sane person.  People can become 
reconciled even to terminal illness, but not to the pain which may frequently 
accompany it.  People, otherwise well, can be tormented, quite beyond endurance, by 
such as back-pain, migraines, or thalamic pain.  Unfortunately, although scientific 
progress in understanding pain in the last twenty years has been great, there is no 
reason to believe that a break-through, or a “wonder drug”, will be found sooner 
rather than later.  Therefore, for those in search of financial reward, patents, 
knighthoods, and peerages – which appear to be the modern currency of academic 
achievement in certain institutions – the study of pain is not recommended.  However, 
one must struggle in vain to reconcile with any concept of a scientific or medical ethic 
the failure by Imperial College London to commit to the continuing study of pain as a 
priority.  
 
        During the past several years, I have been very fortunate to have enjoyed the 
company of fellow doctoral candidates in this Department.  I must mention, in 
particular, Ms. Cleoper Paule, B.Sc., who is an exceptionally skilled and talented 
laboratory scientist, as well as Dr. Mario Cibelli, M.D., and Mr. Antonio Rei Fidalgo, 
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M.Sc., who always manage not to take themselves too seriously, which is an attribute 
which is seldom found in the post-modern era, but is much to be commended.  I am 
very grateful to them indeed for their enduring friendship. 
 
       I wish to record a debt of gratitude to Professor Masao Takata, who has always 
shown a most kind and helpful interest in my progress and has made himself available 
to provide sound advice whenever required.  I am very grateful to him. 
 
       A similar debt of gratitude is owed to Mr. Faruq Noormohamed, M.Sc., who 
brings his usual professionalism to bear in dealing with the myriad of minor and 
major problems which arise in the Department.  An excellent research scientist, he is 
also always there to advise and offer kind assistance.  I am very grateful to him. 
 
      Thanks are also due to Professor Andrew Rice who kindly allowed me to attend 
his tutorial sessions when I was in a position to do so, and, who, again, has always 
made himself available for students. 
 
       My very special thanks are reserved to Dr. Istan Nagy, M.D., Ph.D., who acted as 
my sole supervisor during my course of studies.  Dr. Nagy possesses an unsurpassed 
knowledge of molecular pain, a willingness to engage in constructive argument 
without insisting on the necessity of winning, and very considerable laboratory skills.  
I am very fortunate indeed to have enjoyed the benefit of his tutelage.   I am deeply 
indebted to him. 
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        I am always sustained utterly by the memory of, and the assurance of my future 
re-union with, my most true and wonderful friend, Tom. 
 
 
          John P. M. White. 
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London.  
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CHAPTER 1 
 
 
INTRODUCTION 
 
Contents                            
1.1. Peripheral mechanisms of inflammatory pain 
1.2. Experimental techniques and protocols 
1.3. The role of TRPV1 in burn injury 
1.4. Whether xenon may mediate an analgesic action through its effect 
 on TRPV1 
1.5. Whether isoflurane and sevoflurane occasion pain-inducing spinal  
nociceptive processing 
 
 
1.1. PERIPHERAL MECHANISMS OF INFLAMMATORY PAIN 
           The vast majority of persistent pathological pain conditions – including 
conditions as common as persistent back-pain and osteoarthritis – are instances of 
peripheral inflammatory pain. Peripheral inflammatory pain imposes a huge economic 
burden on society generally, in addition to the burden of misery and disability which 
it imposes on individual sufferers.  Inflammatory agents, released as components of 
the body's response to peripheral tissue damage or disease, excite nociceptive primary 
sensory neurons to generate an electrical signal which will ultimately be interpreted 
by the brain as peripheral pain.  These agents achieve this effect by activating their 
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own receptors on those neurons and, in addition, or in the alternative, by altering the 
sensitivity and expression, or by directly activating,  one, or more, ionotropic 
receptors also found on those neurons.  In the next chapter, I survey the identity, 
nature and mechanisms of action of these inflammatory agents on primary nociceptive 
afferents, with particular reference to ionotropic receptors, to examine the present 
state of research into peripheral inflammatory pain.   
 
 
1.2. EXPERIMENTAL TECHNIQUES AND PROTOCOLS 
 
     During the course of my studies, I performed various techniques in molecular 
biology, extending over the areas of: cell culture; immunohistochemistry; agonist-
activated cobalt uptake and imaging; and enzyme-linked immunosorbent assays 
(ELISAs).  In chapter 3, the theoretical bases of these techniques are described, as are 
the protocols which were employed for their execution. 
 
1.3. THE ROLE OF TRPV1 IN BURN INJURY 
     Pain resulting from severe burn injury is one of the most excruciating pain 
sensations that can be experienced and the absence of consistently effective analgesics 
for its treatment renders its clinical management unsatisfactory. Severe burn injury 
causes major tissue damage and the resulting attempts of the body to defend against 
infection and to effect repair of injured tissues generate a massive inflammatory 
response.  This inflammatory response induces the formation and release of 
inflammatory mediators.  The resulting excitation of a sub-population of nociceptive 
primary sensory neurons is responsible for initiating, and maintaining, the sensation 
of peripheral inflammatory pain.   
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       The transient receptor potential vanilloid type 1 (TRPV1) is known to play an 
important role in several types of heat-induced hyperalgesia, although the more 
extensive claims made on its behalf have not been justified by the experimental 
results.   I have investigated the role of this receptor in the context of a mouse model 
of scalding-type burn injury to the lower hind-paw and show that activation of 
TRPV1 is not always essential for the maintenance of inflammatory pain in mouse 
caused by at least certain types of severe burn injury.   
 
1.4. WHETHER XENON MAY MEDIATE AN ANALGESIC  
ACTION THROUGH AN EFFECT ON TRPV1 
             Xenon is an inert gas which binds to a remarkable range of proteins, including 
ion channels, such as the ionotropic N-methyl-D-aspartate (NMDA) receptor for 
glutamate, as well as certain non-NMDA receptors.  Research into the mechanism of 
action of xenon has focused, almost exclusively, on its role as a general anaesthetic.  
However, in addition to its anaesthetic effect, xenon, in sub-anaesthetic doses, 
provides analgesia.  Such xenon-induced analgesia is believed to be mediated, at least 
in part, through inhibition of spinal nociceptive processing by way of reducing 
noxious stimulation-evoked spiking activity and long term potentiation in spinal cord 
neurons.     If xenon indeed reduces the nociceptive input into the spinal dorsal horn 
by an action on receptors on nociceptive primary afferents, an inhibitory effect on 
TRPV1 activation may be one of the mechanisms through which it mediates that 
effect.  Accordingly, this study was designed to determine the effect of xenon on 
TRPV1 activation in spinal dorsal horn neurons as well as in primary nociceptive 
afferents.    
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1.5. WHETHER ISOFLURANE AND SEVOFLURANE OCCASION 
 PAIN-INDUCING SPINAL NOCICEPTIVE PROCESSING 
     Recent in vitro studies have shown that certain pungent gaseous anaesthetics, can 
activate, or increase the activation of, receptors on primary nociceptive afferents 
which have been implicated as mediators of hyperalgesia in inflammatory pain 
conditions.  These receptors are the transient receptor potential ankyrin, type 1 
(TRPA1) and TRPV1.   The pungent general anaesthetics isoflurane and desflurane 
robustly activate TRPA1, with isoflurane producing inward currents in voltage-
clamped TRPA1-expressing HEK293 cells and in cultured mouse dorsal root ganglion 
neurons.    Moreover, clinically relevant concentrations of isoflurane, sevoflurane, 
enflurane and desflurane have also been shown to sensitise TRPV1 to capsaicin and 
protons and to reduce the threshold for heat activation of this ion channel.   Hence, the 
suggestion that, in the clinical context, volatile general anaesthetics may augment 
nociceptive signalling arising from surgical insults.  In particular, the finding that 
sevoflurane may exert a sensitizing effect on TRPV1 (albeit an effect which is 
substantially less than that elicited by isoflurane) raises an issue of clinical 
importance, given its preferred status as a non-pungent inhalational anaesthetic.    
 
       I have used activation of ERK1/2 in spinal dorsal horn neurons to elicit the extent 
to which exposure to isoflurane and sevoflurane, in clinically relevant concentrations 
results in nociceptive processing in the rat spinal cord.   I have also examined the 
extent to which these inhalational anaesthetics are sensitizers of TRPV1 by exposing 
animals to clinically relevant concentrations of these gases followed by injection of 
the  hind-paw with the archetypical TRPV1 agonist, capsaicin.   
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       Contrary to the suggestions made on the basis of the in vitro data, in these 
experiments,  isoflurane and sevoflurane are both shown to dramatically reduce, 
rather than increase, painful stimulus-evoked nociceptive processing in the spinal 
dorsal horn. Indeed, the data obtained suggest that volatile anaesthetics may mediate 
analgesia in surgery rather than provoke pain as previously suggested.  
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                                                                     CHAPTER 2 
 
PERIPHERAL MECHANISMS OF   
INFLAMMATORY PAIN 
 
 
Contents 
2.1. Introduction  
2.1.1. Scope of Review 
2.1.2. Signal for peripheral inflammatory pain sensation 
2.1.3. Sodium, potassium and chloride ion channels 
  2.1.3.1.   Na+  channels 
  2.1.3.2    K+  channels 
   2.1.3.3.    Cl- channels 
2.1.4. TRPV1 mediates inflammatory thermal hyperalgesia and  
spontaneous pain sensations 
 
2.1.4.1. TRPV1 as an ionotropic receptor 
  2.1.4.2.       Thermal inflammatory pain 
2.1.4.3. Spontaneous pain sensations 
2.1.4.4. Animal models of inflammatory pain 
2.1.5.  TRPAI contributes with TRPV1 in mediating inflammatory  
       pain, including mechanical hyperalgesia and cold hyperalgesia 
 
2.1.5.1.   TRPA1 as an ionotropic receptor 
2.1.5.2.   TRPA1 and inflammatory pain 
2.1.5.3. TRPA1 and mechanical hyperalgesia 
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2.1.5.4   TRPA1 and cold hyperalgesia 
 2.1.6. TRPV4 mediates mechanical hyperalgesia in inflammation 
2.1.6.1.  TRPV4  as an ionotropic receptor 
2.1.6.2. TRPV4 mediates hypotonic and hypertonic nociception 
2.1.6.3.  Inflammation-induced mechanical hyperalgesia 
2.2. Bradykinin and other kinins 
2.2.1. Introduction       
2.2.2.   Kalllikrein-kinin system 
2.2.3.   B1 and B2 kinin receptors 
2.2.4. B1 kinin receptors evade desensitisation 
2.2.5. Bradykinin involvement in mediating inflammatory pain sensation 
 
2.2.6.  Bradykinin involvement in mediating neuropathic pain sensation 
 
2.2.7.  Mechanisms by which kinins mediate pain sensation 
2.2.8. Bradykinin in brain 
2.3.    Eicosanoids 
2.3.1.   Introduction 
2.3.2.   Prostanoids: PGE2; PGI2; TxA2 
2.3.2.1. Prostaglandin-E2 (PGE2) 
2.3.2.1.1.   PGE2 contributes to inflammatory pain 
2.3.2.2.   Prostaglandin-I2 (PGI2; Prostacyclin)  
2.3.2.2.1.   Prostacyclin contributes to 
 inflammatory pain 
 
2.3.2.3  Excitation of dorsal root ganglion and spinal cord 
by PGE2 and PGI2 
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2.3.3. Platelet-activating factor (PAF) 
2.3.3.1. PAF contributes to inflammatory pain 
2.3.4. Leukotrienes  
2.3.4.1. LTB4 contributes to inflammatory pain 
2.4. Nerve growth factor (NGF) 
2.4.1.   Introduction 
2.4.2.  NGF production in inflammation 
2.4.3.   NGF and inflammatory pain 
 2.4.4   NGF involvement in sensitisation of TRPV1 
 2.4.5 Surgical incisional injury and post-operative pain 
2.5. Brain-derived neurotropic factor (BDNF) 
 2.5.1.  Introduction 
 2.5.2 BDNF and inflammatory pain 
2.6.   Artemin, neurturin, and GDNF 
2.6.1.   Introduction 
2.6.2.   Contribution to inflammatory pain 
2.7.   Serotonin (5-Hydroxytryptamine; 5-HT) 
2.7.1.   Introduction 
2.7.2.   Peripheral serotonin, mast cells and inflammation 
2.7.3.   Peripheral serotonin contributes to pain of peripheral inflammation 
2.7.4.   Role of central serotonergic system 
2.8.   Histamine 
2.8.1   Introduction.    
2.8.2    Histamine and inflammatory pain 
2.8.3   Histamine and mechanical pain sensation 
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2.8.4   Activation of TRPV1 to mediate itch sensation 
2.9.   Anandamide 
2.9.1. Introduction 
2.9.2.  Contribution to inflammatory pain 
2.10.   ATP (Adenosine 5' Triphosphate) 
2.10.1.   Introduction  
2.10.2.   ATP and inflammatory pain 
2.10.3.   Extracellular ATP 
2.10.4.   ATP contributes to inflammatory pain 
2.11.  Protons and Other Cations 
  2.11.1.   Introduction        
2.11.2.   High proton (low pH) concentrations result in pain 
2.11.3.   High cation concentrations result in pain 
2.11.4.   Proton activation of TRPV1 
2.11.5.   Cation activation of TRPV1 
2.11.6.   ASICs mediate pain sensations from both minor and  
  TRPV1-sensitive reductions in pH 
 2.11.7.   ASICs as mediators of inflammatory pain 
 2.11.8.   Proton-sensing GPCRs 
2.12.    Cytokines 
2.12.1.   Introduction 
2.12.2.   Growth-related oncogene (GRO/KC: CXCL1) 
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2.1.  INTRODUCTION 
2.1.2.  Scope of Review 
      Peripheral inflammatory pain makes up the vast preponderance of persistent pain 
conditions, including, as it does, pain from osteo-, and rheumatoid, arthritis, back-pain 
from inflamed spinal disc injury, post-operative pain, and pain from tumours and burn 
injuries.  Any attempt to understand the nature of inflammatory pain and, in doing so, 
to move forward and devise a remedy for it, must be prefaced by identification of the 
pharmacological issues involved and their essential parameters. Each of the individual 
topics addressed in this review is, in itself, worthy of an extended review.  However, 
this paper is intended to serve a different purpose.  It offers a tour of the relevant 
terrain as mapped by the literature, rather than a comprehensive “dig” at the site of 
any particular subject which is described.  It is intended to contextualise the work of 
research scientists in many areas relating to the challenge of elucidating the peripheral 
mechanisms of inflammatory pain. 
 
         The inflammatory process gives rise to a multiplicity of chemical agents which 
are designed to protect against infection and to promote the repair of damaged tissue. 
However, the body's inflammatory response to injury, or disease, is not precisely 
regulated, and is often disproportionate, resulting in pain.  Physiological pain – which 
abates with removal of the noxious stimulus – is a purely protective mechanism, 
warning the body of the threat which it has encountered.  However, several 
pathological pain conditions may result from peripheral inflammation, namely:  
hyperalgesia, where an excessive sensation of pain is elicited by a mild noxious 
stimulus, such as heat (thermal hyperalgesia) or mechanical pressure (mechanical 
hyperalgesia); allodynia where pain is elicited by a harmlesss non-noxious stimulus; 
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and spontaneous pain, where pain is evoked without any precipitating stimulus.  In 
cases of severe inflammation, as in the case of serious burn injury, these conditions 
can prevent necessary active treatment of the tissue damage.   In other cases, the 
inflammation may not subside, or the pain may persist notwithstanding the fact that its 
initiating stimulus has abated, leading to a chronic pain condition.    
 
2.1.2.   The signal for peripheral inflammatory pain sensation           
        The inflammatory agents generated by the tissue damage or disease which is the 
cause of inflammatory pain include: bradykinin; eicosanoids; NGF; GDNF; serotonin; 
histamine; anandamide; ATP; cations, especially protons;  and cytokines.  Peripheral 
inflammatory pain is the result of an alteration of the excitability of peripheral sensory 
neurons resulting from the effect of these inflammatory agents..  Alteration of a 
neuron’s firing pattern is reflected in its synaptic transmission of signal in the dorsal 
horn of the spinal cord, where first order primary afferent neurons synapse with 
secondary spinal neurons.   The signal thus relayed to spinal secondary afferents then 
undergoes modulation by descending neuronal inputs, before being transmitted via 
these secondary spinal afferents to the thalamus.  In the thalamus, these secondary 
afferents synapse with third order sensory neurons which relay the signal to the 
primary somatosensory cortex of the brain.  In the brain, after further modulation by 
supraspinal (particularly thalamic and limbic) inputs, the signal falls to be interpreted 
as the sensation of pain.  The main descending neuronal inputs are serotonergic and 
noradrenergic (Yoshimura & Furue, 2006;  Braz & Basbaum, 2008; Geranton et al., 
2008),  Descending pain inhibitory, or facilitatory, pathways from the 
rostroventromedial medulla (RVM) are proposed to act ultimately in the spinal cord in 
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acute and chronic pain states through activation of 5-HT7 and 5-HT3 receptors, 
respectively (Dogrul et al., 2009). 
 
      A variety of agents released in inflammation contribute to alter the firing pattern 
of nociceptive primary sensory neurons.  Many of these inflammatory agents act 
directly on their own receptors found on primary afferents to contribute to excitation 
of these neurons. Thus, bradykinin acts on B1 and B2 receptors expressed by primary 
sensory neurons.   Certain of these inflammatory agents, in addition, or in the 
alternative, directly activate ion channels found on these neurons, or affect the 
sensitivity and expression of these ion channels.  Present evidence suggests that  
TRPV1, TRPA1, TRPV4, and ASIC ion channels are of special relevance in the 
context of inflammation.  These ion channels constitute an essential component of the 
mechanisms whereby inflammatory agents excite primary afferents to result in pain 
conditions. Yet other ion channels generally contribute – regardless of the special 
circumstances resulting from inflammation – to neuronal excitability.  These include 
sodium, potassium, chloride, and calcium ion channels.    Hence, the role of these ion 
channels -- so far as relevant to mediating the nociceptive consequences of the 
inflammatory response -- must be borne in mind as mediators of the effects of 
individual inflammagens. 
  
2.1.3. Sodium, potassium and chloride ion channels 
2.1.3.1.    Na+  channels 
      Altered function of certain Na+ channels contributes to the increased hyper-
excitability of primary afferent neurons in certain pathological pain states and the 
Nav1.9 sub-unit has been implicated in mediating inflammatory pain sensations 
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(Priest et al., 2005; Amaya et al., 2006).  This channel is important in the development 
of inflammation-based bladder dysfunction (Ritter et al., 2009).  Moreover, in a 
distinct population of L3-L5 knee joint afferent DRGs in a rat model of FCA-induced 
chronic inflammatory joint pain, Nav1.9, Nav1.8 and Nav1.7 show increased channel 
expression which is accompanied by unilateral joint hypersensitivity in the FCA-
injected knee (Strickland et al., 2008).  In at least certain instances of inflammation, 
individual inflammagens may, conjointly, produce an effect which they are 
individually incapable of mediating.  In an important study, Delmas and colleagues 
(2008) have shown that bradykinin, ATP, histamine, PGE2, and noradrenaline, when 
applied separately at maximal concentrations, all fail to modulate Nav1.9 current.  
However, when applied conjointly as a soup of inflammatory mediators, they rapidly 
potentiate Nav1.9 channel activity, generating sub-threshold amplification and 
increased excitability (Maingret et al., 2008).  These findings may have profound 
clinical implications because they suggest that, in certain pain states at least, an 
intervention which successfully prevents the contribution to neuronal excitation of 
certain only of the inflammagens may result in a significant analgesic effect.  They 
also confirm the importance of the NaV1.9 channel as a mediator of inflammatory 
pain sensations.  Again, Levine and colleagues (2008) have shown that the level of the 
pro-inflammatory cytokine, interleukin-6 (IL6), is increased following a partial-
thickness burn injury in rat and that spinal intrathecal injection of 
oligodeoxynucleotides antisense for gp130, a receptor subunit shared by members of 
the IL-6 family of cytokines, attenuates both burn-induced, and intrademeral IL-6-
induced, mechanical hyperalgesia, as does intradermal injection of anti-IL-6 function 
blocking antibodies (Summer et al., 2008).   
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          PGE2-induced persistent hypernociception in rats results in up-regulation of  
Nav1.8 mRNA in DRG neurons.  After a period of such recurring inflammatory 
stimuli, an intense and prolonged nociceptive response is elicited by a minimal 
inflammatory stimulus (Villarreal et al., 2009).  A selective blocker of Nav1.8 reduces 
the nociceptive effects of CFA-induced inflammation in rat – as does a TRPV1 
antagonist. Co-administration of both of these agents produces an additive effect in 
this rat pain model, suggesting that such a combination strategy to produce analgesia 
may be valuable in treating inflammatory pain (Joshi et al., 2009). 
 
2.1.3.2.   K+  channels 
      In cultured rat trigeminal ganglion neurons, hypotonicity increases slow-
inactivating K+ current but has no effect on fast-inactivating K+  current.  On the other 
hand, hypertonicity depresses both slow-inactivating, and fast-inactivating, K+   
currents (Chen et al., 2008). 
 
2.1.3.3.   Cl- channels 
      In cultured rat DRG neurons, treatment with a soup comprising NGF, ATP and 
bradykinin for 1 to 3 hours raises intracellular Cl- levels and the driving force for 
depolarizing Cl- efflux (Funk et al., 2008). 
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2.1.4. TRPV1 mediates inflammatory thermal hyperalgesia and spontaneous 
pain sensations 
 
2.1.4.1.    TRPV1 as an ionotropic receptor 
       TRPV1 is a ligand-gated, non-selective, cationic channel with a high permeability 
for Ca2+ (Caterina et al., 1997; Marsh et al., 1987; Heyman and Rang, 1985).  On 
activation, these cation-selective ion channels generate a net inward current which 
depolarises the neuronal membrane and increases the probability of action potential 
generation.  TRPV1 is found in approximately 40 per cent of all primary afferents and 
is expressed in the perikarya, as well as in both the central and peripheral terminals, of 
primary sensory neurons; and it has a wide-spread distribution not only in  peripheral 
tissues, but also in the central nervous system (Guo et al., 1999; Nagy, 2004; Mezey 
et al., 2000). 
      
      Multiple activators gate TRPV1.   Ligands (such as capsaicin and related 
vanilloids), heat, protons, and depolarization induce TRPV1 opening directly 
(Caterina et al., 1997; Tominaga et al., 1998; Voets et al., 2004).  It also appears that a 
reduction in the extracellular Na+  concentration can directly gate and sensitise TRPV1 
to such stimuli (Ohta et al., 2008).  In addition, gating of this ion channel can also be 
evoked indirectly by various inflammatory mediators which activate their own target 
receptors, which are also expressed on nociceptive primary sensory neurons 
expressing TRPV1.   These “own receptors,” in turn,  induce activity in the neuron's 
intracellular second messenger system. That, in turn, results in post-translational 
modification of TRPV1 in a process called “sensitisation” which increases the 
responsiveness of TRPV1, as well as the extent of the expression of TRPV1. 
 
 31 
    TRPV1 is important in its ability to integrate the respective effects of many of the 
agents generated by the inflammatory response. In addition, “co-operation” occurs 
between various ligands of TRPV1 whereby one increases the effect of the other in 
activating TRPV1 in an apparently synergistic, rather than additive, manner (Caterina 
et al., 1997; Tominaga et al., 1998; Kress et al., 1996). The ability of certain ligands 
to potentiate each other’s effect on TRPV1 suggests that the activation sites of 
different activators are in fact coupled in TRPV1.   Given the polymodal nature of 
activation of TRPV1 and the potentiating effect of at least certain of the activating 
stimuli on the effect produced by another activator of TRPV1, this ion channel has 
been described as a “stimulus integrator” of exogenous stimuli  (Tominaga et al., 
1998).  However, TRPV1 also acts similarly in relation to many endogenous agents, 
which makes it particularly relevant given the wide variety of inflammatory agents 
generated as components of the inflammatory response. 
 
2.1.4.2.  Thermal inflammatory pain 
      Heat hyperalgesia secondary to inflammatory tissue injury fails to develop in 
TRPV1 null mice as in wild type mice, although pathological thermal sensations after 
peripheral nerve injury remain the same in both wild type and TRPV1 null animals 
(Caterina et al., 2000; Davis et al., 2000), suggesting that TRPV1 is an essential 
component in the development of pathological thermal hyperalgesia at least in the 
contexts examined, but apparently limited to pain sensations of inflammatory origin.  
Thermal hyperalgesia following inflammation involves an increased level of TRPV1 
expression (Amaya et al., 2003), as well as the sensitisation of existing TRPV1 
channels. NGF and GDNF increase following inflammation and contribute to 
inflammatory thermal hyperalgesia via an increase in TRPV1 expression. These 
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increases in NGF and GDNF, respectively, each follow a different time course and 
they each act on distinct populations of DRG neurons (Amaya et al., 2004).   
Inflammatory mediators, such as ATP, bradykinin, and NGF, increase the temperature 
and proton sensitivity of TRPV1 and contribute to enhanced TRPV1 ion channel 
activity. Chuang and colleagues (2001) injected wild-type and TRPV1-deficient mice 
with bradykinin or NGF and measured paw withdrawal latencies from a radiant heat 
source before, and after, treatment. Each agent produced substantial sensitisation in 
wild-type animals but not in the knockout mice, demonstrating that TRPV1 is 
essential for the development of bradykinin-induced or NGF-induced thermal 
hypersensitivity in vivo. Increased activation of TRPVI channels expressed with BK2 
receptors in HEK293 cells also results from bradykinin, while NGF produces 
increased responses in proton-evoked currents in oocytes expressing both TRPV1 and 
the NGF receptor, TrkA. Both bradykinin and NGF, therefore, mediate their effect  by 
activation of TRPV1 and their own receptors (Chuang et al., 2001).  
.   
2.1.4.3.  Spontaneous pain sensations 
      That TRPV1 functions as a mediator of spontaneous pain sensations and is an 
important mediator of pain sensations resulting from inflammation is indicated by the 
fact that this ion channel is synergistically responsive to two major components of the 
inflammatory response, namely, local reductions in pH and local increases in 
temperature.  The pH threshold for proton-evoked TRPV1 activation is ~6.5. At lower 
pH values, protons can themselves activate TRPV1.  Lowering pH lowers the heat 
threshold for activation of the channel, and stabilises at least one of the open 
conformations of the channel (Ryu et al., 2003). Sensitivity to noxious heat is the 
most distinctive feature of TRPV1. Temperature affects the activation of TRPV1, 
 33 
first, by reducing the threshold for the activation of TRPV1 by all other TRPV1 
activators. Second, heat above ~43ºC independently activates TRPV1 (Tominaga et 
al., 1998). Below 43ºC, gating of TRPV1 occurs only infrequently and briefly. 
However, raising the ambient temperature rapidly increases the frequency of channel 
openings (Liu et al., 2003).   The presence of either reducing, or oxidising, agents also 
appears to result in an increased response to heat by TRPV1 channels (Susankova et 
al., 2006).    The point to emphasise is that, if the temperature activation threshold for 
TRPV1 is reduced to body temperature, i.e., 37 degrees C, whether by reduced pH, or 
otherwise, the result is spontaneous activation of TRPV1, leading to spontaneous pain 
sensations as a result of normal body temperature alone.  Bradykinin has, importantly, 
also been identified as being capable of reducing the heat threshold for activation of 
TRPV1 well below body temperature (Sugiura et al., 2002; Liang et al., 2001).   
Moreover, it is well recognised that local body temperature is increased in 
inflammation.  Hence, an effect of other inflammatory agents which reduces the 
temperature activation threshold to 37 degrees C may be unnecessary to result in the 
development and maintenance of spontaneous pain sensations.   The central role of 
temperature in the activation of TRPV1 is demonstrated by the evidence that cooling 
inhibits capsaicin-induced currents in primary sensory neurons (Babes et al., 2002).  
This explains the efficacy of exposing burned, or itching, skin surfaces to cold water 
which causes TRPV1 activity to abate, reducing the noxious pain or itch sensations.  
 
2.1.4.4.   Animal models of inflammatory pain 
        Three principal animal models of inflammatory pain have gained currency in 
biomedical research, each involving intraplantar injection of an animal’s hind-paw 
with either CFA, carrageenan, or formalin.  TRPV1 activation is an essential feature 
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of the inflammation generated in both the CFA and carrigeenan models.  Intraplantar 
injection of CFA in rat, results in thermal hyperalgesia extending, at least, over a four 
week period, and mechanical allodynia extending over a two week period, with peaks 
in each case at day 7.  TRPV1 expression is increased in medium-sized myelinated A 
fibre (NF200 positive) neurons and in small non-peptidergic (IB4 positive) neurons 
from day 1 to day 14, and in small peptidergic (CGRP positive) neurons from day 1 to 
day 28.  Moreover, intrathecal administration, at day 7, of a selective TRPV1 
antagonist, significantly reduces thermal hyperalgeisa and mechanical allodynia (Yu 
et al., 2009).  In carrageenan-induced hind-paw inflammation, thermal and 
mechanical hyperalgesia result from carrageenan hind-paw injection. TRPV1 null 
mice are unable to develop carrageenan-induced thermal hyperalgesia, demonstrating 
that TRPV1 activation is essential for the development of this form of inflammatory 
hyperalgesia (Davis et al., 2000).  Hydrogen peroxide levels are also significantly 
raised in the carrageen-injected animals.  At the same time, superoxide dismutase and 
catalase significantly reduce the mechanical and thermal hyperalgesia (Keeble et al., 
2009). The third major model of inflammatory pain is that which is induced by 
formalin injection of the hind-paw, but this is exclusively mediated by TRPA1 
(McNamara et al., 2007).   Xylene-induced acute nocifensive behaviour in mice is 
mediated by activation of TRPV1 (Sandor et al., 2009).  TRPV1 channels also appear 
to be involved in the development of acute mechanical hyperalgeisa during repetitive 
noxious colorectal distension in rats (Ravnefjord et al., 2009). 
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2.1.5. TRPAI contributes with TRPV1 in mediating inflammatory  
       pain, including mechanical hyperalgesia and cold hyperalgesia 
 
2.1.5.1.   TRPA1 as an ionotropic receptor 
      TRPA1 is a noxious cold channel which is activated by cold at approximately 17 
degrees C (Story et al., 2003; Bandell et al., 2004; Obata et al., 2005). 
Notwithstanding this, however, mice which lack the TRPA1 receptor display normal 
cold sensitivity (Bautista et al., 2006), suggesting that the association between TRPA1 
activation and noxious cold is qualified.   TRPA1 is a non-selective ligand-gated 
cation channel which is directly gated by Ca2+ (Doerner et al., 2007).   This ion 
channel is found in a subset of nociceptive primary afferents of dorsal root and 
trigeminal ganglia that co-express TRPV1 (Story et al., 2003; Jordt et al., 2004; 
Kobayashi et al., 2005).  TRPA1 is present, with TRPV1, in primary afferents 
innervating the masseter muscle in rats, and both of these ion channels are capable of 
functionally contributing to muscle nociception and hyperalgesia (Ro et al., 2009).  
The converse, however, is not true; and not all primary afferents which express 
TRPV1 also express TRPA1 (Kobayashi et al., 2005). Most compounds known to 
activate TRPA1 are capable of covalently binding cysteine residues. The covalent 
modification of reactive cysteines within TRPA1 can cause channel activation, 
rapidly signalling potential tissue damage through the pain pathway (Mcpherson et 
al., 2007).  
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2.1.5.2.    TRPA1 and inflammatory pain 
       Mice which lack TRPA1 receptors have sensory neurons which are insensitive to 
formalin.  Moreover, pharmacological blockade or genetic ablation of TRPA1 in mice 
produces marked attenuation of the characteristic flinching, licking, and lifting 
responses resulting from intraplantar injection of formalin (McNamara et al., 2007).   . 
TRPA1 is activated by certain at least of the chemical agents generated by the 
inflammatory response. Hence, TRPA1 is responsible for the pain, inflammation and 
robust hypersensitivity to thermal and mechanical stimuli that results from the topical 
application of mustard oil (allyl isothiocyanate) to the skin (Jordt et al., 2004). 
TRPA1is the exclusive receptor through which mustard oil and garlic activate primary 
afferent nociceptors to produce inflammatory pain (Bautista et al., 2006). TRPA1 is 
activated by formalin which induces a robust calcium influx in cells expressing 
TRPA1.   TRPA1 is activated indirectly by bradykinin (Bandell et al., 2004). Mice 
which lack the TRPA1 receptor suffer from obvious deficits in bradykinin-evoked 
nociceptor excitation and pain hypersensitivity (Bautista et al., 2006).   Sensitization 
of TRPA1 by bradykinin is proposed to be mediated by PLC and PKA (Wang et al, 
2008).   TRPA1 channels are activated by 4-hydroxy-2-nonenal (HNE), an 
endogenous alpha, beta-unsaturated aldehyde that is produced when reactive oxygen 
species peroxidate membrane phospholipids in response to tissue injury, 
inflammation, and oxidative stress. Many agents produced during episodes of 
oxidative stress can activate TRPA1 expressed in sensory neurons (Andersson et al., 
2008). Again, a PGD2 metabolite appears to be capable of directly activating TRPA1 
(Taylor-Clark et al., 2007).  15d-PGJ2 induces acute nocicpetive responses when 
administered cuntaneously to mice by activating TRPA1 (Cruz-Orengo et al., 2008).  
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A functional interaction of PAR2 and TRPA1 in dorsal root ganglion neurons may 
contribute to the sensation of inflammatory pain. Frequent co-localisation of TRPA1 
with PAR2 is found in rat dorsal root ganglion neurons.  PAR2 my contribute to 
sensitising TRPA1 since activation of PAR2 increases the TRPA1 currents evoked by 
TRPA1 agonists in HEK293 cells transfected with TRPA1 and in dorsal root ganglion 
neurons (Dai et al., 2007).   
 
     TRPA1 appears to be important in airway inflammation and hyper-reactivity in 
asthma.  Genetic ablation of this ion channel in mice inhibits allergen-induced 
leukocyte infiltration in the airways, reduces cytokine and mucus production, and 
almost completely abolishes airway hyper-reactivity to contractile stimuli (Caceres et 
al., 2009).  
 
2.1.5.3. TRPA1 and mechanical hyperalgesia 
       Mechanical hyperalgesia resulting from inflammation is reduced when TRPA1 
function is inhibited.  Administration of a selective TRPA1 antagonist inhibits all 
formalin responses in rat C fibres and substantially diminishes mechanically-evoked 
action potential firing in C fibres.  Importantly, it fails to affect TRPV1 function, as 
assessed by capsaicin responsiveness.  Hence, the presence of TRPA1 in cutaneous 
sensory neurons is essential to identify at least certain noxious chemical stimuli and to 
respond to certain forms of mechanical stimuli (Kerstein et al., 2009).   Sensitising 
TRPA1, via a PAR2-dependent mechanism, is important in mast cell activation-
induced mechanical hyper-sensitivity of vagal nodose C-fibres in the guinea pig 
oesophagus (Yu et al., 2009). Experimentally induced colitis results in a significant 
increase in visceral sensitivity to colonic distension and chemical irritation 
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accompanied by up-regulation of TRPA1 in colonic afferent dorsal root ganglia.  The 
effects are suppressed by ablation of the TRPA1 gene (Yang et al., 2008).  Intrathecal 
and intraperitoneal injection of a TRPA1 inhibitor suppresses the response to noxious 
gastric distension (Kondon et al., 2009).   
 
1.5.4  TRPA1 and cold hyperalgesia 
       Enhanced sensitivity to cold so that cold elicits an inappropriate sensation of pain 
--  described as “cold hyperalgesia”  -- is a common symptom of both inflammatory 
pain and neuropathic pain conditions.   Pharmacological blockade of TRPA1 in rat 
primary sensory neurons decreases the induction of TRPA1, while reversal of cold 
hyperalgesia caused by inflammation or nerve injury results from pharmacological 
blockade of TRPA1 (Obata et al., 2005).   TRPA1 appears to make a major 
contribution to CFA-induced cold hyperalgesia in rats (Stucky et al., 2009). 
 
2.1.6. TRPV4 mediates mechanical hyperalgesia in inflammation 
2.1.6.1.   TRPV4  as an ionotropic receptor 
     TRPV4 was previously known as vanilloid receptor-related osmotically activated 
channel (VR-OAC).   TRPV4 is a non-selective, ligand-gated, cation channel that 
functions in the transduction of osmotic and mechanical stimuli. This receptor is 
necessary for the maintenance of systemic osmotic equilibrium, and for normal 
thresholds in response to noxious mechanical stimuli (Liedtke et al., 2005). In mice 
which lack the TRPV4 gene,  the animals exhibit a marked reduction in the sensitivity 
of the tail to pressure and acidic nociception.  Low pH, citrate, and inflation gate 
TRPV4 when expressed in vitro in Chinese hamster ovary cells; but neither heat nor 
capsaicin gate this ion channel in this model (Suzuki et al., 2003a).  However, heat 
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above 25 degrees C activates currents and increases intracellular calcium 
concentration in HEK293 cells transfected with TRPV4 and in endogenous TRPV4 in 
mouse aorta endothelium (Watanabe et al., 2002).    Anandamide and arachidonic acid 
employ epoxyeicosatrienoic acids to activate TRPV4 (Watanabe et al., 2003). Cell 
swelling utilises phospholipase A2-dependent formation of arachidonic acid, and its 
subsequent metabolism to 5’,6’-epoxyeicosatrienoic acid, to activate TRPV4.  
Phorbol esters and heat  activate TRPV4 by means of a different pathway which 
depends on an aromatic residue at the N terminus of the third transmembrane domain 
(Vriens et al., 2004).  Src family tyrosine kinases mediate tyrosine phosphorylation of 
TRPV4 in different cell lines, with phosphorylation sites in the cytosolic N- and C-
terminal tails of this ion channel.  The N-terminal tyrosine residue is crucial in the 
activation of TRPV4 by heat, mechanical (shear) stress, hypotonic cell swelling, and 
phorbol 12-myristate 13-acetate. TRPV4 appears to be sensitised, rather than 
activated, by tyrosine phosphorylation.  Moreover, reactive oxygen species strongly 
up-regulate TRPV4 in the presence of Src family tyrosine kinases (Wegierski et al., 
2009).     
 
      TRPV4 is found in peripheral sensory neurons and, in addition, in the central 
nervous system.  Hippocampal neurons express functional TRPV4 (Shibasaki, 2007).  
Both TRPV1 and TRPV4 are co-expressed in DRG neuronal cell bodies and in the 
central terminals of laminae I and II of the spinal dorsal horn. TRPV4 can be 
sensitised by PKC.  TRPV1-mediated, and TRPV4-mediated, responses are observed 
in a population of the same DRG neurons (Cao et al., 2009).   Both small (low 
threshold) and large (high threshold) dorsal root ganglia neurons express TRPV4 in 
mice.  TRPV4 is found in free nerve endings, and is also  specifically located at 
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cutaneous mechanosensory terminals co-localised with neurofilament 200, including 
Meissner, Merkel, penicillate and intraepidermal terminals (Suzuki et al., 2003b).  
 
2.1.6.2.  TRPV4 mediates hypotonic and hypertonic nociception 
         In vivo single-fibre recordings in rat show that hypotonic solution activates 54% 
of C-fibers, an effect enhanced by prostaglandin E2. This osmotransduction causes 
nociception; and the channel is required for hypotonic stimulus-induced nociception 
(Alessandri-Haber et al., 2003). TRPV4 also mediates pain resulting from 
hypertonicity in rat and the aggravation of that pain which results from the addition of 
an inflammatory mediator (Alessandri-Haber et al., 2005). 
 
2.1.6.3.  Inflammation-induced mechanical hyperalgesia 
      Mechanical hyperalgesia occasioned by agents produced in the inflammatory 
process is mediated by TRPV4.  Thus, the nocifensive paw-withdrawal reflex elicited 
by hypotonic, or mechanical, stimuli in rat is enhanced by intradermal injection of 
either carrageenan, or of a soup of inflammatory mediators.  When TRPV4 is knocked 
down by spinal administration of TRPV4 antisense oligodeoxynucleotide, the 
enhancement is blocked without altering baseline nociceptive threshold.  Again, 
inflammatory soup fails to induce any significant mechanical or osmotic hyperalgesia 
in mice which lack the TRPV4 receptor (Alessandri-Haber et al., 2006). Moreover, on 
injection in vivo with PGE2 and serotonin of the mechanical receptive fields of C-
fibres in wild-type and TRPV4 knock-out mice, the percentage of C-fibres responding 
to a hypotonic stimulus and the magnitude of the response is significantly greater in 
wild-type mice when compared to TRPV4 knock-out mice.   TRPV4 is shown to be 
crucial in mediating mechanical hyperalgesia because only C-fibres from wild-type 
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mice, which possess the TRPV4 receptor, exhibit increased spontaneous activity and 
decreased mechanical threshold in response to PGE2 and serotonin (Chen et al., 
2007).  Mechanical hyperalgesia is reduced in TRPV4-deficient mice in various 
models of painful peripheral neuropathy which exhibit mechanical hyperalgesia 
(Allesandri-Haber et al., 2008).  TRPV4 contributes to mechanically-evoked visceral 
pain (Brierley et al., 2008); and is necessary for PAR2-induced mechanical 
hyperalgesia and excitation of colonic afferent neurons in mouse (Sipe et al., 2008).  
TRPV4 appears to play a pivotal role in visceral nociception and hypersensitivity 
(Cenac et al., 2008). 
FIGURE 1. 
 
Table of Characteristics of TRPV1, TRPA1,  
TRPV4 and ASICs as Ionotropic Receptors 
 
 
Principal Features      
• ligand-gated ion channels     
• have central aqueous pore 
• channel-gated  on ligand-binding 
• gating results in ionic flux via pore 
• for fast synaptic transmission 
• Examples: TRPs, ASICs, 5HT3 
 
Possible Inhibiting Mechanisms 
• competitive antagonism  
• conduction blocker of channel pore  
• binding in channel pore to induce failure of “gating
”
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FIGURE 2. 
 
Table of Known Activators of TRPV1, TRPA1, TRPV4  
and ASICs in the Absence of Inflammation 
 
Activator    TRPV1  TRPA1  TRPV4  ASICs     
Heat    Y N N - 
Cold    N Y - - 
Depolarisation   Y - - - 
Hypotonicity   N N Y N 
Hypertonicity   N N Y N 
Capsaicin (& other vanilloids) Y N N N 
Mustard oil   N Y - - 
Garlic    N Y - - 
Protons    & Cations  Y - Y Y  
    (pH <6.5) 
 
Key: Y= yes; N= no; - = not known. 
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FIGURE  3. 
Table of Inflammagens as Activators of Iontropic  
and Their Cognate (Own) Receptors  
in Peripheral Inflammation 
 
Inflammatory Agent   TRPV1  TRPA1  TRPV4  ASICs  Cognate (Own) Receptors 
    (direct or indirect activation) (activation by ligand-binding)
     
Bradykinin   Y Y - Y B1-2 
PGE2    Y - Y - EP1-4 
PGI2    Y - - - IP 
NGF    Y - - Y trkA 
Artemin, neurturin, GDNF Y - - - GFRalpha1-4                                                     
Histamine   Y - - -- H1-4 
Anandamide   Y - - - CB1-2, GPR55 
Protons    & Cations  Y   - Y Y ASICs  
    (pH <6.5) 
LTB4    - - - - BLT1-2 
5-HT    - - - Y 5-HT1A & 2A,5-HT3  
ATP    Y - - - P2X2, P2X3, P2X2/3 
 
Key:  Y = yes;  - = not known. 
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FIGURE  4. 
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Predicted membrane structure of TRPV1 and ASIC ion channels. Like other members 
of the TRP family, TRPV1 has six transmembrane domains. Both the N- and C-termini 
are intracellular. The hydrophobic loop connecting transmembrane domains five and 
six is believed to be part of the channel. In contrast, ASIC ion channels have only two 
transmembrane domains. Both the N- and C-termini are again intracellular. 
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FIGURE  5. 
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Molecular mechanisms involved in the functioning of TRPV1 in inflammatory 
conditions. Reduction of the heat threshold of TRPV1 below body temperature may be 
induced by binding of endovanilloids, protons, anandamide, or lipoxygenase 
products. Post-translational modifications (removal of phosphatidylinositol-4,5-
biphosphate (PtdIns(4,5)P2) and protein kinase C (PKC)-mediated phosphorylation) 
can also produce this effect. Protein kinase A (PKA)-mediated phosphorylation also 
sensitizes TRPV1. Phosphatidylinositol 3-kinase (PI3K) activity induced by nerve 
growth factor (NGF) and ATP-binding also potentiates responses evoked by 
endovanilloids. The molecular mechanisms involved in the functioning of TRPA1 and 
TRPV4 remain to be elucidated. 
NAPE-PLD: N-acylphosphotidylethanolamine phospholipase D involved in 
anandamide production in primary sensory neurons. PLA: phospholipase A. PLC: 
phospholipase C. G prot: G protein. AC: adenylyl cyclase. Question mark refers to an 
unidentified enzyme producing anandamide in a Ca2+-independent manner. 
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2.2. BRADYKININ AND OTHER KININS 
2.2.1. Introduction      
        Bradykinin figures prominently in the context of inflammation and inflammatory 
pain, but it also serves important cardioprotective and other functions (Bhoola et al., 
1992; Marceau et al., 1999; Vidal et al., 2005; Leeb-Lundberg et al., 2005; Araujo et 
al., 2006; Cayla et al., 2007; Wu and Pan, 2007).  Bradykinin is one of a number of 
related peptides, derived from an action of the kallikrein enzyme, which are 
comprised in the so-called "kallikrein-kinin system" (Bhoola et al., 1992; Leeb-
Lundberg et al., 2005; Marceau et al., 2005; Schmaier, 2008). Paradoxically, although 
the effect of bradykinin, when released in the periphery as part of the inflammatory 
response, is to induce the experience of pain sensations, yet, when bradykinin is 
released in certain areas of the brain, it can exert a powerful analgesic effect (Couto et 
al., 1998, 2006).  Several reviews have recently addressed the role of bradykinin as a 
mediator of inflammatory pain sensations (Wang et al., 2006; Sharma and Al-Sherif, 
2006;  Moreau et al., 2005; Calixto et al., 2004). 
      
2.2.2. Kalllikrein-kinin system 
     Bradykinin is a nonapeptide which is produced at sites of tissue injury.  The 
proteolytic enzyme kallikrein acts on high-molecular-weight kininogen, a plasma 
alpha-globulin, to form either bradykinin or kallidin.  Kallidin (which is also known 
as lysyl bradykinin (lys-BK) is a peptide which is almost identical with bradykinin, 
but comprises an additional amino acid residue.   The kallikrein enzyme is derived 
from prekallikrein, which is an inactive precursor present in plasma.  Prekallikrein can 
be converted to kallikrein in several ways, including by reaction with Hageman factor 
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(which is factor XII of the clotting sequence).   Hageman factor is normally in an 
inactive form in the plasma and is activated by contact with surfaces having a 
negative charge, including collagen, basement membrane, and bacterial 
lipopolysaccharides.  The increased vascular permeability which accompanies 
inflammation results in leakage of plasma, containing prekallikrein, Hageman factor, 
and kininogen, which leads to bradykinin formation.  Kallikrein enzymes are also 
found in the pancreas, salivary glands, colon, and skin.  In these tissues, they act on 
kinninogens to generate, for the most part,  kallidin --  an action which is required for 
normal physiological function. (Bhoola et al., 1992; Leeb-Lundberg et al., 2005; 
Schmaier, 2008).  Prekallikrein is also capable of digesting high-molecular-weight 
kininogen to release bradykinin, but this effect is inhibited by the presence of C1 
inhibitor (Joseph et al, 2009).  The “kallikrein-kinin system is exceptionally complex 
and has been well described as constituting an “endogenous metabolic cascade” 
whose complexity is derived from the importance of the several critical functions 
which it subserves (Moreau et al., 2005).  
 
2.2.3. B1 and B2 kinin receptors 
          Bradykin receptors are denominated B1 and B2 kinin receptors, respectively 
(Moreau et al., 1998).  Bradykinin mediates its effects through these receptors and  
also, as has been observed, through the actions of certain ionotropic receptors (supra).  
The relevance of B1 and B2 receptors in the context of inflammatory pain resides in 
their ability, on exposure to agonist generated by the inflammatory process, to set in 
motion an intracellular chain of events which results in excitation of the primary 
sensory neuron, or secondary (spinal cord) afferent, on which they are expressed.  
Both the extent of kinin receptor expression and the extent of the availability of 
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agonist are key factors in determining whether a nociceptive signal is generated and 
the strength of that signal.   
 
     Bradykinin receptors are found in primary sensory neurons, as well as in the spinal 
cord, and also in myocardial/coronary visceral afferent fibres in guinea pig (Steranka 
et al., 1998).    The B1 and B2 kinin receptors are both G-protein coupled receptors.  
B2 receptors are found throughout the body and are constitutively expressed.   B1 
receptors are not expressed in most normal tissues, although there is a basal level of 
expression of these receptors in the spinal cord dorsal horn (Wotherspoon and Winter, 
2000; Ma and Heavens, 2001).  Generally, B1 receptors are induced within several 
hours under conditions of inflammation and tissue damage in the presence of pro-
inflammatory cytokines, especially interleukin-1beta (Marceau et al., 1998; Phagoo et 
al., 1999; Phagoo et al., 2001;  Prado et al., 2002).   Interleukin-1beta is important in 
the events which result in the increased expression of B1 receptors.  Bradykinin, 
acting at the B2 receptor, induces the synthesis of IL-1beta (Pan et al., 1996).   In turn, 
this cytokine increases B1 receptor expression (Zhou et al., 1998). Up-regulation of 
the B1 receptor by IL-1beta and by agonists at the B1 receptor occurs through 
independent and synergistic intracellular signalling mechanisms in human lung 
fibroblasts (Phagoo et al., 2001).  Thus, B2 receptors predominate in the acute phase 
of inflammatory pain while B1 receptors predominate in the chronic phase.     The 
response of B2 receptors to bradykinin may vary with the cell upon which the 
receptors are expressed.  Thus, in the lung fibroblast cell line IMR-90, binding of 
bradykinin to B2 receptors triggers down-regulation of receptor surface expression.   
However, the same treatment with bradykinin of cells from the human lung epithelial 
cell-line BEAS2B leads to up-regulation of B2 receptors in BEAS2B cells (Bengston 
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et al., 2008).   HEK293 cells are widely employed in biological research as cells 
which are devoid of functional receptors and which, therefore, may be employed to 
explore in isolation the activation properties of receptors which are introduced into 
these naieve cells by transfection.  However, these cells have now been shown to 
express endogenous functional B2 receptors.  Exposure of HEK293 cells to 
bradykinin results in a concentration-dependent rise in intracellular Ca2+, increases in 
ECAR and a rapid increase in ERK1/2 phosphorylation – all of which are blocked by 
a B2 receptor antagonist (Kramarenko et al., 2009). 
 
     B1 receptors and B2 receptors, when co-expressed by a cell, directly interact to enhance 
signalling (Kang et al., 2004).    B2 receptors are stable plasma membrane components 
without agonist but in the presence of agonist, B2 receptors recruit beta-arrestin 2, 
internalise in a clathrin-dependent manner, and recycle rapidly. On the other hand, B1 
receptors, when induced, are constitutively active, and constitutively internalise without 
agonist via a clathrin-dependent pathway.  Agonist transiently stabilises these receptors by 
delaying B1 receptor endocytosis (Enquist et al., 2007).  NGF, and to a lesser extent GDNF, 
up-regulate the expression of B2 receptor mRNA and B2 receptor protein in the surface 
membrane of mouse dorsal root ganglion neurones.  NGF is also an important factor 
responsible for up-regulating B2 receptor expression after nerve crush injury in vivo (Lee et 
al., 2002).   Functional B1 receptors are expressed in only a small percentage of freshly 
isolated dorsal root ganglion neurons, but their expression is up-regulated by exposure to the 
related neurotrophins GDNF and neurturin, while NGF has no effect in this regard.  GDNF 
may be released from surrounding tissue following injury or inflammation and may act to 
up-regulate B1 receptor expression (Vellani et al., 2004). In rabbit aortic smooth muscle 
cells, interleukin-1beta and epidermal growth factor (EGF) each increase B1 kinin receptor 
expression at 4 hours (Kuombadinga et al., 2009).   The metalloendopeptidase thimet 
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oligopeptidase (EC 3.4.24.15; EP24.15) serves as an intracellular peptidase in the 
degradation of bradykinin which has been specifically internalised via the B2 
receptor, and also negatively regulates B2 responsiveness to bradykinin (Sanden et 
al., 2008). 
  
      Bradykinin (BK) and lysyl-bradykinin (Lys-BK) can each activate the B2 
receptor.  The ligands for the B1 receptor are des-Arg9-BK and Lys-des-Arg9-BK, 
which are formed through the actions of carboxypeptidases on BK and Lys-BK, 
respectively. Both B1 and B2 receptors each act through G q to stimulate 
phospholipase C  followed by phosphoinositide hydrolysis and intracellular free Ca2+ 
mobilization and through G i to inhibit adenylate cyclase and stimulate mitogen-
activated protein kinase pathways (Leeb-Lundberg, 2005).    des-Arg9-bradykinin, 
des-Arg10-kallidin, and des-Arg10-kallidin-like-peptide are equipotent agonists at the 
B1 receptor. Bradykinin, kallidin and kallidin-like-peptide are equipotent agonists at 
the B2 receptor (Zubakova et al., 2008).    There is also evidence from in vitro studies 
that kallikrein may activate B2 receptors in the absence of kininogen (Biyashev et al., 
2006).   A further important point is that B1 and B2 receptors are not exclusively 
activated by kinins.  Thus, the endogenous opioid, dynorphin A, can activate 
bradykinin receptors.  Activation of bradykinin receptors by dynorphin A induces 
calcium influx via voltage-sensitive calcium channels in sensory neurons (Lai et al., 
2006;  Lai et al., 2008).  Chronic peripheral inflammation induces a significant up-
regulation of the endogenous opioid dynorphin A, which, at pathological levels, may 
activate spinal bradykinin receptors to contribute to inflammatory hyperalgesia (Luo 
et al., 2008).   
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2.2.4. B1 kinin receptors evade desensitisation 
     The importance of kinins, and of the B1 receptor, in mediating long-term pain 
conditions is likely to be due in substantial measure to the B1 receptor’s apparent 
immunity to desensitisation.  In an important study, Proud and colleagues (1999) 
showed that the B2 receptor responds to agonist stimulation with a rapid loss of 
functional response, receptor sequestration, and ligand dissociation.  On long term 
stimulation, this receptor becomes down-regulated.  However, once B1 receptor 
expression is induced under pathological conditions, agonist stimulation of this 
receptor results in persistent signalling due to the absence of ligand dissociation and 
the failure of desensitisation and receptor sequestration to occur.  Moreover, on long 
term stimulation, the B1 receptor actually exhibits increased expression (Faussner et 
al., 1999).   Marceau and co-workers (2002) have described how inducible B1 
receptors, when stimulated by des-Arg9-kinins, are neither phosphorylated nor 
internalised upon agonist stimulation but, instead, undergo a reversible re-distribution 
to caveolae-related rafts (Marceau et al., 2002).   Calixto and colleagues (2004) 
observe that B1 receptors are apparently not subject to desensitisation and that ligand-
binding at these receptors results in sustained elevation of Ca2+ concentration (Calixto 
et al., 2004). 
 
 3.5. Bradykinin involvement in mediating inflammatory pain sensation 
       Consistent with their role as inflammogens, kinins provoke the standard features 
of the inflammatory response.  Thus, local vasodilation, exudation, and pain result 
from injection of BK into tissues (Marceau et al., 1999).   Increases in the interstitial 
levels of bradykinin and kallidin in the trapezius muscle in patients with chronic 
work-related trapezius myalgia and in patients with whiplash associated pain, when 
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compared to  healthy controls, suggest that these algesic kinins are involved in these 
forms of muscle pain (Gerdle et al., 2008).   Treatment with B1 receptor agonist at a 
dose which has no effect on withdrawal latency to a noxious heat stimulus in the case 
of a naïve rat, may result in 50 per reduction of withdrawal latency following 
exposure of one hind-paw of the rat to strong ultraviolet radiation (Perkins and Kelly, 
1993).  Following an inflammatory insult, both B1 and B2 receptors are involved in 
mediating the resulting mechanical hyperalgesia (Davis and Perkins, 1994).  Both B1 
and B2 receptors are involved in mediating formalin-induced persistent pain in mouse 
(Correa and Calixto, 1993); and both these receptors are also involved in mediating 
bradykinin-induced rat paw oedema (Campos and Calixto, 1995).  Mice lacking the 
B1 receptor are healthy, fertile and normotensive.  However, under normal non-
inflamed conditions, they are analgesic in behavioural tests of chemical and thermal 
nociception.  Moreover, B1 receptor null nice exhibit a reduction in activity-
dependent facilitation (wind-up) of nociceptive spinal reflexes (Pesquero et al., 2000).  
Substance P and capsaicin induce a mechanical hyperalgesia when injected into the 
rat knee joint.  The development of both substance P-induced, and capsaicin-induced, 
hyperalgesia is blocked by injection of a B2 receptor antagonist.  The same antagonist 
also reverses an established hyperalgesia similarly induced.  B1 receptor antagonists 
(at least in the experimental doses employed) only block the development of 
substance P-induced hyperalgesia for a short interval after administration and fail to 
reverse an established substance P-induced hyperalgesia.  However, the same B1 
receptor antagonist blocks capsaicin-induced hyperalgesia and also reverses an 
established capsaicin-induced hyperalgesia (Davis and Perkins, 1996). 
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     Kinins act at both B1 and B2 receptors at the spinal level to contribute to 
nociceptive processing and the development of inflammatory hyperalgesia.  The 
intrathecal administration of B2 receptor agonists produces dose-related thermal 
hyperalgesia, demonstrated in the hot-plate test, which is abolished by the 
administration of a B2 receptor antagonist.  The intrathecal injection of B1 receptor 
agonists also causes dose-related thermal hyperalgesia. However, this differs from 
that induced by B2 agonists in that B1 receptor agonists cause a weak, but prolonged, 
hyperalgesia.  This effect is blocked by a B1 receptor antagonist (Ferreira et al., 
2002).  In the model of inflammatory hyperalgesia constituted by injection of CFA 
into one hind-paw of rat, there is a significant increase in B1 protein expression in 
both ipsilateral and contralateral dorsal root ganglion neurons measured 24 hours after 
injection, whereas axotomy results in reduction of B1 protein in the ipsilateral doral 
root ganglia.  Intrathecal, or systemic, administration of the B1 agonist, desArg9BK, 
in the same model of inflammation, causes a marked mechanical hyperalgesia of the 
contralateral, un-inflamed, hind-paw (Fox et al., 2003).   Calixto and colleagues 
(2001) demonstrated that the B1 receptor, but not the B2 receptor, is important in 
regulating the persistent inflammatory hyperalgesia induced by CFA in mouse.   The 
role of the B2 receptor appears to be confined to a minor function in the amplification 
of the earlier stage of CFA-induced paw oedema formation.   Thus, intradermal 
injection of CFA in mouse produces time-dependent and marked hyperalgesic 
responses in both ipsilateral and contralateral paws of wild-type mice.  Ablation of the 
gene for the B1 receptor reduces the hyperalagesia in both ipsilateral and contralateral 
paws at 12 hours after injection.  However, the absence of the B2 receptor has no such 
effect.  Intradermal injection of CFA produces a time-related and long-lasting (up to 
72 hours) increase in paw volume in wild-type mice. Loss of the B1 receptor does not 
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affect this swelling.  However, the B2 receptor null mice exhibit a longer earlier stage 
of oedema development in the paw (Ferreira et al., 2001).  Bradykinin, acting at the 
B1 receptor, mediates phorbol myristate acetate (PMA)-induced nociceptive 
behaviour in mouse as evidenced by the fact that injection of PMA into the mouse 
paw results in pain behaviour which is abolished by a selective B1 receptor antagonist 
or by B1 receptor gene deletion (Ferreira et al., 2008).   
 
      B2 kinin receptors, but not B1 receptors, are involved in the normal 
physiological functioning of the of the mouse colon (Hara et al., 2007).  Studies of 
the B1 and B2 receptor activation in a mouse model of colitis show that both 
receptors are up-regulated in the context of inflammatory disease of the colon (Hara 
et al., 2007; Hara et al., 2008).  During inflammatory states of inflammatory bowel 
disease, the endotoxin level is increased.  Lipopolysaacharide promotes IL-1beta 
secretion from enteric glial cells, resulting in augmentation of the neural response to 
bradykinin through PGE(2) release via glial PLA(2) and COX-2 (Murakami et al., 
2009). 
 
           Nociceptive inputs result in the production of bradykinin in the spinal cord, 
thereby providing local activators for spinal B2 receptors (Wang et al., 2005).   Woolf 
and colleagues (2008) have found that B2 receptors are co-expressed in dorsal horn 
neurons with PKA and the delta isoform of PKC.  Augmentation by bradykinin of 
AMPA and NMDA receptor-mediated currents in lamina II neurons requires co-
activation of both PKC and PKA. The activation of PKA is downstream of COX1 
(cyclooxygenase-1), while ERK1/2 activation is involved after the PKC and PKA co-
activation.  Moreover, while intrathecal administration of bradykinin induces thermal 
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hyperalgesia in rat in vivo, inhibition of ERK, PKA and PKC diminishes such 
hyperalgesia (Kohno et al., 2008). Aspirin is a widely used analgesic, anti-thrombotic, 
and anti-inflammatory drug which alters B2 receptor ligand binding properties and 
appears to function as an allosteric inhibitor of the B2 receptor. Aspirin reduces the 
apparent affinity of the receptor for [3H]-bradykinin by accelerating the dissociation 
rate of [3H]-bradykinin-receptor complexes.  Aspirin also diminishes the ability of 
unlabelled bradykinin, or the B2 receptor antagonist, icatibant, to destabilise pre-
formed [3H]-bradykinin-receptor complexes (Gardes et al., 2008). 
 
       Metabotropic glutamate receptors, mGluRs, more specifically of subtype-5, are 
involved in the nociceptive response induced by intrathecal  injection of excitatory 
aminoacids, substance P, bradykinin, and cytokinesSP, BK and cytokines in mice 
(Jesse et al., 2008).   Studies in human retinal  pigment epithelial (ARPE) cells show 
that bradykinin stimulates glutamate uptake as well as the mRNA expression of 
excitatory amino acid transporter 4 (EAAT4) and excitatory amino acid carrier 1 
(EAAC1), which is blocked by treatment with B1 and B2  receptor siRNA, suggesting 
a role of B1 and B2 receptors.  The application of various additional antagonists 
shows that glutamate uptake is stimulated by bradykinin through a PKC-Akt-COX-2 
signalling cascade in ARPE cells (Lim et al., 2008). 
 
2.2.6.   Bradykinin involvement in mediating neuropathic pain sensation 
     B1 receptor activation appears to be an important component in the development 
of neuropathic pain.   Thus, partial sciatic nerve ligation induces an up-regulation of 
B1 receptor mRNA in the ipsilateral paw, sciatic nerve, and spinal cord of wild-type 
mice. While the paw-withdrawal responses to thermal, or mechanical, stimulation do 
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not differ between B1 receptor-null mice and wild-type mice in the absence of 
neuropathy, yet partial ligation of the sciatic nerve in the wild-type mouse produces a 
profound and long-lasting decrease in thermal and mechanical thresholds in the paw 
ipsilateral to the nerve lesion (Ferreira et al., 2005).   B1 and B2 receptor-mediated 
mechanisms have been found to contribute significantly to the maintenance of hind-
paw cold and mechanical allodynia and thermal hyperalgesia induced by L5/L6 spinal 
nerve ligation in rats (Werner et al., 2007).   Treatment with a selective B1 receptor 
antagonist generally does not affect basal nociception in normal rats, whereas it 
induces a significant time-dependent and dose-dependent attenuation of hyperalgesia, 
or even restores nociceptive responses, in experimental diabetic neuropathy models.  
Again, diabetic hyperalgesia is absent in streptozotocin-induced type 1 diabetic 
knockout mice which lack the B1 receptor (Gabra et al., 2005a, 2005b, 2006).   B1 
and TRPV-1 receptor genes are over-expressed in the injured spinal cord of animals 
manifesting thermal hyperalgesia following experimental spinal cord injury compared 
with similarly injured animals without hyperalgesia (DomBourian et al., 2006).  
Thermal heat hyperalgesia resulting from experimental spinal cord injury is reduced 
by the administration of either a TRPV1 ion channel antagonist or a B1 receptor 
antagonist (Rajpal et al., 2007).  The B1 receptor has also been shown to be important 
in mediating neuropathic pain-like behaviour in a mouse-model of brachial plexus 
avulsion (Quintao et al., 2008). 
 
     NGF, and to a lesser extent GDNF, up-regulates the expression of B2 receptors in 
mouse DRG neurones in vitro;  and NGF is an important factor in up-regulating B2 
receptor expression after nerve crush injury in mouse in vivo (Lee et al., 2002). 
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2.2.7. Mechanisms by which kinins mediate pain sensation 
    Bradykinin is a potent activator of primary afferents (Higashi et al., 1983; Oh and 
Weinreich, 2004).  Bradykinin decreases K+ and increases Ca2+-activated Cl- 
conductances in guinea pig vagal afferent neurones (Oh et al., 2004). Bradykinin also 
inhibits the transient outward K+ current in mouse Schwann cells by cAMP/PKA-
dependent pathways via activation of B2 receptors (Zhang et al., 2009). Bradykinin 
and ATP facilitate the removal of action potential-induced Ca2+ loads by accelerating 
Ca2+  efflux from rat sensory neurons via protein kinase C and the plasma membrane 
Ca2+  pump isoform 4 (Usachev et al., 2002).   In wild-type mice, intraplantar 
bradykinin injection produces immediate licking and flinching and a later decrease in 
mechanical threshold and hot-plate latency.  However, in mice which lack the Nav1.9 
channel (which is present in TRPV1-expressing primary sensory neurons), the pain 
hypersensitivity elicited by bradykinin is reduced, while basal thermal and mechanical 
pain sensitivity remains unchanged (Amaya et al., 2006).  Bradykinin also has 
important effects on TRPV1 and TRPA1 ion channels leading to nociceptive 
responses by primary sensory afferents. It seems unlikely, however, that bradykinin-
evoked nociception  is dependent only on its activation of  TRPV1 and TRPA1, and it 
is likely that further ionic mechanisms are involved in mediating the excitatory effect 
of bradykinin on primary afferents (Katanosaka et al., 2008).   
 
      However, the intracellular messenger sequences initiated by B1 and B2 receptors 
remain to be comprehensively elucidated.  Bradykinin stimulates the synthesis of 
inositol trisphosphate (IP3) and the breakdown of phosphatidylinositol bisphosphate, 
the synthesis of diacylglycerol, and the release of arachidonic acid from rat dorsal root 
ganglion neurones in vitro. Bradykinin also mobilises intracellular Ca2+ stores in rat 
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DRG cells from stores which are distributed equally between the cell soma and cell 
processes (Thayer et al., 1988).  Bradykinin stimulates B2 receptors in rat dorsal root 
ganglion neurones to activate phospholipase C and occasion subsequent Ca2+ release 
which, in turn, triggers calcineurin-dependent NFAT (nuclear factor of activated T-
cells) translocation to the nucleus and subsequent NFAT-dependent transcription.  
Activation of this cascade leads to increases in mRNA for cyclooxygenase-2 (Jackson 
et al., 2007). 
 
    Complex mechanism mediate the effect of bradykinin on the activation of  TRPV1 
ion channels. Bradykinin lowers the threshold temperature for heat activation of 
TRPV1 to below physiological body temperature (Sugiura et al., 2002). Bradykinin 
activates protein kinase C-epsilon (PKC-e) to enhance the activity of TRPV1 ion 
channels in primary sensory neurones. PKC-epsilon is translocated to the cell 
membrane by bradykinin. The TRPV1 ion channels become sensitised when 
constitutively active PKC-epsilon is incorporated into nociceptive neurons. 
Conversely, bradykinin-induced sensitisation is suppressed by a specific peptide 
inhibitor of PKC-epsilon (Cesare et al., 1999).   In addition, B2 receptors are activated 
by bradykinin to, in turn, activate an intracellular second messenger pathway 
involving mobilisation of arachidonic acid by phospholipase A2, and generation of 
the 12-lypoxygenase product, 12-HPETE, which is capable of activating TRPV1.  
Bradykinin-induced thermal hyperalgesia is completely blocked by an inhibitor of 12-
lipoxygenase (Shin et al., 2002).  Again, bradykinin-mediated potentiation of thermal 
sensitivity in vivo requires expression of TRPV1 on primary sensory neurones. 
Diminution of plasma membrane phophatidylinositol-4,5-bisphosphate levels, through 
antibody-sequestration or PLC-mediated hydrolysis, mimics the potentiating effects 
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of bradykinin at the cellular level (Chuang et al., 2001).   Moreover, bradykinin, 
through its B2 receptor, activates phospholipase C and cyclooxygenase-1. The B2 
receptor facilitates non-selective Ca2+ channel activity, thereby increasing the 
intracellular Ca2+ concentration from the extracellular pool, leading to sensitisation of 
TRPV1 (Tang et al., 2004).   In addition, a three hour treatment with bradykinin 
potentiates capsaicin-induced substance P release in cultured rat dorsal root ganglion 
neurones and also induces cyclooxygenase 2.  This potentiation of substance P release 
by bradykinin can be reversed by administration of either a PKA inhibitor or a CB1 
receptor agonist (Oshita et al., 2005).  Bradykinin-evoked substance P release from 
cultured rat DRG neurones is attenuated by either a mitogen-activated protein kinase 
kinase (MEK) inhibitor or cycloheximide, which is an inhibitor of protein 
biosynthesis.  However, while the long-term exposure of such neurones to bradykinin 
enhances substance P release induced by capsaicin, it attenuates substance P release 
induced by potassium (Tang et al., 2006).  
    
    The scaffolding protein AKAP79/150 is proposed to be essential in the formation 
of a signalling complex between several enzymes and TRPV1.  The enzymes in 
question are the protein kinases, PKA and PKC, and the phosphatase, calcineurin. 
Modulation of the sensitivity of TRPV1 by PKA, PKC and calcineurin depends on the 
formation of this signalling complex between these enzymes, this scaffolding protein 
and TRPV1.   A region in the C-terminal of TRPV1 is involved in the binding of this 
scaffolding protein.  Failure of binding of this scaffolding protein, abolishes 
sensitization of TRPV1 by both bradykinin and PGE(2) (Zhang et al., 2008). 
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     Bradykinin has recently been proposed to be also capable of potentiating the 
activation of the TRPA1 ion channel which is an important component of the 
transduction machinery through which environmental irritants and endogenous pro-
algesic agents depolarise nociceptors to elicit inflammatory pain sensations (Wang et 
al., 2008).    TRPA1 can, in fact, be activated by bradykinin. TRPA1 knockout mice 
show impaired responses to bradykinin and impairment of mechanical nociception.  
TRPA1 contributes to bradykin-induced visceral mechanical hypersensitivity (Yu 
and Ouyang, 2009). 
 
 2.2.8. Bradykinin in brain 
     An action of bradykinin on the activity of neurons in the brain may be relevant in 
when considering the effect in terms of pain sensations resulting from nociceptive 
inputs consequent on peripheral inflammation.  This is because the electrical signal 
generated by the excitation of primary afferents by inflammatory mediators may be 
modulated by an effect of bradykinin in the brain.  Thus, bradykinin, when introduced 
into certain brain areas, produces an anti-nociceptive effect. Thus, the microinjection 
of bradykinin into the lateral or fourth cerebral ventricles induces an antinociceptive 
effect, and to a lesser extent the third ventricle.  The locus coeruleus, the principal 
nucleus, the oral part of the spinal sensorial trigeminal nucleus, and the sensory root 
of the trigeminal nerve, have been identified as brain sites where microinjection of 
bradykinin causes an anti-nociceptive effect. The antinociceptive effect is more 
intense when bradykinin is injected into the locus coeruleus (Couto et al., 1998, 
2006).   Thr6-bradykinin (Thr6-BK) is the active peptide in the venom of the social 
wasp, Polybia occidendalis.   Injection of this peptide into the lateral ventricle of 
naive rats reduces noxious heat-evoked responses both in tail-flick and hot plate tests. 
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This Thr6-BK-evoked anti-nociceptive effect is mediated through B2 receptors, and is 
superior to, or comparable with, the anti-nociceptive effects produced by 
intracerebroventricular injection of bradykinin, or morphine, respectively (Mortari et 
al., 2007).   The powerful antinociceptive effect of Thr6-BK, and, indeed, of 
bradykinin itself, when administered intraventricularly, appears to be profoundly 
paradoxical in the context of the established role of bradykinin in contributing to 
peripheral pain.  The additional finding that Thr6-BK and bradykinin may, on central 
administration, actually reduce noxious heat-evoked behavioural responses appears 
even more contradictory, because bradykinin contributes to the development of heat 
hyperalgesia in the periphery.   However, the paradox is illusory.  There is nothing in 
the kinin peptides which is specific to pain induction.  On the contrary, everything 
depends on the localisation of their receptors and the functions subserved by the 
neruons which the bradykinin receptors serve to excite.  
 
     Bradykinin selectively transiently increases the permeability of the blood-brain 
barrier (BBB). This bradykinin-mediated increase in BBB permeability is due to 
accelerated formation of adenosine 5'-triphosphate-sensitive potassium channels 
(Zhang H et al., 2007).  Bradykinin receptors are expressed in all major cell types in 
the brain, and migration of microglia to a site of injury in the brain is mediated by B1 
receptors (Ifuku et al., 2007).    Kinins mediate apparently contradictory effects in the 
brain.   Administration of bradykinin into the right amygdala of adult male rats 
induces thermal hyperalgesia in the animals (Dalmolin et al., 2007).   However, apart 
from this instance of kinins acting to increase nociception, in other cases they act in 
the brain to mediate an anti-inflammatory response, or even induce analgesia.   
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       Bradykinin may exercise anti-inflammatory and neuroprotective effects in the 
central nervous system by modulating microglial function. In cultured mouse 
microglia, BK induces mobilisation of intracellular Ca2+, microglial migration, and 
increases the release of NO and PGE2, in addition to attenuating lipopolysaacharide-
activated TNF-alpha and Il-1beta release (Noda et al., 2006).   The action of 
bradykinin in attenuating lipopolysaccharide-induced release of TNF-alpha and IL-
1beta from microglial cells is anti-inflammatory in nature.  However, bradykinin also 
enhances formation of PGE2 and expression of microsomal prostaglandin E synthase. 
Expression of bradykinin receptors and EP2/EP4 receptors are also enhanced (Noda et 
al., 2007).  Kinins appear to influence prostaglandin synthesis in brain inflammation 
in an apparently regulated manner. Thus, bradykinin, a B2 receptor agonist, enhances 
both basal and lipopolysaccharide-induced PGE2 synthesis in rat neonatal glial cells 
in culture, whereas administration of a B1 receptor agonist attenuates both basal and 
lipopolysaacharide-induced production of PGE2 in glia (Levant et al., 2006). 
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2.3. EICOSANOIDS 
2.3.1.  Introduction 
    The term "ecosanoids" refers to the originating 20-carbon unsaturated fatty acid 
from which a family of lipid messengers are derived, “eikosi” meaning “twenty” in 
Greek.  The principal such substrate is arachidonic acid.  Hence, the eicosanoids are 
commonly referred to as “arachidonic acid-derived” lipid messengers.  These 
bioactive lipid messengers are not constitutively expressed in tissues and must be 
generated de novo in response to appropriate stimuli.  Free arachidonic acid is not 
available in cells but is found esterified in the cell’s membrane phospholipids.  Many 
physiological and pathological stimuli, including general cell damage, can result in 
the release of arachidonic acid from membrane phospholipids either by an action of 
phospholipase A2 (PLA2) or an action of phospholipase C (PLC) followed by an 
action of diacylglycerol lipase.   The biochemistry of eicosanoid production is 
complex, with several pathways being available for the synthesis of these mediators 
from arachidonic acid.  The two pathways which have been most studied are those in 
which a cyclooxgenase enzyme, or a 5-lipoxygenase enzyme, initiates the process of 
synthesis.  In both of these pathways, the initiating oxygenase catalyzes the synthesis 
of an unstable intermediate which is subsequently acted upon by other enzymes 
(Brock and Peters-Golden, 2007).   Eicosanoids have important homeostatic functions 
in physiology which should not be overlooked (Harizi et al., 2008), especially in 
relation to neural function (Tassoni et al., 2008).  Indeed, their association with 
inflammation and pain is essentially secondary to their physiological functions. The 
principal members of the eicosanoid family are: the prostanoids; the leukotrienes; and 
platelet activating factor. 
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2.3.2.  Prostanoids: PGE2; PGI2; TxA2 
     The prostanoids include the prostaglandins (PGE2, PGF2alpha, PGD2, PGJ2), 
prostacyclin (PGI2),  and thromboxane A2 (TxA2).   Bioactive prostanoids derived 
from arachidonic acid are of two classes, designated “stable” and “labile,” 
respectively.  Stable prostanoids include the stable prostaglandins, such as PGE2, 
PGF2alpha, PGD2 and PGJ2.  The labile prostanoids include the PG endoperoxides 
(PGG2, PGH2), TxA2, and prostacyclin (PGI2).  TXA2 has a half-life of only 30 
seconds at 37 degrees C.  It produced mostly by blood platelets and possesses 
powerful vasoconstrictor, cytotoxic and thrombogenic properties (Gryglewski, 2008).  
However, unlike other prostanoids, it is not yet noted to be of importance in relation 
to inflammatory pain and will not receive further consideration here.  
 
      The prostanoids are a group of bioactive lipids which work as local mediators, 
exerting their actions on other cells near their cell of synthesis.  Prostanoids are 
typically described as being the products of a “cyclooxygenase pathway,” they are 
formed by the action of a cycloxygenase enzyme on arachidonic acid. The receptors 
which mediate the actions of prostanoids are G protein-coupled receptors with seven 
transmembrane domains. Eight types and subtypes of prostanoid receptors, which are 
encoded by different genes, have been identified.  Together, these receptors constitute 
a sub-family in the super-family of the rhodopsin-type receptors (Narumiya et al., 
1999).  
 
     There are two cyclooxygenase (COX) enzymes, namely, COX-1 and COX-2.  
Either of these enzymes can initiate the biosynthesis of both prostaglandins and 
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thromboxanes from free arachadonic acid within the cell.  COX-1 is constitutively 
expressed in most tissues; and the prostanoids which it produces are most likely 
involved in normal homeostasis.  Hence, the non-steroidal anti-inflammatory drugs 
(NSAIDs), such as aspirin and ibuprofen, which inhibit both COX-1 and COX-2 have 
harmful side-effects with extensive use which are thought to be due to inhibition of 
COX-1.   It was formerly assumed that COX-2 was an inducible enzyme only, with 
no house-keeping functions in normal human physiology  and only producing harmful 
prostanoids in inflammatory conditions.  Hence, drugs were developed which would 
target the COX-2 enzyme exclusively, thereby eliminating the effects of these harmful 
prostanoids believed to be emanating from the action of COX-2.  Unfortunately, 
although specific inhibitors of COX-2 have been developed, it has transpired that 
COX-2 is also constitutively expressed in certain tissues, with the result that these 
inhibitors may affect the homeostatic functions served by these enzymes in the tissues 
where they are constitutively produced.    In tissues where the COX-2 enzyme is not 
constitutively expressed, this enzyme is induced by an inflammatory stimulus to 
produce pathological prostanoids (Brock and Peters-Golden, 2007; Lin et al., 2006).  
Thus, COX-2 induction leads to a shift in arachidonic acid metabolism from the 
production of several prostanoids with diverse effects as mediated by COX-1 to the 
preferential synthesis of two prostanoids, prostacyclin and prostaglandin E2 (Brock et 
al., 1999).   COX-1 and COX-2 are found both in the dorsal root ganglia and in the 
spinal cord (Inoue et al., 2006; Ebersberger et al., 1999; Beiche et al., 1998;  Goppelt-
Struebe and Beiche, 1992).  Moreover, COX-2 is up-regulated in the dorsal root 
ganglia and in the spinal cord during peripheral inflammation (Goppelt-Struebe and 
Beiche, 1997; Beiche et al., 1998; Ebersberger et al., 1999; Inoue et al., 2006).   
        
 66 
2.3.2.1.   Prostaglandin-E2 (PGE2) 
       COX-1 and COX-2 catalyze the formation of prostaglandin H2 (PGH2) from 
arachidonic acid.  Three different prostaglandin E synthases (PGE synthases) then act 
on PGH2 to transform it into PGE2. Two of these PGE synthases are membrane-
bound (mPGES-1 and mPEGES-2), while the third is found in the cytosol (cPEGES).   
cPGES acts on PGH2 derived from the action of COX-1, while mPEGES-1 uses 
PGH2 endoperoxidase derived from the action of COX-2.  m-PEGES-2 uses both 
these substrates. mPEGES 1 is mainly an induced enzyme, whereas the other two 
PGE synthases are constitutively expressed.  mPEGES-1 is also glutathione-
dependent. The availability of this PGE synthase is increased, as is that of COX-2, in 
response to various pro-inflammatory stimuli, but this increase is in both these 
enzymes is reversed by glucorticoids  (Samuelsson et al., 2007). Glutathione is found 
to bind in a U-shaped conformation at the interface between sub-units in the protein 
trimer. The glutathione is exposed to a site facing the lipid bilayer which forms the 
specific environment for the oxidoreduction of PGH2 to PGE2 after displacement of 
the cytoplasmic half of the N-terminal transmembrane helix (Jegerschold et al., 2008). 
.   
       PGE2 may be induced in both dorsal root ganglia and in the spinal cord (Inoue et 
al., 2006; Ebersberger et al., 1999).  PGE2 mediates its effects by binding to four G 
protein-coupled receptors, denominated EP1, EP2, EP3, and EP4, each of which 
shows selective ligand-binding specificity which distinguishes it from the others 
(Narumiya et al., 1999; Lin et al., 2006).  In addition, at least four isoforms of the EP3 
receptor exist.  These EP3 isoforms, which differ only at their C-terminal tails and are 
produced by alternative splicing, couple to different G proteins to activate different 
second messenger systems (Namba et al., 1993).     
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2.3.2.1.1.   PGE2 contributes to inflammatory pain 
      PGE2 generally exerts a pro-nociceptive effect, being capable of exciting primary 
sensory neurons. Infusion of PGE2 into healthy human subjects induces headaches in 
those subjects (Wienecke et al., 2009).   The importance of PGE2 as a mediator of 
pain in humans is evidenced by the fact that NSAIDs, which inhibit the production of 
PGE2, are the most widely used analgesic drugs in clinical practice.  An injection of 
PGE2 into the mouse paw results in oedema formation which is mediated by EP3 
receptor activation, and also involves the stimulation of PLC, PKC, and MAPKs 
pathways and the participation of TRPV1 and NK1 receptors (Claudino et al., 2006).   
Moreover, PGE2 enhances the sensitivity of sensory neurons to various forms of 
noxious stimulation, in part, by the suppression of a delayed rectifier-like potassium 
current in these neurons (Jiang et al., 2003; Evans et al., 1999).  PGE2 can also 
potentiate nociceptor activation by protons in human skin and muscle.  Intradermal 
injections of PGE2 into the forearm skin, or intramuscular injections of PGE2 into the 
anterior tibial muscle, induces only very low levels of pain similar to injection of 
saline.    Administration of low pH causes moderate pain within 5 seconds which 
declines rapidly over 15 to 20 seconds.   However, co-injection of low pH with PGE2 
leads to a biphasic pain response, with no increase in pain immediately after co-
injection, but with significantly increased pain in the second phase, from 20 to 100 
seconds, both in skin and muscle, with muscle pain being less than skin pain in the 
initial phase, but greater in the second phase (Rukwied et al., 2007).   
 
     Several receptor subtypes are involved in mediating the sensation of inflammatory 
pain.  Thus, the EP4 receptor subtype is expressed by a subset of dorsal root ganglion 
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(DRG) neurons, and its levels, but not the levels of the other EP1-3 subtypes, increase 
in the DRG after CFA-induced peripheral inflammation in rat. Administration of both 
an EP4 antagonist and EP4 knock-down attenuates inflammation-induced thermal and 
mechanical behavioural hypersensitivity, without changing basal pain sensitivity. The 
EP4 antagonist also reduces the PGE(2)-mediated sensitisation of capsaicin-evoked 
currents in DRG neurons in vitro (Lin et al., 2006).  
  
   Spinal EP3 receptors are involved in hyperalgesia induced in mice by a low dose of 
PGE2, while spinal EP1 receptors are involved in allodynia in mice induced by PGE2 
(Minami et al., 2001). Intraspinal release of PGE2 occurs during peripheral 
inflammation (Ebersberger et al., 1999).  Spinal application of agonists at EP1, EP2, 
and EP4 receptors in nociceptive dorsal horn neurons, having their main input from 
the knee joint in rat, result in spinal hyperexcitability in the absence of inflammation 
which is similar to that resulting from PGE2 application.  The effect of spinal EP 
receptor activation changes during joint inflammation. When the knee joint is 
inflamed for 7-11 hours, only activation of the EP1 receptor causes additional 
facilitation, whereas spinal application of EP2 and EP4 receptor agonists has no 
effect. However, an EP3-alpha receptor agonist reduces responses to mechanical 
stimulation. The EP3-alpha agonist also attenuates spinal hyperexcitability induced by 
spinal PGE2 (Bar et al., 2004).   
 
     PGE2 contributes to the pathogenesis of rheumatoid arthritis by its action on the 
EP4 receptor.  Homozygous deletion of the EP1, EP2, or EP3 receptors does not 
affect the development of arthritis in a mouse model of the disease, whereas EP4 
receptor-deficient mice show decreased incidence and severity of disease. These 
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animals also show reduced inflammation, as assessed by circulating IL-6 and serum 
amyloid A levels, reduced bone destruction, proteoglycan loss, and type II collagen 
breakdown in cartilage, when compared with EP4(+/+) mice (McCoy et al., 2002).   
PGE2 enhances dendritic cell-derived IL-6 production and induces a shift in the IL-
23/IL-12 balance in favour of IL-23 in a mouse model of rheumatoid arthritis, 
resulting in increased IL-17 production and exacerbation of collagen-induced arthritis 
in mice (Sheibanie et al., 2007). PGE2, acting through EP receptors, controls human 
adult articular cartilage homeostasis and is linked to the pathophysiology of 
osteoarthritis (Li et al., 2009). 
 
     When dorsal root ganglia cultures are treated with the pro-inflammatory cytokines 
tumour necrosis factor alpha (TNF-alpha) or interleukin-1beta (IL-1beta) for 24 
hours, COX-2 expression and PGE2 production is increased.  The increase in PGE2 
production is blocked by pre-treatment with a COX-2 inhibitor. At the same time, 
exposing these cultures to PGE2, or to either of these cytokines, does not alter EP 
receptor mRNA levels.  Thus, these cytokines induce the functional expression of 
COX-2, but not EP receptors, in dorsal root ganglia cells in culture, which suggests 
that cytokine-induced sensitisation of sensory neurons is secondary to prostaglandin 
production and not to alterations in EP receptors (Fehrenbacher et al., 2005).   The 
EP4 receptor appears to be mainly involved in the inhibition of cytokine release in 
C3H/HeN peritoneal macrophages, and gene expression of EP2 and EP4 appears to be 
differentially regulated during macrophage activation (Ikegami et al., 2001).         
 
    Prostaglandin D2 (PGD2) is known to be involved in inflammatory diseases like 
allergy and asthma.  PGD2 acts through two seven-transmembrane receptors, DP 
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(DP1) and CRTH2 (DP2), which are also activated by several endogenous metabolites 
from the arachidonic acid cascade (Ulven & Kostenis, 2006).  However, topical 
application of PGD2 to the spinal cord of the rat appears to attenuate spinal 
hyperexcitability under inflammatory conditions.  Thus, in rats with inflamed knee 
joints,  either PGD2 or a DP1 receptor agonist decreases the responses to mechanical 
stimulation of the inflamed knee and the non-inflamed ankle, thereby reducing 
established inflammation-evoked spinal hyperexcitability. Again, spinal co-
application of PGD2 with PGE2 attenuates the PGE2-induced facilitation of responses 
to mechanical stimulation of the rat knee joint (Telleria-Diaz et al.). 
 
2.3.2.2.   Prostaglandin-I2 (PGI2; Prostacyclin)  
     Prostaglandin-I2 (PGI2) is also known as "prostacyclin."  Prostacyclin has a half-
life of 4 minutes at 37 degrees C.   It is synthesised in the blood vessel wall (mainly 
by the endothelium).  It has a range of important physiological actions, including 
acting as a physiological antagonist of TxA2. It exerts its effect through activation of 
adenylate cyclase, followed by an intracellular accumulation of cyclic-AMP in 
various types of cells, and is important in cell protection (Gryglewski, 2008).  It is 
also an important inflammatory agent. 
 
2.3.2.2.1.  Prostacyclin contributes to inflammatory pain 
       Prostacyclin acts synergistically with other inflammatory mediators, such as 
histamine and bradykinin. It mediates its effects by binding to IP receptors.  Infusion 
of prostacyclin into healthy human subjects induces headache associated with 
dilatation of the superficial temporal artery (Wienecke et al., 2008).  Mice which lack 
the prostacyclin receptor are found to be viable, reproductive and normotensive. 
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However, their susceptibility to thrombosis is increased, and their inflammatory and 
pain responses are reduced to the levels observed in indomethacin-treated wild-type 
mice. Thus, prostacyclin is an antithrombotic agent and has a role as a mediator of 
inflammation and pain (Murata et al., 1997).  PGI2 is also implicated as a mediator of 
chronic inflammation.  In a rat model of osteoarthritis, using monoiodoacetate 
injection into the knee joint, an IP antagonist reduces pain with an efficacy 
approaching that of the NSAID diclofenac. In a chronic model of rheumatoid (i.e., 
inflammatory) arthritis -- namely, the collagen-antibody induced arthritis model in 
mice -- IP receptor-deficient mice display a 91% reduction in arthritis score. In fact, 
the development of inflammation in CIA, is not dependent on any single EP receptor 
type, although a partial suppression of CIA is achieved by the combined inhibition of 
EP2 and EP4.    Thus, it appears that inhibition of PGI(2) synthesis by NSAIDs and 
COX-2 inhibitors, in addition to their inhibition of PGE(2) synthesis, contributes to 
their efficacy in treating the signs of arthritis (Pulichino et al., 2006; Honda et al., 
2006).  It should also be noted that both PGI2 and PGE2 are abundantly present in the 
synovial fluid of rheumatoid arthritis patients. Mice lacking the PGI2 receptor, when 
subjected to collagen-induced arthritis (CIA), also show significant reduction in the 
levels of pro-inflammatory cytokines, such as interleukin-6, in arthritic paws, while 
the addition of an IP agonist to cultured synovial fibroblasts significantly enhances 
IL-6 production and induces expression of other arthritis-related genes.  Thus, both 
PGI2-IP and PGE2-EP2/EP4 signalling are important in the development of CIA, and 
inhibition of PGE2 synthesis alone may not be sufficient for suppression of symptoms 
of rheumatoid arthritis (Honda et al., 2006).    
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2.3.2.3.  Excitation of dorsal root ganglion and spinal cord by PGE2 and PGI2 
       Prostaglandins released in the dorsal root ganglia excite those neurons by 
lowering the threshold for activation by heat of TRPV1 ion channels.  PGE2 and 
PGI2 each, individually, increase, or sensitise, TRPV1 responses through their 
respective EP1 or IP receptors, predominantly in a PKC-dependent manner in both 
HEK293 cells expressing TRPV1 and in mouse DRG neurones. In the presence of 
PGE2 or PGI2, the temperature threshold for TRPV1 activation is reduced below 35 
degrees C, so that body temperature itself is sufficient to activate TRPV1, resulting in  
the phenomenon of spontaneous pain sensations.  A PKA-dependent pathway is also 
involved in the potentiation of TRPV1 through EP4 and IP receptors upon exposure to 
PGE2 and PGI2, respectively. In TRPV1 null mice and EP1 null mice, both PGE2-
induced thermal hyperalgesia and inflammatory nociceptive responses are diminished.  
Moreover, PGI2-induced thermal hyperalgesia observed in wild type mice is almost 
completely absent in both TRPV1 null mice and IP null mice (Moriyama et al., 2005). 
ATP-sensitive potassium currents reduce the PGE2-mediated enhancement of 
excitability in adult rat sensory neurons. Thus, activation of K(ATP) can reverse the 
sensitisation produced by PGE(2) and may provide a mechanism of reducing the 
enhanced excitability that results from inflammation (Chi et al., 2007).    
 
      Synthesis of prostaglandins by spinal dorsal horn neurons is important for the 
induction and initial expression, but not for the maintenance, of spinal cord 
hyperexcitability. Spinal PGE2 application facilitates dorsal horn neuronal firing 
elicited by ionophoretic delivery of NMDA, suggesting that an interaction of 
prostaglandins and NMDA receptors may contribute to inflammation-induced central 
sensitisation. However, after development of inflammation, spinal indomethacin fails 
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to reduce responses to ionophoretic delivery of NMDA or AMPA, suggesting that 
such an interaction is not required for the maintenance of central sensitisation 
(Vasquez et al., 2001).   
 
2.3.3.  Platelet-activating factor (PAF) 
     Platelet-activating factor (PAF) describes a family of structurally-related lipid 
messengers which act on a wide variety of targets.  Two major pathways for the 
production of these lipids have been described.   One involves the production of PAF 
by an action of a PAF-phosphocholine transferase on CDP-choline and 
alkylacetylglycerol.   The other involves an action of a lyso-PAF AT enzyme on lyso-
PAF which results from an action of acetyl CoA and PLA2 (Teather et al., 2002a;  
Snyder, 1995).   This latter pathway was believed to synthesise PAF under 
inflammatory conditions.   However, it is now known that there are two types of lyso-
PAF AT enzymes: one (lysoPAFAT/LPCAT2) is inducible and activated by 
inflammatory stimulation;  and the other (LPCAT1) is constitutively expressed.  Each 
lyso-PAF-AT synthesises inflammatory and physiological amounts of PAF, 
depending on the cell type (Harayama et al., 2008). 
 
       PAF has many different functions.  It appears to be involved in polymorphonucler 
leuckcoyte recruitment to dermal inflammatory sites in rats (Belanger et al., 2008).  It 
also functions in relation to bone metabolism and disease (Hikiji et al., 2008), and is 
an important mediator of anaphylaxis in animals such that interventions that block 
PAF can prevent fatal anaphylaxis (Vadas et al., 2008).  The human PAF receptor 
(PAFR) is a G-protein-coupled receptor.  After stimulation, this receptor is rapidly 
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desensitised. This refractory period depends on receptor phosphorylation, 
internalization and down-regulation (Dupre et al, 2007).   
 
2.3.3.1.  PAF contributes to inflammatory pain 
      PAF is an important mediator for inflammation. A receptor for PAF is found on 
the plasma membrane but, in addition, it has intracellular microsomal binding sites.   
The nociceptive responses in the late, but not the early, phase of formalin-induced 
nociception in rat is significantly reduced in animals receiving systemic PAF 
antagonists (Teather et al., 2002b).   Morita and colleagues (2004) found that both 
thermal hyperalgesia and tactile allodynia are induced in mice by intrathecally 
administered platelet-activating factor (Morita et al., 2004).  Inoue and co-workers 
found that PAF-receptor null mice display almost normal responses to thermal and 
mechanical stimuli.  However, these mice exhibit attenuated persistent pain 
behaviours resulting from tissue injury by locally injecting formalin at the periphery, 
or resulting from capsaicin application, or from visceral inflammatory pain (Tsuda et 
al., 2007a).   Inhibition of PAF receptors in hippocampal plasma membranes 
attenuates the inflammatory nociceptive response in rats, but intracellular  PAF 
binding sites do not appear to be involved in processing inflammatory pain sensations 
(Teather et al., 2006).   Injection into the rat paw of platelet-activating factor (1-30 
nM per paw) results in a dose-related overt nociception, but only the dose of 10 nM 
per paw results in a significant and time-related mechanical hypersensitivity.   
Distinct mechanisms appear to be involved in the spontaneous nociception and the 
mechanical hypersensitivity caused by platelet-activating factor (Moretta et al., 2009).                              
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2.3.4.   Leukotrienes  
    Leukotrienes are metabolites of arachidonic acid which are produced by the 
lipoxygenase pathways.  5-Lipoxygenase acts on arachidonic acid to give 5-
hydroperoxyeicosatetraenoic acid (5-HPETE), which is converted to leukotriene A4.  
This, in turn, can be converted to either leukotriene B4 (LTB4) or to a series of 
cysteinyl-leukotrienes which have amino acids incorporated in their structure 
(Murphy and Gigon, 2007).  Leukotriene B4 acts through its receptors, BLT1 and 
BLT2. Both receptors are G protein-coupled seven transmembrane domain receptors.  
However, the two receptors differ in their affinity and specificity for LTB4 and also in 
their patterns of expression.  Thus, BLT1 is a high-affinity receptor specific for LTB4, 
whereas BLT2 is a low-affinity receptor that also binds other eicosanoids.  Again, the 
two receptors also differ in their pattern of expression.  Thus, BLT1 is expressed 
primarily in leukocytes, whereas BLT2 is more widely expressed  (Tager and Luster, 
2003). 
 
2.3.4.1.     LTB4 contributes to inflammatory pain 
      LTB4 is known to be an important inflammatory mediator, but the nature and 
extent of its contribution to inflammatory pain is not settled.   There is evidence of 
LTB4 involvement in rheumatoid arthritis in mice (Chen et al., 2006;  Grespan et al., 
2008), yet treatment of patients with active rheumatoid arthritis with a potent oral, 
long-acting, LTB4 receptor antagonist produces only modest improvements in disease 
activity, suggesting that LTB4 is not a major contributor to the inflammatory process 
in this disease (Diaz-Gonzalez et al., 2007).  On the other hand, after intracutaneous 
infiltration in humans of LTB4 (10 uM) a significant decrease in the pain threshold on 
exposure to heat can be detected as compared with controls, with a maximum effect 
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between 6 and 24 hours after injection (Bisgaard et al., 1985).   In the hyperalgesia 
induced by application of nucleus pulposus to the lumbar nerve root in the rat, an 
LTB4 antagonist injected into the epidural space decreases mechanical hyperalgesia at 
both three and seven days after epidural injection, but has no significant effect on 
sensitivity to noxious thermal stimuli (Kawakami et al., 2001).  Joint injection of 
LTB4 induces a dose-dependent articular hypernociception (Guerrero et al., 2008).   
Importantly, several products of lipoxygenases, including LTB4, have been shown to 
directly activate TRPV1 in isolated membrane patches of rat sensory neurons (Hwang 
et al., 2000). 
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2.4. NERVE GROWTH FACTOR (NGF) 
2.4.1.  Introduction 
     Nerve growth factor (NGF) was initially identified as a molecule that promotes the 
survival and differentiation of sensory and sympathetic neurons.  NGF has two known 
cell-surface receptors, TrkA and p75.   TrkA is a receptor with tyrosine kinase activity 
that forms a high-affinity binding site for NGF.  The ligand-binding domain of TrkA 
consists of two patches, one of which is specific for the interaction between NGF and 
TrkA (Wiesmann et al., 1999).  Recently, the p75 receptor has also been found to be 
associated with inflammatory thermal hypersensitivity.  Pro-NGF is the dominant 
ligand of the p75 receptor in vivo; and both pro-NGF and mature NGF play an 
important roles in inflammation-induced hyperalgesia mediated through the p75 
receptor (Watanabe et al., 2008). 
  
     The functions of NGF in neural development have been characterised extensively, 
but recent studies indicate that its role in development is only one of several 
biological actions of NGF.  In particular, NGF constitutes an important inflammatory 
mediator and is an important component in the process of sensitisation of TRPV1 ion 
channels in primary sensory neurons.    
 
2.4.2. NGF production in inflammation 
     NGF is produced by a variety of cells in the context of inflammation.  Monocytes, 
produce, store and release NGF, BDNF and NT-3 (Rost et al., 2005); as do 
eosinophils (Noga et al., 2003). Mast cells also synthesise, store and release NGF 
(Leon et al., 1994).  Histamine -- itself an inflammatory mediator – powerfully 
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stimulates the production of NGF in both the central and peripheral nervous systems. 
Histamine is released by mast cells during inflammatory or allergic reactions.  The 
main signalling pathway by which histamine stimulates the production of NGF 
involves the activation of the histamine H(1)-receptor, and stimulation of Ca(2+)-
dependent protein kinase C and mitogen-activated protein kinase.  Histamine and IL-
1beta have an additive stimulatory effect on NGF secretion, but the interaction 
between histamine and IL-6 causes a long-term synergism (Lipnik-Stangelij, 2006).   
Brain macrophages also release NGF when stimulated by lipolysaacharide (Mallat et 
al., 1989).   NGF is constitutively expressed in cells of the anulus fibrosus and nucleus 
pulposus in humans.  Moreover, the pro-inflammatory cytokines, IL-1beta and TNF-
alpha, stimulate the expression of nerve growth factor by these cells (Abe et al., 
2007).  It appears likely that other tissues constitutively express NGF and that pro-
inflammatory cytokines have an important role in stimulating its production.  Thus, 
for example, TNF-alpha markedly stimulates the synthesis and secretion of 
biologically active NGF in quiescent fibroblasts and also in glioblastoma cells 
(Hattori et al., 1993).  Moreover, inflammation induced by intraplantar injection of 
Complete Freund's adjuvant in adult rats results in significant elevation in the levels 
of TNF alpha, IL-1beta and NGF in the inflamed paw (Woolf et al., 1997).   The 
prostaglandins PGD(2) and PGE(2) potently induce the secretion of NGF from 
cultured mouse astrocytes, with PGE(2) or PGD(2) inducing an approximately 12-
fold or 19-fold increase in NGF secretion after a 24-hour incubation, respectively.  
Even more strikingly, the sequential metabolites of PGD(2), PGJ(2), Delta(12)-
PGJ(2), and 15-deoxy-Delta(12,14)-PGJ(2), induce NGF secretion to the culture 
medium 60 fold to 98-fold of the control after a 24-hour incubation. These 
prostaglandins also stimulate the secretion/synthesis of brain-derived neurotrophic 
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factor (BDNF) (Toyomoto et al., 2004). Activation of TNF-alpha receptors 1 and 
TNF-alpha receptors 2 by TNF-alpha in cultured astroycytes promotes expression of 
both NGF and GDNF. Both exogenous TNF-alpha and also TNF-alpha produced by 
astrocytes have this effect.  Thus, TNF-alpha appears to be of considerable 
importance in contributing to the production of these neurotrophic factors in the 
context of inflammation (Kuno et al., 2006).  
 
2.4.3. NGF and inflammatory pain 
     NGF acts on nociceptive afferent neurones, increasing their electrical excitability 
(Shu and Mendell, 2001). Acutely, NGF exerts profound effects on nociceptive 
transmission and produces pain and hyperalgesia.  Thus, injection of NGF into human 
masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia 
(Svensson et al., 2003).  Injection of NGF into the tibialis anterior muscle of human 
beings results the development in an area of hyperalgesia at the injected site 3 hours 
after injection which expands both proximally and distally on day 1.  This effect 
subsides by day 4 (Andersen et al., 2008).   NGF is also up-regulated after muscle 
incision in rat and contributes to guarding pain behaviour (Wu et al., 2009).   Again, 
increased NGF after rat plantar incision contributes to guarding behaviour and heat 
hyperalgesia (Banik et al., 2005).   When nerve growth factor is injected into the 
temporomandibular joint of a rat which has been sensitised by a prior injection of 
carrageenan, significant nociceptive behaviour is elicited which is absent when the 
same injection is made into the same joint when not inflamed.  Moreover, the 
nociceptive response appears to depend on the synergistic activity of NGF and 
sympathetic amines released during inflammation of that joint acting on beta2-
adrenergic receptors (Pelegrinin-da-Silva et al., 2008).   In CFA-induced hind-paw 
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inflammation, and in spinal nerve ligation and streptozotocin-induced neuropathic 
pain rodent models, a single intraperitoneal injection of a polyclonal anti-NGF 
antibody reverses established tactile allodynia from approximately day 3 to day 7 after 
treatment in rats and mice (Wild et al., 2007).  There is also evidence that over-
expression of NGF may induce endoneurial sprouting and trigger the development of 
thermal hyperalgesia in peripheral nuropathic pain states (Ruiz et al., 2004).  
 
       NGF plays a significant role in the maintenance of fracture pain, but not in the 
acute generation of such pain (Jiminez-Andrade et al., 2007).  It has also been 
implicated in contributing to migraine pain, having been shown to make an important 
contribution to nociceptive signalling by trigeminal sensory neurons (D’Arco et al., 
2007).  It has also been suggested that NGF induces rapid, reversible, up-regulation of 
P2X3 receptor function via protein kinase C phosphorylation to contribute to migraine 
pain.  These up-regulated receptors acquire the ability to repeatedly respond to 
extracellular ATP, thereby enhancing the signalling of painful stimuli (Giniatullin et 
al., 2008). 
 
     The p75 receptor has recently been associated with inflammatory thermal 
hypersensitivity.  Thus, administration of neutralizing antibody to the p75 receptor 
blocks hyperalgesia which otherwise develops with CFA-induced inflammation or 
with an intraplantar injection of NGF.  Blocking the p75 receptor also abolishes the 
up-regulation of CGRP levels in primary sensory neurons consequent on CFA 
injection.  Pro-NGF is the dominant ligand of the p75 receptor in vivo; and both pro-
NGF and mature NGF play an important roles in inflammation-induced hyperalgesia 
(Watanabe et al., 2008).  In rat, most dorsal root ganglion neurons innervating 
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intervertebral discs, as well as the intervertebral discs themselves, express both the 
TrkA  and p75 receptors (Sugiura et al., 2008). 
 
       NGF and its TrkA receptor are found in human degenerative lumbar facet joint 
specimens (Surace et al., 2009).  NGF acts on nociceptive dorsal root ganglion 
neurons in rat to make them hyper-excitable so as to generate spontaneous action 
potentials and to generate spontaneous intracellular calcium fluctuations (Ozaki et al., 
2009).  In rats, bladder-derived NGF, acting through trk receptors, appears to at least 
contribute to peripheral sensitisation to mechanical stimuli associated with acute, and 
sub-acute, acrolein-induced cystitis (Guerios et al., 2008).   
     
2.4.4. NGF involvement in sensitisation of TRPV1 
     Chronic exposure to high NGF increases the proportion of neurons that exhibit an 
inward current in response to anandamide (Evans et al., 2007).   The importance of 
the role of NGF in the excitation of nociceptive primary afferents in the context of 
inflammation is strongly suggested by the evidence relating to its role in sensitising 
TRPV1 ion channels.   NGF is known to be capable of sensitising TRPV1 ion 
channels (Shu and Mendell, 2001).  By binding to, and activating, its trkA receptor, 
NGF sets in motion a biochemical chain of events which, if sustained, results in the 
sensitisation of TRPV1.  As a cell membrane surface receptor, trkA relies on the 
further activation of intracellular messengers to mediate this effect.  The issue relates 
to which one, or more, of three intracellular signalling pathways perform this 
function.  These pathways are those denominated: PLC, PI3K, and MAPK, 
respectively.   
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      Chuang and colleagues (2001) proposed that activation of trkA by NGF activates 
PLC which, turn, hydrolyzes PIP2 to sensitise TRPV1.  PIP2 is proposed to tonically 
inhibit activation of TRPV1 and its hydrolysis by PLC results in releasing the ion 
channel from this inhibition (Chuang et al., 2001).  PIP2 is proposed to inhibit TRPV1 
by direct binding by PIP2 to a site within the C terminal domain of TRPV1.  Deletion 
of this site precludes sensitisation of TRPV1 by NGF (Prescott and Julius, 2003).   
Woolf and co-workers (2002) proposed that p38 MAPK activation by NGF in primary 
sensory neurones after inflammation increases TRPV1 levels and contributes to 
thermal hyperalgesia (Ji et al., 2002).  Bonnington and McNaughton (2003) found that 
specific inhibitors of ras/MEK (mitogen-activated protein kinase and extracellular 
signal-regulated kinase) pathway and of phospholipase C fail to abolish NGF-induced 
sensitisation of TRPV1, but a specific inhibitor of phosphatidylinositol-3-kinase 
(PI3K) totally abolishes the effect of NGF.  In addition, pharmacological blockade of 
PKC or CaMKII prevents NGF-induced sensitisation, while blockade of PKA is 
without effect (Bonnington and McNaughton, 2003).   Ji and co-workers (2004) 
proposed that NGF binds to TrkA which stimulates phosphatidylinositol-3-kinase to 
activate ERK in primary sensory neurones and thereby sensitises TRPV1 to generate 
inflammatory heat hyperalgesia (Zhuang et al., 2004).       
 
    According to McNaughton's group (2005), PI3K exercises the major role in 
sensitising TRPV1 consequent upon TrkA activation by NGF.   They propose two 
pathways, major and minor, by which NGF activates trkA to induce sensitisation of 
TRPV1.  Their major pathway involves the introduction of TRPV1 into the surface 
membrane and commences with autophosphorylation of the Y760 site of TrkA.  
Activation of PI3 kinase follows and Src is ultimately directly responsible for 
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phosphorylating TRPV1 at Y200.  Their minor pathway involves activation of PKC-
epsilon by trkA, leading to phosphorylation of TRPV1 at S502 and S801 (Zhang et 
al., 2005).  Gordon and co-workers (2006) have also proposed that NGF acts through 
the PI3K pathway, and not through PLC, to facilitate trafficking of TRPV1 to the 
plasma membrane and hence increase TRPV1 function to contribute to hyperalgesia.  
In their model, TRPV1, PI3K and trkA physically interact in a signal transduction 
complex in which activation of trkA by NGF facilitates trafficking of TRV1 to the 
plasma membrane (Stein et al., 2006).  Further evidence of the non-involvement of 
PLC in the trkA signalling sequence initiated by its being bound by NGF has been 
offered by Oxford and Zhu who propose that PI3K and MAPK pathways underlie the 
acute sensitisation of TRPV1 by NGF, but not the PLC pathway (Zhu and Oxford, 
2007).            
 
2.4.5. Surgical incisional injury and post-operative pain 
      Incisional injury in rat is commonly employed as a model for post-operative pain 
following surgical incision in humans.  Most of the studies emanate from the Brennan 
laboratory.  They developed a rat model of incisional pain involving a 1 cm 
longitudinal incision through skin, fascia, and muscle, of the plantar aspect of the 
hind-paw in halothane-anaesthetised rats. This results in a reliable and quantifiable 
mechanical hyperalgesia which persists for several days after surgery.  Different areas 
around the wound manifest different withdrawal thresholds over time, while even 
remote sites, as much as 10 mm from the wound, show persistent mechanical 
hyperalgesia.  Both the sural and tibial nerves are responsible for transmitting 
nociceptive input from the hyperalgesia-inducing incision (Brennan et al., 1996).   
Mechanical hyperalgesia, tactile allodynia and reduction in weight-bearing are 
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employed to characterise the development of post-incisional pain in rat (Whiteside et 
al., 2004). 
 
     NGF has been implicated as an important component of the inflammatory process 
mediating responses to thermal stimuli after plantar incision of rat paw, although it 
does not exercise any influence on responses to mechanical stimuli (Zahn et al., 
2004).  Increased NGF is found in rat skin over several days after plantar incision 
which contributes to heat hyperalgesia and some incision-induced pain behaviours 
(Banik et al., 2005).  Not only is NGF increased in the area of the incision, but, in 
addition, a large-molecular-weight form of NGF protein is expressed in the region 
adjacent to the incision.   Nerve bundles exhibit NGF immunoreactivity, with 
Schwann cells and axons being labelled (Wu et al., 2007).   After muscle incision in 
the rat, NGF protein increases from 4 hours after incision and is sustained for several 
days.  NGF is localised in many CGRP-positive axons, few N52-positive axons and is 
not found in isolectin B4-positive axons of incised muscle.  The source of NGF 
includes keratinocytes in the epidermis and fibroblasts in deeper tissues (Wu et al., 
2009).   A distinct class of afferents outside the mechano-heat-sensitive afferent 
population is proposed to be a likely contributor to heat hypersensitivity after rat 
plantar incision. Knock-out of TRPV1 reduces spontaneous activity in these 
unclassified afferents in incised rat skin (Banik & Brennan, 2009).    
 
       Several other important studies on incisional pain are conveniently addressed at 
this juncture.  Brain derived neurotrophic factor (BDNF) is increased in the ipsilateral 
lumbar DRG and spinal cord after hind-paw incision in rat.  Intrathecal injection of 
BDNF antibody greatly inhibits the mechanical allodynia induced by incision (Li et 
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al., 2008).    A decrease in pH occurs immediately after a plantar incision of the hind-
paw, or incision of the gastrocnemius muscle, in rat, and is sustained for at least 4 
days, during which time pain behaviours are evident in the animal.  When tissue pH 
returns to normal, these pain behaviours diminish.   The fall in pH is restricted to the 
incision site and does not extend to areas surrounding  the incision (Woo et al., 2004).  
Antagonists of bradykinin’s cognate B1 and B2 receptors, given either as a pre-
treatment dose or in post-treatment doses, fail to reduce pain-related behaviour after 
plantar paw incision (Leonard et al., 2004).  However, this does not preclude an effect 
of bradykinin after incisional injury that is mediated via another receptor, most 
obviously TRPV1.  AMPA/kainate receptors are proposed to be implicated in 
mediating mechanical hyperalgesia inasmuch as antagonists for these receptors, if 
administered spinally, decrease the responses to mechanical stimuli after plantar 
incision (Lee et al., 2006; Zahn et al., 1998).  However, spinal NMDA and mGluR 
antagonists do not have the same effect (Pogatzki et al., 2000).   
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2.5. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDN) 
2.5.1. Introduction 
      Brain-derived neurotrophic factor (BDNF) is misleadingly named inasmuch as 
this agent is neither confined to, nor originates exclusively within, the central nervous 
system, but is found extensively in the periphery.  Like NGF, BDNF is one of the  
“neurotrophin” molecules and acts via a tyrosine kinase (trk) receptor, namely, the 
trkB receptor, which it shares with the neurotrophin NT-4/5 (Maness et al., 1994).  In 
adult rat, BDNF is found mainly in the subpopulation of DRG cells that contain 
CGRP and express the trkA receptor for NGF.  From 80 to 90 per cent of BDNF-
expressing cells also express trkA.  BDNF protein is anterogradely transported both 
peripherally and centrally so that BDNF is found in CGRP containing terminal arbors 
in the dorsal horn of the spinal cord.  NGF causes an increase in BDNF within these 
neurons with the result that almost 90 per cent of trkA-expressing neurons contain 
BDNF mRNA after intrathecal NGF treatment   BDNF is found in finely myelinated 
and unmyelinated axons and in axon terminals where it is most concentrated over 
dense-cored vesicles (Michael et al.,1997).  BDNF is found in varicosities of sensory 
nerve terminals in laminae I and II of the dorsal horn.   Most BDNF nerve terminals 
also contain CGRP or the low affinity neurotrophin receptor p75, but the converse is 
not the case (Luo et al., 2001).    
 
     The release of BDNF from the terminals of primary nociceptive afferents in the 
spinal cord is associated with increased nociceptive processing in the spinal cord.  
Activation of spinal ERK1/2 is a recognised marker of spinal nociceptive processing.  
Ji and colleagues (1999) showed that peripheral capsaicin injection into the left hind-
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paw of rat activates ERK1/2 by phosphorylation (pERK1/2) in dorsal horn spinal cord 
neurons and induces pain-related behaviour in the animal (Ji et al., 1999).  Noxious 
chemical, mechanical, or thermal, stimuli cause phosphorylation of the BDNF high-
affinity receptor, trkB, in the spinal cord.   Both in vitro and in vivo exogenous BDNF 
induces a rapid activation of ERK1/2.  Moreover, sequestering BDNF in vivo with a 
TRkB-IgG fusion molecule significantly reduces the activation of ERK1/2 evoked by 
noxious stimulation (Pezet et al., 2002).  BDNF in primary sensory neuron cell bodies 
and in central terminals potentiates nociceptive spinal reflex responses in an in vitro 
spinal cord preparation and induces c-fos expression in dorsal horn neurons.  
Moreover, exogenous BDNF enhances NMDA receptor-mediated responses (Kerr et 
al., 1999).   
 
2.5.2. BDNF and inflammatory pain 
         Peripheral tissue inflammation produced by an intraplantar injection of CFA 
into rat hind-paw results in significant increases in the number of BDNF 
immunoreactive neurons in the L5 DRG and causes marked elevation of 
immuoreactive BDNF terminals in the spinal dorsal horn.  This is consistent with 
peripheral inflammation causing an increase in BDNF synthesis in the DRG followed 
by an elevated anterograde transport of BDNF to the neuronal terminals in the dorsal 
horn of the spinal cord (Cho et al., 1997).   Systemic NGF treatment – to mimic 
peripheral inflammatory states – increases BDNF levels in primary sensory neurons 
and increases nociceptive spinal reflex excitability.  Behavioural nociceptive 
responses induced by intraplantar formalin and by intraplantar carageenan injections, 
respectively, are significantly attenuated by trkB-IgG, a BDNF antagonist (Kerr et al., 
1999).   In spinal cord slice preparations from rat with CFA-induced inflammation  at 
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2 to 4 days after CFA injection,  BDNF acts pre-synaptically to increase the frequency 
of excitatory miniature EPSCs in substantia gelatinosa neurons through activation of 
lidocaine-sensitive, TTX-resistant Na+ channels. In addition, the number of 
monosynaptic A-beta afferent inputs to the substantia gelatinosa significantly 
increases 7 days after the onset of inflammation.  This increase is significantly 
suppressed by treatment with a BDNF antiserum.  Moreover, treatment with anti-
BDNF antiserum significantly attenuates CFA-induced hyperalgesia and/or allodynia 
(Matayoshi et al., 2005).  Intrathecal administration of BDNF in mouse produces an 
acute, dose-dependent, thermal hyperalgesic response.  Selective inhibition of BDNF 
expression by intrathecal antisense oligodeoxynucleotide treatment results in 
antinociception in normal mice and attenuates carrageenan-induced hyperalgesia. 
Similar knock-out treatment directed against the full-length trkB receptor attenuates 
carrageenan-induced hyperalgesia (Groth & Aanonsen, 2002).   Intrathecal co-
administration of an NMDA receptor antagonist with BDNF dose-dependently 
inhibits BDNF-induced hyperalgesia, suggesting that BDNF mediates hyperalgesia in 
a process which is dependent on NMDA receptor activation (Groth & Aanonsen, 
2002).   BDNF contributes to pain hypersensitivity after surgical incision in rats.  
After hind-paw incision, BDNF is up-regulated in the ipsilateral lumbar DRG and 
spinal cord. Intrathecal injection of BDNF antibody greatly inhibits the mechanical 
allodynia resulting from the incision (Li et al., 2008). 
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2.6.  ARTEMIN, NEURTURIN, AND GDNF 
2.6.1.   Introduction 
    Artemin, neurturin, and GDNF are members of the glial cell line-derived 
neurotrophic factor (GDNF) family and are potent regulators of TRPV1 function and 
possess the ability to potentiate TRPV1 signalling and to induce behavioural 
hyperalgesia (Malin et al., 2006).  Members of the GDNF family are produced in the 
form of a “prepro” precursor. The signal sequence is cleaved on secretion, and 
activation of the “pro” derivative is suggested to occur by proteolytic cleavage.  
GDNF family members appear to bind to heparin-sulphate side chains of 
extracellular-matrix proteoglygans, but little is known of the gene regulation and 
mechanisms of secretion of these proteins, or of the activation of their precursors 
(Airaksinen & Saarma, 2002).   Within sensory terminals located in the sacral spinal 
cord, and in bladder-projecting sacral dorsal root ganglion neurons of adult rats,  
distinct distribution patterns in the spinal cord are found for nerve fibres 
immunolabelled for GFRalpha1 (GDNF receptor), GFRalpha2 (neurturin receptor), 
and GFRalpha3 (aretemin receptor), respectively (Forest & Keast, 2008).   
 
2.6.2.   Contribution to  inflammatory pain 
        Artemin, neurturin, and GDNF, each individually potentiate capsaicin-evoked 
TRPV1 signalling in isolated mouse dorsal root ganglion neurons and cause thermal 
hyperalgesia when injected into mouse hindpaw in vivo.  Artemin mRNA (but not 
neurturin or GDNF) is hugely up-regulated during cutaneous inflammation evoked by 
hind-paw injection of CFA, suggesting that artemin, in particular, enhances TRPV1 
signalling in response to inflammatory injury.  Hindpaw injection of artemin, 
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neurturin, GDNF, or NGF produces acute thermal hyperalgesia that lasts up to 4 
hours.   Moreover, a single combined injection of artemin and NGF produces 
hyperalgesia which persists for 6 days (Malin et al., 2006).  Over-expression of 
artemin in the skin of mice enhances expression of TRPV1 and TRPA1 in cutaneous 
sensory neurons and results in increased behavioural sensitivity to heat and cold (Elitt 
et al., 2006).  It also increases the total number of dorsal root ganglion neurons (Wang 
et al., 2008).  In addition, over-expression of artemin in the tongue increases the 
expression of TRPV1 and TRPA1 in trigeminal afferents and causes oral sensitivity to 
capsaicin and mustard oil in mice (Elitt et al., 2008). Interestingly, artemin has 
recently also been found to have potent neurotrophic actions on injured C-fibres 
(Bennet et al., 2008).  It also has a significant effect on the neurite growth of dorsal 
root ganglion neurons and activates axonal growth via Src family kinases  and ERK-
dependent signalling pathways in mature dorsal root ganglion neurons (Jeong et al., 
2008).  Exposure of isolated mouse sensory neurons in culture to GDNF, neurturin, 
and artemin enhances the capsaicin-stimulated release of immunoreactive calcitonin 
gene-related peptide (CGRP) two to threefold, but does not increase potassium-
stimulated release of iCGRP.  A similar profile of sensitisation is found in freshly 
dissociated spinal cord slices (Schmutzler et al., 2009).   Acute administration of 
GDNF sensitises primary sensory neurons and produces mechanical hyperalgesia in 
the rat (Bogen et al., 2008). 
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2.7. SEROTONIN (5-HYDROXYTRYPTAMINE; 5-HT) 
2.7.1. Introduction 
      Serotonin (5-Hydroxytryptamine; 5-HT) is formed from dietary tryptophan, which 
is converted by tryptophan hydroxylase to 5-hydroxytryptophan, and then to serotonin 
by a non-specific decarbosylase.  It is transported into serotonin-containing cells by a 
specific transporter system.  Degradation occurs mainly by monoamine oxidase 
forming 5-HIAA (5-hydroxyindoleacetic acid) which is excreted in the urine.  Seven 
types of serotonin receptors have been identified, demoninated 5-HT1-7, with further 
subtypes (A-D) of 5-HT1 and 5-HT2.  All are G-protein coupled receptors, except 5-
HT3 which is a ligand-gated ion channel which is found in several locations, 
including on nociceptive primary sensory neurones.  Serotonin is an important 
neurotransmitter in the central nervous system.  It is also found throughout the body, 
outside the central nervous system, being present: in platelets in the blood; in mast 
cells; in enterochromaffin cells, which are found mainly in the stomach and small 
intestine; and in neurons of the myenteric plexus, where it functions as an excitatory 
neurotransmitter.  About 95 per cent of peripheral serotonin is synthesised and stored 
in the enterochromaffin cells.  Serotonin released into the circulation is taken up by 
platelets and stored in platelet dense granules (Jonnakuty and Cragnoli, 2008). 
 
2.7.2.  Peripheral serotonin, mast cells and inflammation 
     Serotonin is involved in inducing mast cell adhesion and chemotaxis (Kushnir-
Sukhov et al., 2006). Moreover, human mast cells are capable, not only of storing 
serotonin for release, but, also, of synthesising serotonin (Kushnir-Sukhov et al., 
2007). Mast cells are key cells of type I hypersensitivity reactions. They contribute to 
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host defence through the release of a myriad of pro-inflammatory and 
immunoregulatory molecules and can significantly influence multiple features of the 
inflammatory and immune responses (Metcalfe et al., 1997; Crivellato and Ribatti, 
2005; Galli and Tsai, 2008).  The 5-HT1A receptor is the principal receptor mediating 
the effects of serotonin on mast cells.  Serotonin induces the accumulation of mast 
cells in the dermis of mice which possess the 5-HT1A receptor, but not in 5-HT1A  
receptor null mice (Kushnir-Sukhov et al., 2006). Intracranial headaches, such as 
migraine, are putatively attributed to activation of sensory trigeminal nociceptive 
neurones that supply intracranial blood vessels and the meninges.  Serotonin, 
prostacyclin (PGI(2)), and, to a lesser extent, histamine, can provoke a robust 
sensitisation and activation of meningeal nociceptive neurones and may be involved 
in the development of this type of headache (Zhang et al., 2007). 
 
2.7.3. Peripheral serotonin contributes to pain of peripheral inflammation 
        Serotonin, when injected locally in the periphery causes pain, and wheal and 
flare responses (Jensen et al., 1990a; Jensen et al., 1990b). Serotonin released from 
mast cells contributes to the development of capsaicin-induced mouse ear oedema via 
5-HT2 receptors in the ear skin to which capsaicin has been applied (Inoue et al., 
1995).  Intradermally injected serotonin produces a dose-dependent hyperalgesia in 
rat that is not attenuated by sympathectomy, polymorphonuclear leukocyte depletion 
or cyclooxygenase inhibition.  The latency to onset of serotonin hyperalgesia is 
extremely short, with maximal hyperalgesia observed in less than one minute, and the 
effect is attenuated only by a 5-HT1A antagonist, suggesting that, in that model, the 
hyperalgesic effects of serotonin are exerted by direct action on primary afferent 
neurons via 5-HT1A receptors (Taiwo and Levine, 1992).  Intradermal injection of the 
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5-HT1A receptor agonist, 8-OH-DPAT, produces a dose-dependent hyperalgesia 
which is attenuated by a cAMP kinase inhibitor, but prolonged by the inhibition of 
endogenous phosphodiesterase, supporting a role for the cAMP second messenger 
system in mediating serotonin-induced peripheral hyperalgesia (Taiwo et al., 1992).  
Mice which lack the serotonin transporter and which, therefore, have reduced levels 
of serotonin in their tissues, have attenuated hyperalgesia to heat, when compared to 
wild type mice, after hind-paw inflammation induced by intraplantar CFA injection 
(Palm et al., 2008). 
  
      The peripheral 5-HT2A receptor is involved in the development of thermal 
hyperalgesia in the carrageenan model of inflammation in rat.  Intraplantar injection 
of carrageenan dramatically reduces paw withdrawal latency to noxious heat (47 
degrees C) and causes paw swelling in the rat.  Pre-treatment with ketanserin, a 
selective antagonist of the 5-HT2A receptor, in the hindpaw, results in dose-
dependent inhibition of the hyperalgesia, up to, and including, full relief. This agent 
also moderately reduces carrageenan-induced paw swelling in a dose-dependent 
manner. Carrageenan administration induces conspicuous expression of c-fos-like 
immunoreactivity in the spinal dorsal horn of segments L4-5 which is markedly 
reduced by ketanserin (Wei et al., 2005).   Serotonin, released in peripheral tissues 
after mild thermal injury to the rat hind-paw, acts via peripheral 5-HT2A receptors to 
contribute to the sensitisation of nociceptive primary afferents which results in 
allodynia and thermal hyperalgesia (Sasaki et al., 2006).   The 5-HT2A receptor is 
mainly expressed in nociceptive sensory neurons in rat lumbar dorsal root ganglia 
(Van Steenwinckel et al., 2009).   After formalin injection into the hind-paw of rat, 
serotonin is released into the formalin injection site in a formalin concentration-
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dependent manner.   Local pre-treatment with selective 5-HT2A and 5-HT2C receptor 
antagonists reduces the number of flinches in the early part of phase 2 of the formalin 
test in a dose-dependent  manner.  Moreover, peripheral pre-treatment with a mast cell 
membrane stabiliser completely suppresses serotonin release and inhibits phase 2 
responses to the formalin test (Nakajima et al., 2009). 
 
     The 5-HT3 receptor is of varying significance in its contribution to the activation 
of primary nociceptive afferents.  This receptor is not required for acute nociception 
in response to pain-inducing stimuli in several pain models in mouse, including the 
CFA intraplantar injection model of peripheral inflammation.  However, it contributes 
to persistent nociception in the context of injury by an action on both myelinated and 
unmyelinated noceptive neurons in the same models, although it does not contribute 
to oedema.  In addition, 5-HT3 receptors in the spinal cord facilitate the transmission 
of nociceptive impulses and have a pro-nociceptive effect (Zeitz et al., 2002).   
Serotonin markedly and specifically stimulates vagal mucosal chemosensitive 
afferents via 5-HT3 receptors (Grundy et al., 1995).   Again, colonic serosal and 
mesenteric endings exhibit increased sensitivity to serotonin in inflammation, with 
both an increase in the proportion of responders and an increase in sensitivity, which 
is maintained after healing of the inflammation. This is associated with alterations in 
the roles of 5-HT3 receptors and mast cells (Coldwell et al., 2007). The 5-HT3 
receptor also facilitates at-level mechanical allodynia following spinal cord injury 
(Oatway et al., 2004;  Chen et al., 2009).  The 5-HT(3A) receptor is found co-
localised with GABA and enkephalins in the spinal dorsal horn and it has been 
suggested that serotonin may activate GABAergic and enkephalinergic neurons via 5-
HT(3), thereby affecting the release of GABA and enkephalins (Huang et al., 2008) 
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      Activation of the 5-HT7 receptor appears to be capable of exerting an anti-
nociceptive effect in mice. Thus, mechanical hypersensitivity resulting from 
sensitisation to capsaicin in mice is reduced by systemic administration of 5-HT7 
agonists and increased after administration of 5-HT7 antagonists (Brenchat et al., 
2009)   
 
2.7.4.  Role of central serotonergic system 
       Central serotonergic neurons in the brain which project to the spinal cord – the 
so-called “descending serotonergic projections originating in the  rostral ventromedial 
medulla – are believed to exercise vital functions in modulating nociceptive impulses 
in the spinal cord (Fields et al., 1991; Zhuo & Gebhart, 1991; Urban & Gehart, 1999; 
Millan, 2002;  Suzuki et al., 2004;  Zhao et al., 2007), in conjunction with central 
noradrenergic neurons projecting to the spinal cord (Fields and Basbaum, 1978;  
Basbaum and Fields, 1984;  Millan, 2002.  This hypothesis is supported by the 
success in the management of chronic pain enjoyed by tricyclic antidepressants which 
increase central serotonergic and noradrenergic neurotransmission (Lynch, 2001).  In 
mice in which the central serotonergic system has been ablated, the animals survive to 
adulthood and exhibit normal locomotor activity (Zhao et al., 2006).   These mice 
have normal acute thermal thresholds and visceral pain responses, but are generally 
less sensitive to mechanical stimuli.  Thus, in general, the mechanical thresholds of 
the mutant mice are increased relative to the wild type mice, which suggests a 
facilitatory role of the central serotonergic system in modulating mechanical 
sensitivity in these circumstances. However, the contrary is found after hind-paw 
injection with capsaicin, and also in the carrageenan model of inflammatory pain, 
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where the mutants exhibit increased mechanical hypersensitivity in response to these 
noxious stimuli.  Thus, in the capsaicin experiment, the mutants show significantly 
greater mechanical hypersensitivity when compared with wild type mice.  Again, after 
injection of 5 per cent formalin into the hind-paw, flinching and licking behaviours of 
wild type and mutant mice were not significantly different during the first phase.  In 
contrast, licking and flinching responses in the second phase were significantly 
enhanced in the mutants when compared with the wild type animals (Zhao et al., 
2007).   5-HT2A receptors in the trigeminal sub-nucleus caudalis/upper cervical 
spinal cord junction region appear to mediate anti-nociceptive effects in craniofacial 
nociception (Okamoto et al. 2007). 
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2.8.  HISTAMINE 
2.8.1. Introduction.    
      Histamine is a basic amine and is an important neurotransmitter in both the central 
and peripheral nervous systems.  Histamine mediates its physiological functions 
through binding to four known histamine receptors, namely:  H1; H2; H3; and H4.  
These are all G protein coupled receptors and have been cloned (Yamashita et al., 
1991; Gantz et al., 1991; Lovenberg et al., 1999; Nguyen et al., 2001). The H3 
receptor appears to serve a general regulatory function.  H3 receptor density is highest 
in the brain, but these receptors also exist in dorsal root ganglia, spinal cord and in 
certain peripheral tissues, including whisker pads and hairy and glabrous hind paw 
skin of rats and mice (Cannon et al., 2007a).  “Constitutive activity” (i.e., spontaneous 
activity in the absence of agonist) of H3 receptors is found in rodent brain and 
controls histaminergic neuronal activity in vivo.  Thus, a proportion of the H3 receptor 
population spontaneously undergoes an allosteric transition, leading to a conformation 
that can bind G proteins, independently of activation by any agonist (Morrisset et al., 
2000; Arrang et al., 2007; Bongers et al., 2007). 
 
      In the periphery, histamine is found mainly in mast cells and basophils.   
Histamine is secreted when complement components C3a and C5a interact with 
specific membrane receptors, or when antigen interacts with cell-fixed IgE.  
Histamine has several well-known peripheral actions in humans including:  
stimulation of gastric secretion; contraction of most non-vascular smooth muscle; 
cardiac stimulation; vasodilation;  and increased vascular permeability. It can also be 
responsible for type 1 hypersenstivity reactions, including urticaria and hay fever 
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(Jutel et al., 2005;  Akdis et al., 2008; Ohtsu, 2008)   Histamine also has an 
established effect of inducing the itch sensation when released in the periphery (Shim 
et al., 2007;  Shim & Oh, 2008).   It also has an important role as an agent which 
contributes to inflammatory pain sensations. 
  
2.8.2. Histamine and inflammatory pain 
     Histamine contributes to pain sensation resulting from peripheral inflammation, 
although, paradoxically, histamine, acting through its H3 receptor, may apparently 
have an antinociceptive effect even in the context of inflammatory pain.  More 
generally, H1 receptor null mice show significantly fewer nociceptive responses to the 
hot-plate, tail-flick, tail-presure, paw-withdrawal, capsaicin, abdominal constriction, 
as well as formalin, tests (Mobarakeh et al., 2000). 
       Injection of formalin into the paw of an animal results in a peripheral 
inflammatory response.  Histamine is one of the agents generated by injection of 
formalin.   The histamine thus released also contributes to the inflammatory response, 
with H1 receptors being relatively more important than H2 receptors in mediating 
formalin-induced nociceptive behaviour (Parada et al., 2001; Mobarakeh et al., 2000). 
Local administration of a H1 receptor antagonist prevents formalin-induced 
nociception in the temporomandibular joint (TMJ) in rats in a dose-dependent manner 
(Ting et al., 2007). Histamine H4 receptors participate in the early phase of acute 
inflammation induced by carrageean in rats, influencing both oedema formation and 
thermal hyperalgesia.  Thus, highly selective H4 antagonists significantly reduce paw 
oedema and hyperalgesia in rats provoked by subplantar injection of carrageenan in 
the early (2 hour) phase of inflammation (Coruzzi et al., 2007). 
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     However, histamine is apparently not unidirectional in its effects on nociception.  
Thus, the H3 agonist, pro-drug BP2-94, attenuates swelling and nociceptive 
behaviours in some mouse models of inflammatory pain (Rouleau et al., 1997; 
Rouleau et al., 2000). In rats subjected to the formalin test, activation of H3 receptors 
by administration of a H3 agonist reduces formalin-induced swelling and flinching 
(Cannon et al., 2007b). 
 
2.8.3.  Histamine and mechanical pain sensation 
      Histamine also appears to be involved in reducing at least certain forms of 
mechanical pain sensation.  Activation of spinal H3 receptors attenuates nociceptive 
responses to low-intensity tail-pinch stimulation. Thus, intrathecal administration of a 
H3 receptor agonist produces an antinociceptive effect on the tail-pinch test in wild 
type mice, but not in knock-out mice lacking this receptor (Canon et al., 2003). 
 
2.8.4.  Activation of TRPV1 to mediate itch sensation 
      One effect of histamine on a subset of primary afferents is mediated by activation 
by histamine of phospholipase A2 and 12-lipoxygenase, which leads to the production 
of 12-HPETE and activation of TRPV1 ion channels.  Activation of TRPV1 then 
leads to excitation of the primary sensory neurones on which they are expressed.  
Histamine-induced itching is proposed to be mediated, in part, by this pathway (Shim 
et al., 2007). Pain generally inhibits itch, which indicates an inter-communication 
between the (apparently) different neuronal pathways which mediate itch and pain 
(Shim & Oh, 2008). 
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2.9. ANANDAMIDE 
2.9.1. Introduction 
      Anandamide (N-arachidonylethanolamine) is an endogenous ligand of 
cannabinoid receptors.   It is a member of the group of bioactive lipids known as 
"long chain C18 N-acylethanolamines (NAEs)".  In animal tissues, anandamide is 
principally formed, together with other NAEs, from glycerophospholipid by two 
successive enzymatic reactions: (i) N-acylation of phosphatidylethanolamine to 
generate N-acylphosphatidylethanolamine (NAPE) by Ca2+-dependent N-
acyltransferase; and (ii) release of NAE from NAPE by a phosphodiesterase of the 
phospholipase D type (NAPE-PLD) (Okamoto et al., 2007;  Simon & Cravatt, 2008).   
A major sub-population of capsaicin-sensitive primary sensory neurons expresses 
NAPE-PLD (Nagy et al., 2009).  Fatty acid amide hydrolase (FAAH) is an integral 
membrane protein which has been identified as the primary enzyme responsible for 
NAE degradation in most tissues, including brain (Cravatt et al., 1996), and is found 
in neural tissue involved in peripheral nociceptive transmission in rat, such as dorsal 
root ganglia, sciatic nerve, and spinal cord (Lever et al., 2009).  When the action of 
this enzyme is inhibited, there is a resulting increase in anandamide levels coupled 
with anti-inflammatory and analgesic effects mediated through cannabinoid receptors 
(Cravatt et al., 2001;  Kathuria et al., 2003).  
 
2.9.2. Contribution to inflammatory pain 
      Anandamide is implicated in acute and inflammatory pain conditions by reason of 
its ability to activate TRPV1 ion channels.  Anandamide is one of several endogenous 
agents which have been proposed as direct activators of the TRPV1 ion channel 
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(Zygmunt et al., 1999). Others of these endogenous agonists include N-arachidonoyl-
dopamine (NADA) (Huang et al., 2002), N-oleoyldopamine (OLDA) (Szolcsanyi et 
al., 2004), lipoxygenase products, such as 12- or 15-(S)-HPETE (Hwang et al., 2000), 
and unsaturated C18 N-acylethanolamines (Movahed et al., 2005). All of these 
agonists have been shown to compete for the capsaicin binding site, leading to their 
characterisation as “endovanilloids” (i.e., endogenous vanilloids).   Anandamide is the 
best characterised of the endogenous TRPV1 agonists     The capacity of anandamide 
to activate TRPV1 in normal physiological conditions is very limited. This limitation 
is necessary in order to prevent unnecessary activity of TRPV1, thereby signalling 
pain, in the absence of a relevant pain-inducing stimulus. However, when TRPV1 is 
activated by other stimuli, such as inflammatory mediators, anandamide becomes a 
powerful activator of TRPV1 (Olah et al., 2001; Singh et al., 2005) and, hence, a 
contributor to the pain sensations mediated by inflammogens.  Anandamide and other 
endogenous activators of TRPV1 have therefore been described as “conditional 
activators” of this ion channel.   Consistent with a role for anandamide in mediating 
inflammatory pain is the finding that AM404, an anandamide re-uptake inhibitor, 
induces an anti-nociceptive effect when formalin is injected into the rat hind-paw.  
While Fos-positive neurons are increased in the dorsal superficial and deep laminae of 
the lumbar spinal cord in formalin-injected rats, AM404 significantly reduces such 
Fos induction (Borsani et al., 2007). 
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2.10. ATP (ADENOSINE 5'TRIPHOSPHATE) 
2.10.1. Introduction  
      ATP (adenosine 5’triphosphate) is a metabolite which functions as a 
neurotransmitter in both the central and peripheral nervous systems.   ATP, in its role 
as a metabolite, functions intracellularly.   However, it mediates its action as a 
neurotranmitter extracellularly.  ATP, in its role as a neurotranmitter in the peripheral 
nervous system, functions on its own as a mediator and, in addition, as a co-
transmitter at noradrenergic nerve terminals.  Notwithstanding that ATP is an 
endogenous agent, it is capable of inducing pain in humans in certain conditions, a 
phenomenon which was reported, some thirty years ago, when it was observed that it 
induces a sensation of pain when it is applied to a blister-base preparation (Bleehen 
and Keele, 1977).  Since then, the role of ATP in nociception has been the subject of 
considerable research on the assumption that it may act as an inflammagen when 
released from cells which are lysed by tissue damage or otherwise (Chizh & Illes, 
2000;  North, 2003).        
 
2.10.2. ATP and inflammatory pain 
      ATP is a ligand at type 2 purinergic receptors (P2), of which there are two 
subtypes, namely, P2X and P2Y.  P2X receptors are ionotropic receptors, whereas 
P2Y receptors are G-protein coupled receptors.  Several P2X receptor sub-types are 
known to be involved in mediating pain sensations.  P2X2 and P2X3 receptor 
subunits can form homomultimeric P2X2 receptors, homomultimeric P2X3 receptors, 
or heteromultimeric P2X2/3 receptors (Lewis et al., 1995).  P2X2 and P2X3 receptors 
account for virtually all ATP responses in sensory and autonomic ganglion neurons in 
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mice. In addition to P2X3 receptors, P2X2/3 receptors (and possibly P2X2 receptors) 
are important in sensory modulation in at least one model of persistent pain and in the 
regulation of urinary bladder reflexes in mice (Cockayne et al., 2005).  P2X2 and 
P2X3 receptor expression occurs in a subset of dorsal root ganglion neurons in both 
mouse and rat (Chen et al., 1995; Lewis et al., 1995; Collo et al., 1996; Cockayne et 
al., 2005). After formalin injection to the hind-paw of rat, P2X3 immunoreactivity is 
detected mainly in the cytoplasm and plasma membrane of small and medium-size 
dorsal root ganglion neurons.  P2X3 transcript expression in the dorsal root ganglia 
remains unchanged at 1 hour after formalin injection, but is increased after 12 hours.   
In the spinal cord, P2X3 staining is not obviously increased by 1 hour post-injection, 
but is increased by 24 hours (Pan et al., 2009). P2X2 and P2X3 receptor expression 
occurs predominantly on small to medium-sized trigeminal afferent neurons in rat.  
The majority of neurons innervating the dura express P2X2 and/or P2X3 receptors, 
suggesting that purines may be involved in nociceptive processing in pain conditions 
such as migraine headache (Staikopoulos et al., 2007).  In cultured trigeminal 
neurons, CGRP  and NGF each enhances P2X3 receptor trafficking to the neuronal 
membrane and activates the gene transcription of these receptors. These P2X3 
receptors are then capable of responding repeatedly to extracellular ATP to induce 
pain sensation (Giniatullin et al., 2008).   
 
      P2X3 receptors are capable of undergoing rapid constitutive and cholesterol-
dependent endocytosis which is accompanied by preferential targeting of the receptor 
to late endosomes/lysosomes, with subsequent degradation.  At steady state the P2X3 
receptor localises mainly in lamp1-positive intracellular structures, with a small 
number found at the plasma membrane.  The amount of functional receptors 
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expressed on the cell surface is rapidly up-regulated in response to agonist 
stimulation, which also augments receptor endocytosis (Vacca et al., 2009).  TRPV1 
receptors are co-expressed with P2X3 receptors in many dorsal root ganglion neurons 
and interact with each other in an inhibitory manner, probably by a physical 
association established by a motif located at the C-terminal end of the P2X3 receptor 
distal to Glu362 (Stanhev et al, 2009).   The C-terminal Src inhibitory kinase (Csk) 
directly phosphorylates the tyrosine 393 residue of the P2X3 receptor and potently 
inhibits receptor currents. In mouse trigeminal sensory neurons, the activity of Csk is 
tightly controlled by the extracellular amount of NGF.  Silencing endogenous Csk 
potentiates P2X3 receptor responses thereby demonstrating constitutive Csk-mediated 
inhibition of receptor function (D’Arco et al., 2009).  The activation of P2X3, 2/3 
receptors by endogenous ATP is essential to the development of mechanical 
hyperalgesia induced by carrigeenan (Oliveira et al., 2009).   Allodynia in mouse 
evoked by the P2X receptor agonist, –methylene ATP,  is mediated by the 
prostaglandin F2 receptor, possibly via the functional coupling  between the activation 
of P2X2/3 receptors on the central terminal of capsaicin-insensitive fibres and 
prostaglandin F2 receptors on spinal neurons (Kunori et al., 2009).                   
 
          P2X4 receptor null mice exhibit reduced tactile allodynia and swelling of the 
injected hind-paw in CFA-hind-paw-induced inflammation (Tsuda et al., 2009).  
Blockade of P2X7 receptors in vivo in mouse results in significant anti-nociception in 
mouse models of inflammatory pain, an effect which is likely to be mediated by 
inhibiting the release of IL-1beta from macrophages and microglial cells which is 
otherwise released as a result of the action of ATP on these receptors (Honore et al., 
2009).  An inhibitory effect of P2X7 receptors on the expression of P2X3 receptors 
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has also been demonstrated.  P2X7 receptors in glial satellite cells of dorsal root 
ganglia tonically inhibit the expression of P2X3 receptors in nociceptive neurons and 
thereby reduce pain through down-regulation of neuronal P2X3 (Chen et al., 2008).      
 
      The P2Y2 receptor is highly expressed in dorsal root ganglia in mice.  Mice which 
lack this receptor exhibit impaired thermal nociception.  Mutant mice fail to develop 
thermal hypersensitivity in response to CFA-induced inflammation.  TRPV1 function 
is also reduced in P2Y2 null mice, as measured by the frequency and magnitude of 
capsaicin responses in vitro and behavioural responses to capsaicin administration in 
vivo. (Malin et al., 2008).  Activation of P2X7 receptors on satellite cells of dorsal 
root ganglia evokes ATP release which, in turn, stimulates P2Y1 receptors in primary 
sensory afferents.  P2Y1 receptor activation appears to be necessary sufficient for the 
inhibitory control of P2X3 receptor expression in dorsal root ganglia (Chen et al., 
2008). 
 
      Caution is always required when considering the effect in humans of the results of 
animal experiments, but this is especially so in the case of ATP because substantial 
inter-species differences have been found in the expression of ATP receptors.   Thus, 
only 30 per cent of dorsal root ganglia neurons in cat express P2X3 receptors 
compared with 90 per cent in rat and in mouse, and a substantial difference in P2Y1 
receptor expression is also found in cat when compared to rat and mouse (Ruan et al., 
2005).  Nevertheless, there is evidence that extracellular ATP may contribute to 
certain forms of neuropathic pain and inflammatory pain by an action on its receptors 
located on primary sensory neurones.  There is also evidence that ATP, acting on 
different of its receptors in the central nervous system, may be important in mediating 
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peripheral pain sensations.  Thus, ATP, acting through the glial P2X7 receptor, exerts 
a wide-ranging influence on spinal neuronal activity following a chronic injury. There 
is evidence that antagonism of the P2X7 receptor may, in turn, modulate central 
sensitisation and produce anti-nociception in animal models of pathological pain 
(McGaraughty et al., 2007). Moreover, it has also been suggested that antagonism of 
spinal P2X3/P2X2/3 receptors results in an indirect activation of the opioid system to 
alleviate inflammatory hyperalgesia and chemogenic nociception (McGaraughty et 
al., 2005). 
 
2.10.3. Extracellular ATP 
    In the periphery, ATP can be released as a result of tissue injury, visceral 
distension, or sympathetic activation (Chizh and Illes, 2000). Human plasma contains 
ATP, independent of platelet dense body release, which is subject to diurnal variation 
(Ryan et al., 1996), while ATP is also released as a neurotransmitter in non-
pathological conditions.  These sources of ATP obviously do not result in the 
experience of pain in humans, or of pain-like behaviour in mammals.  Were it 
otherwise, individuals would, in normal conditions, be subjected to pain sensations in 
the absence of an appropriate noxious stimulus. It is apparent, therefore, that the 
extracellular ATP which acts as a noxious stimulant is sourced elsewhere, most 
obviously from cells damaged in tissue injury.  The concentrations of ATP within the 
cytoplasm of lysed cells (>1 mM) are sufficient to excite P2X receptors (North, 
2003). The release of ATP into the extracellular environment is inevitable on the 
occurrence of tissue damage and inflammation.  ATP released from mechanically 
lysed cells results in a direct excitation of P2X receptors on sensory neurones in vitro 
(Cook and McCleskey, 2002). Of course, in the abnormal circumstances resulting 
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from tissue damage and inflammation, ATP discharged from neurones may 
conceivably combine with released cytosolic ATP to contribute to the experience of 
pain sensations. 
 
2.10.4.  ATP contributes to inflammatory pain 
      Even low concentrations of ATP evoke action potentials and large inward currents 
in pain-sensing and stretch-sensing neurons (Cook et al., 1997).  Souslova and 
colleagues (2000) found that ablation of the P2X3 gene in mice results in the loss of 
rapidly desensitizing ATP-gated cation currents in dorsal root ganglion neurons, while 
the responses of nodose ganglion neurons to ATP show altered kinetics and 
pharmacology resulting from the loss of expression of P2X2/3 heteromultimers. 
Behavioural responses of these knock-out mice to noxious mechanical and thermal 
stimuli are also normal, except that formalin-induced pain behaviour is reduced. 
However, deletion of the P2X3 receptor causes enhanced thermal hyperalgesia in 
chronic inflammation. In addition, although dorsal horn neuronal responses to 
mechanical and noxious heat application are normal, P2X3-null mice are unable to 
code the intensity of non-noxious 'warming' stimuli (Souslova et al., 2000). More 
recently, Cockayne and co-workers confirmed that neurons from P2X2 null mice and 
P2X2/P2X3 mull mice exhibit reduced pain-related behaviours in response to 
intraplantar injection of formalin.   They also showed that these knock-out mice have 
reduced urinary bladder reflexes and decreased pelvic afferent nerve activity in 
response to bladder distension (Cockayne et al., 2005). 
 
       Iontophoretic delivery of ATP to the forearm skin of human volunteers 
consistently produces a modest burning pain, within 20 seconds of starting 
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iontophoresis, which is maintained for several minutes.  Persistent iontophoresis of 
ATP leads to desensitisation within 12 minutes but recovery from this is almost 
complete by 1 hour later.  Pain sensation is dose-dependent and is greatly potentiated 
under conditions of hyperalgesia (Hamilton et al., 2000).  In accord, inflammation 
also potentiates the effect of ATP in mediating pain-like sensations in the rat 
(Hamilton et al., 1999).  Inflammation causes a two-fold to three-fold increase in both 
ATP-activated currents, alters the voltage dependence of P2X receptors, and enhances 
the expression of P2X2 and P2X3 receptors. The increase in ATP responses gives rise 
to large depolarisations that exceed the threshold of action potentials in inflamed DRG 
neurons (Xu and Huang, 2002). A selective non-nucleotide antagonist of P2X3 and 
P2X2/3 receptor-activation reduces thermal hyperalgesia in the CFA-induced model 
of chronic inflammatory pain in rat.  However, it is ineffective in reducing 
nociception in animal models of acute pain, post-operative pain, and visceral pain 
(Jarvis et al., 2002).  
 
       ATP appears to be more generally implicated in mediating neuropathic pain.  
Acute systemic administration of a selective antagonist for the P2X3 and P2X2/3 
receptors reverses nerve injury-induced tactile allodynia and thermal hyperalgesia 
(Jarvis et al., 2002). Moreover, the P2X3 receptor plays an important role in 
promoting heat hyperalgesia in a rat model of trigeminal neuropathic pain (Shinoda et 
al., 2007).  Activation of cytosolic phospholipse A2 resulting from  P2X3/P2X2/3 
receptor-activation has been advanced as a key event in neuropathic pain (Tsuda et 
al., 2007b).  
 109 
 
2.11.  PROTONS AND OTHER CATIONS 
2.11.1.  Introduction        
        Protons (hydrogen ions) are potent activators of TRPV1 and they also affect 
neuronal excitability by activating acid-sensing ion channels.  Cations also have the 
ability to activate TRPV1.  The reduction in pH and local acidosis in inflamed tissues 
are potent contributors to pain and hyperalgesia. 
 
2.11.2.  High proton (low pH) concentrations result in pain 
     An increase in the local hydrogen ion concentration is a common accompaniment 
of inflammation consequent upon tissue damage or disease.  It has long been known 
that low pH (down to 4.7) is commonly found in inflamed tissues and that acidic 
solutions are particularly painful when injected into the skin (Habler 1929; von Gaza 
and Brandi, 1926; Steen et al., 1996). Protons selectively induce lasting excitation of 
nociceptors in rat skin with sensitisation to mechanical stimulation in vitro (Steen et 
al., 1992). In vivo, a decrease in pH occurs immediately after plantar incision in rats 
and is sustained for at least 4 days.  During the period of decreased tissue pH, pain 
behaviours are evident, with these diminishing when the tissue pH returns to normal.  
The fall in pH is localised at the incision site and does not extend to areas surrounding 
the incision.  However, the magnitude of the pH change varies between tissues (Woo 
et al., 2004). Continuous administration of low pH buffered solutions into human skin 
causes dose-dependent sustained pain and hyperalgesia to mechanical stimulation 
(Steen and Reeh, 1993). Inflammatory mediators potentiate the pain induced by 
experimental tissue acidosis.  Thus, continuous infiltration of human forearm skin 
with a phosphate buffered electrolyte solution of pH 5.2 results in constant ongoing 
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pain.  Subsequent injections of an acidic combination of BK, 5-HT, HIS, PGE2  into 
the same (acidotic) forearm and injections of a non-acidic combination of the same 
inflammatory mediators in the other forearm produces a dose-dependent, transient 
burning pain in both arms which is markedly more intense and prolonged in the 
acidotic skin (Steen et al., 1996). 
 
2.11.3.  High cation concentrations result in pain 
     Acute pain-related behaviour may be evoked by elevated ionic strength.  
Intraperitoneal injection of MgSO4 evokes writhing responses in mice, while salt 
(NaCl), when applied to injured tissue, evokes a burning pain sensation similar to that 
evoked by capsaicin, heat, or extracellular protons.  Extracellular cations, therefore, 
can result in acute burning pain sensation (Ahern et al., 2005). 
 
2.11.4.  Proton activation of TRPV1 
     Protons are able to activate the TRPV1 ion channel at pH below 6.5. Hence, minor 
reductions in pH below (neutral) 7.4 do not, as such, activate this ion channel. 
Capsaicin-binding, the temperature threshold for activation of the ion channel, and 
channel-gating are all affected by pH.  Lowering pH enhances the apparent binding 
affinity of capsaicin, and lowers the heat threshold for activation of the channel. It 
also promotes the occurrence of long openings and short closures, and stabilises at 
least one of the open conformations of the channel. Moreover, capsaicin-binding and 
protonation of the channel interact allosterically, where the effect of one can be offset 
by the effect of the other (Ryu et al., 2003). Jordt and colleagues thought that protons 
modulate TRPV1 activity by interacting with specific amino acid residues on the 
extracellular surface of the channel protein (Jordt et al., 2000). The response of 
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TRPV1 to protons may be the result of at least two different mechanisms, namely, 
first, activation of the channel and, second, potentiation of the currents generated by 
an already activated channel (Ryu et al., 2003). These mechanisms appear to be 
distinct and separate although originating at the site where protonation is initiated. 
Mutations at the extracellular E648 residue selectively abrogate proton-evoked 
channel activation without diminishing the channel’s responses to other noxious 
stimuli. However, while mutation at this site blocks proton-evoked activation, it does 
not affect proton-evoked potentiation. Another extracellular residue, E600 in the 
region linking the fifth transmembrane domain with the putative pore-forming region 
of the channel, constitutes the key regulatory site involved in the dynamic potentiation 
of the TRPV1 response to capsaicin or heat. It has been suggested that this site could 
set the sensitivity to other noxious stimuli in response to changes in extracellular 
proton concentration (Jordt et al., 2000). 
 
2.11.5.  Cation activation of TRPV1 
     In addition to protons, excess positive charges carried by various other ions are 
also able to activate TRPV1.  Ahern and colleagues showed that extracellular Na+, 
Mg++, and Ca2+ can directly gate the TPRV1 ion channel under extreme or 
pathophysiological concentrations.  However, even discrete pathology may result in 
the generation of extracellular microenvironments which readily achieve 
concentrations of cations which are sufficient to directly gate TRPV1.   For example, 
in bone, the [Ca2+] surrounding resorbing osteoclasts approaches 40 mM (Silver et al, 
1998). A yet more significant effect of extracellular cations may occur under normal 
physiological conditions where millimolar increases in cation concentrations (1-5 
mM) are sufficient to sensitise TRPV1 to various ligands, including capsaicin, AEA, 
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and NADA. Site E600 and, to a lesser degree, site E648, are proposed to mediate 
cation activation of TRPV1, whereas site E648 is proposed to selectively support 
cation sensitisation of agonist-evoked responses (Ahern et al., 2005). This is the 
converse of the response previously observed by Jordt and colleagues with protons, in 
which E600 mediates proton sensitisation of agonist-mediated currents (Jordt et al., 
2000). It is also proposed that divalent cations are more potent agonists than protons, 
because they impart a greater net positive charge at their binding sites (Ahern et al., 
2005).  
   
2.11.6. ASICs mediate pain sensations from both minor and  
TRPV1-sensitive reductions in pH 
    Acid-sensing ion channels (ASICs) are activated by extracellular protons.  In the 
periphery, they contribute to the excitation of primary sensory neurons when exposed 
to an acid solution, including that comprised in an acidic microenvironment. ASICs 
are H+-gated Na+ channels which belong to the degenerin/epithelial sodium 
(Deg/ENaC) superfamily of ion channels (Waldmann et al., 1997). Six different 
members of the ASIC subfamily have been cloned (ASIC1a, ASIC1b, ASIC2a, 
ASIC2b, ASIC3, and ASIC4), which are encoded by four genes. ASIC1b and ASIC2b 
are splice variants of ASIC1a and ASIC2a (Bassler et al., 2001).  All ASICs -- with 
the exception of ASIC4 -- are expressed in sensory neurons of the dorsal root 
ganglion. Homomeric acid-sensing ion channel 1 (ASIC1) can be activated by 
extracellular H+ in the physiological pH range. Extracellular, divalent cations like 
Ca2+ and Mg2+, as well as the polyvalent cation spermine, shift the steady-state 
inactivation of ASIC1a and ASIC1b to more acidic values. This leads to a potentiation 
of the channel response and is due to a stabilization of the resting state. ASIC1b is an 
effective sensor of transient H+ signals during slight acidosis and, in addition to 
 113 
alternative splicing, interaction with divalent and polyvalent cations extends the 
dynamic range of ASIC H+ sensors (Babini et al., 2002). ASIC2b (a splice variant of 
ASIC2a) is acid-insensitive (Smith et al., 2007b). 
      Studies of ASIC3 in rat suggest that protons open ASIC3 by speeding release of 
Ca2+ ions from a high-affinity binding site on the extracellular side of the pore.  The 
bound Ca2+ ions block permeation and the channel conducts when multiple H+ ions 
relieve this block (Immke and McCleskey, 2003). Consistent with this hypothesis, 
there is evidence that activation of ASIC1 (in fish) is mediated by displacement of 
Ca2+ from the extracellular domain either by reducing the concentration of 
extracellular Ca2+ or by competing with protons for the same binding sites (Zhang et 
al., 2006). ASIC4 – where it is expressed -- appears to perform a regulatory function 
in relation to acid-sensitive ASICs.  Transfected ASIC4 is targeted to the plasma 
membrane in CHO-K1 cells, where it associates with ASIC1a and down-regulates 
exogenous ASIC1a expression.  ASIC4 performs a similar function with ASIC3 in 
similar circumstances (Donier et al., 2008). 
      After activation in the presence of an extracellular acidic environment, ASICs 
become desensitised over time, although desensitisation slows as temperature 
decreases (Askwith et al., 2001).     The rate of desensitisation is affected by 
mutations on, or near, the first transmembrane domain (Coric et al., 2003;  Pfister et 
al., 2006).  Cushman and colleagues have shown evidence of a specific conformation 
change in extracellular domain of ASIC3 associated with desensitisation (Cushman et 
al., 2007).   
       During conditions that normally induce steady-state desensitisation, exogenous 
and endogenous arginine-phenylalanine-amide-related peptides profoundly enhance 
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ASIC1a activity. The human ASIC1a requires more acidic pH to undergo steady-state 
desensitisation compared with mouse ASIC1a.  Moreover, steady-state desensitisation 
of human ASIC1a is also affected by a greater number of peptides compared with 
mouse ASIC1a.  Mutation of five amino acids in a region of the extracellular domain 
changes the characteristics of human ASIC1a to those of mouse ASIC1a (Sherwood 
& Askwith, 2008).  
 
2.11.7.   ASICs as mediators of inflammatory pain 
          ASIC expression is increased in inflammatory conditions. This increase is 
contributed to by the pro-inflammatory mediators NGF, serotonin, interleukin-1, and 
bradykinin. A mixture of these mediators increases ASIC-like current amplitude on 
sensory neurons as well as the number of ASIC-expressing neurons and leads to 
higher sensory neuron excitability (Mamet et al., 2002).  Arachidonic acid potentiates 
the currents carried by ASIC1a and ASIC3 in rat dorsal root ganglion neurons (Smith 
et al., 2007b).  Acidic microenvironments may be created by osteoclasts in bone 
disorders with increased osteoclastic bone resoprtion.  The resulting hyperalgesia is 
mediated, in part at least, by up-regulation of ASICs’ expression (Nagae et al., 2007).   
Three ASIC isoforms -- ASIC1a, ASIC2a, and ASIC2b -- are expressed at a high 
level in dorsal horn neurons of rat spinal cord.  Peripheral CFA-induced inflammation 
results in increased expression of both ASIC1a and ASIC2a in dorsal horn neurons 
(Wu et al., 2004).   Following formalin injection, ASIC1 null mice and ASIC2 null 
mice show enhanced pain behaviour, predominantly in the second phase of the test.  
However, this does not occur with ASIC3 null mice (Staniland & McMahon, 2009).   
Nitric oxide (NO) has a direct external effect on acid-sensitive ASIC ion channels and 
potentiates their activity (Cadiou et al., 2007).  ASIC1a and ASIC2a are the most 
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abundant ASICs in mouse adult spinal cord and are co-expressed by most neurons 
throughout all the laminae (Baron et al., 2008).  There is evidence that increased 
ASIC activity in spinal dorsal horn neurons promotes pain by central sensitisation 
(Duan et al., 2007).    
 
      Approximately 60 per cent of rat cutaneous sensory neurons express ASIC3-like 
currents.  Moderate pH, either alone or in conjunction with hypertonicity and 
arachidonic acid, increases neuronal excitability and results in pain which is 
suppressed by a specific blocker of ASIC3.  Blockade of ASIC3 and in vivo 
knockdown of this ion channel with a specific siRNA have potent analgesic effects 
against primary inflammation-induced hyperalgesia in rat (Deval et al., 2008).   In 
mice, ASIC3 immunoreactivity is found in 31 per cent of knee joint afferents, but, 
after joint inflammation due to carrageenan-induced arthritis, ASIC3 immunoreactive 
neurons increase in number by about 50 per cent (Ikeuchi et al., 2009).  ASIC3 is also 
associated with hyperalgesia in response to hind-paw injection with acetic acid of rats 
with the L5 SNL model of neuropathic pain (Omori et al., 2008).    
      The extent of the respective roles performed by ASICs and TRPV1 ion channels 
in mediating acid-induced pain varies between species.  Thus, there are significant 
differences between rat and mouse in the contribution of TRPV1 and ASIC subunits 
to proton sensitivity of sensory neurons (Leffler et al., 2006). It may also be the case 
that the extent of the respective roles performed by ASICs and TRPV1 in mediating 
acid-induced pain varies between tissues and, indeed, within tissues (Sugiura et al., 
2007). ASIC expression may also be affected by tissue damage. Thus, gastric ulcers 
alter the properties of acid-elicited currents by increasing pH sensitivity and current 
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density and changing current kinetics in gastric dorsal root ganglion neurons (Sugiura 
et al., 2005). 
 
     The TRPV1 ion channel is modulated by acid at lower pH values than ASICs 
(Tominaga et al., 1998; Jones et al., 2004). There is evidence that, in humans, TRPV1 
plays a relatively minor role in signalling  cutaneous acid induced pain of moderate 
intensity, with ASICs being the main mediators of pain in that context.  However, it 
may well be that TRPV1 plays a more prominent role in more acidic conditions 
(Jones et al., 2004).  In situ hybridization studies suggest that ASIC1a receptors are 
expressed in 20-25 per cent of (mostly small diameter) DRG neurons in rat;  ASIC1b 
are expressed by 10 per cent, and ASIC3 by 30-35 per cent, of small-to-medium 
diameter DRG neurons.  ASIC1a and ASIC1 are essentially found in distinct 
populations of DRG neurons.  There is some overlap between ASIC1 and ASIC1b, 
respectively, with ASIC3 channels.  ASIC1a is strongly expressed in  40-45 per cent 
of TRPV1 positive neurons.  ASIC1b is very rarely found in neurons expressing 
TRPV1, but 30 per cent of TRPV1 positive neurons express ASIC3 receptors. 
Approximately 13 per cent of TRPV1 positive neurons also express both ASIC1a and 
ASIC3. (Ugawa et al., 2005).   
 
2.11.8   Proton-sensing G-protein-coupled receptors (GPCRs) 
       Proton-sensing GPCRs have been identified in primary sensory afferents but the 
extent to which they contribute to neuronal excitation and peripheral nociception 
remains unclear.  These GPCRs were initially identified as subserving other functions 
and it was only more recently discovered that, in addition, they are capable of being 
activated by certain extracellular proton concentrations (pH).    OGR1 (ovarian cancer 
 117 
G-protein-coupled receptor 1) and GPR4 (G-protein-coupled receptor 4) were first 
reported as proton-sensing GPCRs (Ludwig et al., 2003), followed by G2A 
(Murakami et al., 2004), and TDAG (T cell death-associated gene 8) (Wang et al., 
2004;  Ishii et al, 2005).  The members of this GPCR group share 40 to 50 per cent 
homology with each other and sense extracellular protons (i.e.,  pH) through histidine 
residues of their receptors to stimulate a variety of intracellular signalling pathways 
through several types of hetero-trimeric G-proteins (Tomura et al., 2005).  
Acidification of the extracellular environment significantly increases the constitutive 
activities of OGR1, GPR4, and TDAG8, but not G2A, as measured by production of 
IP or cAMP (Radu et al., 2004).   These proton-sensing GPCRs are  all fully activated 
at pH 6.4-6.8 in vitro (Huang et al., 2007).   GPCRs of the OGR1 family are widely 
expressed in neuronal and non-neuronal tissues in mouse.  Their transcripts are 
expressed in mouse DRG and most (75-82 per cent) are present in small-diameter 
nociceptive neurons.   Approximately 31 to 40 per cent of all DRG neurons express at 
least two proton-sensing GFCRs. Moreover, in ASIC3 null mice, gene expression of 
proton-sensing GPCRs is also altered (Huang et al., 2007).   
 
       The fact that proton-sensing GPCRs are found in DRG neurons indicates that 
these receptors are localised to structures which are relevant to the induction of 
peripheral nociception (Huang et al., 2007).   The inflammatory agents capsaicin, 
carrageen, and CFA alter the expression of proton-sensing GPCRs in mouse DRG, 
each to a different extent.  The expression of TDAG8 is increased 24 hours after CFA 
injection.  Indeed, the number of DRG neurons that express both TDAG8 and TRPV1 
is also increased.  Moreover, TDAG8 activation sensitises the TRPV1 response to 
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capsaicin leading to the suggestion that TDAG8 may be involved in CFA-induced 
inflammatory pain through regulation of TRPV1 function.  (Chen et al., 2009) 
 
 
2.12.   CYTOKINES 
2.12.1.   Introduction 
          “Cytokine” is a generic term which embraces many different kinds of cell 
signalling molecules.  Thus, “lymphokines” and “monokines” are signalling 
molecules made by lymphocytes and monocytes, respectively.  “Chemokines” are 
signalling molecules which possess chemotactic properties, while interleukins are 
cytokines made by one leukocyte which act on other leukocytes.  Cytokines may 
exhibit autocrine, paracrine, or endocrine, actions where they act on same cells that 
secrete them, or on nearby cells, or on more remote cells, respectively.   Some 
cytokines are described as “pro-inflammatory,” while other cytokines are described as 
“anti-inflammatory.”  Maintaining the balance between both types may be important 
for reducing inflammatory pain sensation. Cytokines are literally legion, and of those 
identified, some are important in mediating the pain signal in inflammatory 
conditions.    In carrageenan-induced inflammation, although the related dorsal root 
ganglion shows elevated expression of only Scya2 (chemokine C-C motif ligand 2), 
the inflamed tissues exhibit 42 known cytokine and endothelial-related genes with 
elevated expression (Yang et al., 2007).  Carageenan injection in the rat tail results in 
both thermal and mechanical hyperalgesia which coincides with significant increases 
in the concentration in the tissues of TNF-alpha, IL-1beta, IL-6 and CINC-1 
(cytokine-induced neutrophil chemoattractant), peaking at 6 hours after injection 
(Loram et al., 2007a).  However, the pattern of cytokine release during carrageen-
induced inflammation differs in muscle inflammation from that seen in cutaneous 
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inflammation (Loram et al., 2007b). Up-regulation of IL-6, IL-8 and CCL2 gene 
expression contributes to the development of acute inflammation and inflammatory 
pain in an oral surgery model of tissue injury and acute pain (Wang et al., 2009).                                                                         
 
     However, it is important to note that not only may the pattern of cytokine release 
vary from one injury type to another, but, also, that the fact that cytokines are released 
as a result of tissue damage and ensuing inflammation does not make their action a 
condition precedent to the development of inflammatory pain.  In other words, one, or 
more, cytokines may not be essential, given other inflammagens, to produce the 
inflammatory pain sensation.   Thus, surgery to the rat tail results, within two hours of 
surgery, in mechanical hyperalgesia which lasts for 6 days.   However, the tissue 
concentration of IL-1beta, IL-6, and CINC-1 increases only within 24 hours of 
surgery, and TNF-alpha increases only within 48 hours of surgery.  Thereafter, 
cytokine concentrations remain elevated for four days (IL-1beta and IL-6) to 8 days 
(CINC-1, TNF-alpha) after surgery.  Hence, secretion of these inflammatory 
cytokines is not essential for the development of post-operative hyperalgesia in this 
model of surgery (Loram et al., 2007c).  
 
     Several cytokines which have attained particular prominence in the literature in the 
context of inflammatory pain are considered here.   
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2.12.2.  Growth-related oncogene (GRO/KC: CXCL1) 
      Neuronal inflammation per se, in the absence of nerve injury, causes large 
increases in Na+ channel density, increased K+ currents, and overall enhanced 
neuronal excitability (Wang et al., 2007)    Levels of the cytokine growth-related 
oncogene (GRO/KC: CXCL1) are rapidly elevated in  dorsal root ganglion cells in 
inflammatory pain models.  Thus, when CXCL1 is incubated overnight with acutely 
isolated small diameter rat (adult) sensory neurons in vitro, both TTX-resistant and 
TTX-sensitive currents increase from 2- to 4-fold, in both IB4-positive and IB4-
negative sensory neurons, without altered voltage dependence or kinetic changes. 
Two of the three types of Na+ channels expressed show marked increases in 
expression, while CXCL1 cause a marked increase in neuronal excitability and a 
striking ability of neurons to fire repetitively (Wang et al., 2008).   In IB4-negative 
acutely cultured adult rat small diameter sensory neurons, voltage-activated potassium 
current densities of both transient and sustained components  increase after overnight 
incubation with CXCL1, without marked changes in voltage dependence or kinetics 
(Yan et al., 2009). 
 
         CXCL1, CXCL5, and LTB4 act sequentially in antigen-induced arthritis (a 
model of rheumatoid arthritis) to induce neutrophil migration.  Elevated levels of 
CXCL1 and CXCL5 are also found in the synovial compartment of rheumatoid 
arthritis patients suggesting that these chemokines are indeed implicated in the 
pathogenesis of rheumatoid arthritis (Grespan et al., 2008) 
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2.12.3.  Interleukin-1alpha 
      Interleukin-1alpha (IL-1alpha) regulates substance P expression and release in 
adult sensory neurons.   When cultured dorsal root ganglion neurons of adult rat are 
exposed to either IL-1alpha or IL-1beta, the neurons, in each case, secrete 
substantially more substance P on stimulation with capsaicin than do neurons of 
control cultures.  However, the addition of IL-1beta reduces the amount of substance 
P secreted in the presence of IL-1alpha on its own. Both of these cytokines alter 
substance P expression via the IL-1 receptor (Skoff et al., 2009).   
 
2.12.4.   Interleukin-1beta 
      CFA-induced inflammation in rats results in signification elevation in Il-1B and 
NGF in the inflamed tissues and of the peptides, substance P and calcitonin gene 
related peptide in the L4 dorsal root ganglion 48 hours after CFA injection (Safieh-
Garabedian, et al, 1995).  IL-1beta when injected intrathecally in mice with CFA-
induced inflammation results in a marked increase in spinal COX-2 mRNA and 
persistent thermal hyperalgesia in mice.  Moreover, the hypersensitivity resulting 
from the CFA-induced inflammation is significantly reduced by repeated intrathecal. 
pre-injection with an agent which sequesters endogenous IL-1beta (Narita et al., 
2008) 
 
       IL-1beta is believed to be important in the pathogenesis of osteoarthritis.  Up-
regulation of IL-1beta initiates a cascade of intracellular events that can result in 
activation of proteinases, creation of an articular milieu which is tissue destructive, 
inhibition of anabolic pathways, and reduced synthesis of cartilage extracellular 
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matrix (Daheshia & Yao, 2008).  Hyperalgesia, synovitis, and multiple biomarkers of 
inflammation are suppressed by Il-1 inhibition in a mouse model of gout arthritis 
(Torres et al., 2009).   
 
2.12.5.   Tumour necrosis factor-alpha 
    Tumour necrosis factor-alpha (TNF-alpha) induces hyperalgesia and also up-
regulates IL-1beta.  CFA-induced inflammation in rat results in significant elevation 
in the levels of TNF-alpha, Il-1beta and NGF in the inflamed paw (Woolf et al., 
1997).  TNF-alpha when injected intrathecally in mice with CFA-induced 
inflammation results in a marked increase in spinal COX-2 mRNA and persistent 
thermal hyperalgesia in mice.  Moreover, the hypersensitivity resulting from the CFA-
induced inflammation is significantly reduced by repeated intrathecal. pre-injection 
with an agent which sequesters endogenous TNF-alpha (Narita et al., 2008). 
 
       Peripheral administration of TNF-alpha induces thermal hypersensitivity in wild-
type mice but not in TRPV1 null mice.  In contrast, TNF-alpha application results in 
similar mechanical hypersensitivity in TRPV1 null mice and in wild-type mice, 
suggesting a role for TRPV1 in TNF-alpha-induced thermal, but not mechanical, 
hypersensitivity (Jin & Gereau IV, 2006).  Again, acute application of TNF-alpha 
rapidly enhances TTX-resistant Na+ currents in isolated mouse dorsal root ganglion 
neurons.   This increase in Na+ currents is substantially reduced in dorsal root 
ganglion neurons taken from TNF receptor 1 mull mice and is blocked by a p38 
mitogen-activated protein kinase inhibitor.  Mechanical hypersensitivity induced by 
peripherally applied TNF-alpha is also significantly reduced by the same inhibitor (Jin 
& Gereau IV, 2006).  In rats with chronic antigen-induced arthritis in the knee joint 
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neutralization of TNF-alpha results in pronounced anti-nociceptive effects (Boettger 
et al., 2008).  Inhibition of TNF-alpha reduces nociception in the first and second 
phases of formalin-evoked nociception in rats.   Thus, when formalin is injected into 
the rat right upper lip, there is a marked reduction of the first and second phases of 
formalin-evoked nociception  as result of systemic pre-treatment with the preferential 
inhibitor of TNF-alpha synthesis, thalidomide (Seadi Pereira et al., 2009). 
 
2.12.6.  Endothelins 
       Endogenous endothelin (ET) peptides are involved in mediating inflammatory, 
and other, pain conditions (Khodorova et al., 2009;  Hans et al., 2008).   Local 
injection of endothelin-1 results in nociceptive behaviour and excitation of C-fibres 
and A-delta-fibres in rats.   Subcutaneous hind-paw injection of ET-1 in rat results in 
hind-paw flinching within minutes, which peaks at 30 minutes, and lasts for 60 
minutes.  This response is strongly inhibited by an endothelin-A receptor antagonist 
(Gokin et al., 2001;  Davar et al., 1998.   However, local injection of a selective 
endothelin-B receptor agonist inhibits ET1-induced nociceptive behaviour and 
excitation of primary afferents in a naloxone-sensitive manner. Hence, ET(A) and 
ET(B) receptors provide for dual modulation of acute nociceptive signalling in 
cutaneous tissues (Khodorova et al., 2002).  ET-1 potentiates TRPV1 by a PKC-
dependent mechanism in rat dorsal root ganglion cells in vitro and in HEK-293 cells 
co-expressing TRPV1 and the ET(A) receptor (Plant et al., 2007).   Sensitisation of 
TRPV1, through an ET(A)-PKC pathway appears to contribute to ET-1-induced 
thermal hyperalgesia. Thus, intraplantar ET-1 injection produces thermal hyperalgesia 
in a dose-dependent manner.  This thermal hyperalgesia is reduced by inhibition of 
the ET(A) receptor and PKC.  However, inhibition of the ET(B) receptor does not 
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have this effect. In addition, ET-1-induced thermal hyperalgesia is significantly 
reduced in TRPV1 null mice when compared with wild-type mice (Kawamata et al., 
2008).   The increased in  capsaicin-induced nociception caused by ET-1 is abolished 
in rat by prior administration of an ET(A) receptor antagonist, but not by an ET(B) 
receptor antagonist. However, the increase of capsaicin-induced hyperalgesia in rat 
caused  by ET-1 is attenuated by both of these antagonists (Mottta et al., 2009).   
 
     Endogenous endothelins contribute to knee-joint inflammation in zymosan-
induced arthritis in mice.  Acting through ET(A) and ET(B) receptors, these cytokines 
modulate oedema formation, neutrophil recruitment, and production of inflammatory 
mediators (Conte Fde, 2008). 
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2.13. NEUROGENIC INFLAMMATION 
2.13.1.   Introduction  
   Neurogenic inflammation is the term employed to describe that inflammation which 
originates from the release of inflammatory neuromediators from the peripheral 
terminals of primary afferent fibres (Jansco et al., 1967; Szolcsanyi, 1988, 1996).  
These neuromediators in turn act on target cells in the periphery, such as mast cells, 
immune cells, and vascular smooth muscle cells, to produce inflammation, which is 
characterised by redness and warmth, swelling, and pain (Durnett Richardson & 
Vasko, 2002). The neuromediators released include calcitonin gene-related peptide 
(CGRP) and substance P (SP), which are found in a population of primary sensory 
neurons (Gibbins et al., 1985; Alvarez et al., 1988; Aoki et al., 2005).  Neurogenic 
inflammation arises in two contexts.  First, there exists a “pure neurogenic form of 
inflammation” identified by Jansco and colleagues (1967), the existence of which is 
“supported by the finding that antidromic stimulation of the sensory nerve evokes an 
inflammatory response.”  A group of inflammation-inducing agents, such as 
capsaicin, exert their inflammatory action by this neurogenic route (Jansco et al., 
1967).  Thus, intradermal capsaicin injection is employed experimentally to induce 
neurogenic inflammation, manifested as CGRP and substance P release, with resulting 
arteriolar vasodilation, plasma extravasation and pain.  Such inflammatory response 
as is evoked by the pin-prick of the injection, as such, bears no relation to the almost 
immediate “pure neurogenic” inflammatory response which develops in the area of 
the injection.  This “pure neurgogenic” inflammatory response is to be distinguished 
from neurogenic inflammation which is secondary to major inflammation which 
initially results from tissue damage or disease.  The inflammation resulting from this 
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tissue damage or disease initiates a barrage of activity of primary afferent fibres 
which, in turn, results in antidromic activation of those afferents and the release by 
them of inflammatory neuromediators which enhance the excitability of those 
afferents as well as contributing further to the primary inflammation. Many 
inflammatory diseases, including arthritis, inflammatory bowel diseases, and 
migraine, are believed to comprise a neurogenic element.  The subject of neurogenic 
inflammation has been recently extensively reviewed (Jansco, 2009). 
 
2.13.2.  Cellular mechanisms of neurogenic inflammation 
        Antidromic activation of primary sensory afferents, driven by dorsal root 
reflexes (DRRs), are involved in mediating the release of inflammatory neuropeptides 
from the peripheral terminals of primary afferents (Jansco et al., 1967; Lin et al., 
1999; Willis, 1999; Lin et al., 2000; Lin et al., 2007; Li et al., 2008).   Excessive 
depolarisation of the central terminals of primary afferents in the dorsal horn of the 
spinal cord goes to generate DRRs.  Willis and colleagues (2006) have proposed that 
DRRs are triggered by an excessive primary afferent depolarisation (PAD) which 
results from the opening of Cl- channels and the efflux of Cl- ions from the synaptic 
terminals of primary afferents.  The high gradient of Cl- ions in primary afferent 
neurons is maintained by the Na+K+22Cl- co-transporter (NKCC).  The increased 
activity of the NKCC co-transporter contributes to the generation of DRRs and 
subsequently to the development of neurogenic inflammation (Valencia-de Ita et al., 
2006).  Sustained PAD also results in the phenomenon of central sensitisation of 
nociceptor specific neurons in the dorsal horn of the spinal cord.  A sustained 
discharge of peripheral primary sensory afferents develops a capacity on the part of 
nociceptor specific neurons in the dorsal horn of the spinal cord to acquire low-
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threshold inputs and enhances their excitability.  This sensitisation can be reduced, or 
even reversed, by GABAA receptor antagonists, thereby implicating GABAA 
receptors in the development of central sensitisation (Garcia-Nicas et al., 2006).   
DRRs are also dependent on GABAA receptor activation of nociceptive specific 
neurons of the spinal dorsal horn (Lin et al., 2007).  Hence, GABAA receptor 
activation appears to be important in developing that enhanced excitability of 
peripheral, and spinal cord, nociceptive neurons which is characteristic of neurogenic 
inflammation, and central sensitisation, respectively. 
 
      Local intradermal paw injection in the rat of capsaicin, CGRP, or substance P 
results in cutaneous vasodilation and oedema.  Removal of DRRs, either by spinal 
dorsal rhizotomy, or by intrathecal administration of the GABAA receptor antagonist, 
bicuculline, reduces the capsaicin-induced vasolidation and oedema dramatically. 
Hence, DRRs are essential for driving the release of inflammation-inducing 
neuropeptides, at least in the context of neurogenic inflammation induced by 
intradermal capsaicin injection in rat.  On the other hand, inflammation induced by 
injection of CGRP or of substance P is not significantly affected after DRR removal.   
A TRPV1 antagonist, administered peripherally, can almost completely abolish the 
capsaicin-evoked inflammation, whereas pre-treatment at the periphery with 
antagonists at the receptors for CGRP and substance P, respectively, only reduce the 
inflammation (Lin et al., 2007).  When primary afferent nociceptive fibres are 
sensitised by capsaicin (manifested by an increase in afferent responses and a 
lowering of the response threshold to mechanical stimuli), the capsaicin-evoked 
sensitisation is significantly reduced after DRRs are removed by dorsal rhizotomy.  
Moreover, peripheral after-treatment with CGRP dose-dependently restores 
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capsaicin–induced sensitisation under dorsal rhizotomised conditions.  Hence, it 
appears that CGRP released by primary sensory afferents in conditions of neurogenic 
inflammation “feeds back” on those afferents to enhance their state of excitation (Li et 
al., 2008).   
 
2.14.  CONCLUSION 
      TRPV1 initially appeared to hold out the promise of explaining much of the 
mystery of peripheral inflammatory pain and, equally importantly, of providing a 
target for scientists attempting to devise a drug which would relieve that pain.  That 
promise has not been fulfilled.  TRPA1 has newly emerged as a potent contributor to 
primary afferent excitation in inflammation, and the importance of the role of voltage-
gated sodium channels in this regard is also becoming apparent.  In any event, there 
appears to be considerable redundancy at the periphery in terms of the availability of 
mechanisms which are capable of responding to inflammatory agents and contributing 
to neuronal excitation and nociceptive signalling.  Hence, “combination therapy,” in 
which two, or more, mediating mechanisms are blocked may be a logical 
development in proposed analgesic therapies.  However, this ignores the fact that the 
ongoing elucidation of the extent of the distribution of TRPV1 throughout the body 
and its involvement in multiple physiological functions suggests that TRPV1 
antagonists are likely to offer more of a lethal, than a “magic,” bullet for analgesia.  It 
may well prove more rewarding in terms of analgesic effect if researchers were to 
focus their attention on neutralising certain of the agents of inflammatory pain since it 
has been shown that the excitability of primary afferents may be reduced by 
eliminating certain of the complex of inflammatory mediators which would otherwise 
be active (Maingret et al., 2008; Summer et al., 2008).    In any event, it is surely a 
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sobering consideration that billions of dollars, of euros, and of pounds, have yet to 
achieve the success in pain relief achieved by Friederick Serturner, at the age of 20, in 
1805, when he obtained pure morphine from the poppy plant, and by Felix Hoffman 
who, in 1897, rediscovered acetylsalicylic acid, which was subsequently patented and 
marketed as “Aspirin.”   
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3.1.   INTRODUCTION 
     The experimental work required for this dissertation was based on various 
techniques in molecular biology, extending over the areas of: cell culture; 
immunohistochemistry; agonist-activated cobalt uptake and imaging; and enzyme-
linked immunosorbent assays (ELISAs).  Here, the theoretical bases of these 
techniques are described, as are the protocols which were employed for their 
execution. 
 
        I do not address the techniques involved in sacrificing animals, administering 
injections, administering scalding-type burn injury, inducing and maintaining 
anaesthesia in animals, or spinal cord extraction, as colleagues kindly performed on 
my behalf those aspects of the experiments which involved exposure to animal fur.  
 
3.2.   CELL CULTURE TECHNIQUES 
3.2.1. Requirements for culturing cells 
     Most kinds of plant and animal cells are able to survive, proliferate, and even 
express differentiated properties in a tissue culture dish in appropriate conditions.  
These conditions are quite elaborate.  Most obviously, they require a suitable 
environment and a medium which contains the necessary nutrients to sustain cell life, 
as well as various other factors, such as growth factors, which stimulate cell 
proliferation, and transferrin, which carries iron into cells. These nutrients and other 
factors were traditionally supplied by constituting a medium comprising specified 
quantities of small molecules such as salts, glucose, amino acids, and vitamins, 
together with a poorly defined mixture of macromolecules in the form of horse serum, 
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or foetal calf serum, or a crude extract made from chick embryos.  Such media are 
still used today for routine cell culture.  Various serum-free, chemically defined, 
media have been developed which, in addition to the usual small molecules, include 
one, or more, specific proteins that most cells require in order to survive and 
proliferate in culture, such as growth factors and transferrin (Alberts et al., 1994).   It 
must also be emphasised that the growth of cells in culture requires a controlled 
environment, especially in terms of temperature, oxygen and carbon dioxide. 
 
     Defined cell culture media generally consists of four basic chemical groups:  
amino acids; carbohydrates; inorganic salts; and vitamins.  This balanced mixture 
provides the sources for protein synthesis, energy metabolism, cell membrane 
functions, and catalytic processes.  Many of these basal media need to be 
supplemented with serum, or other appropriate proteins, for promoting cell growth.  
Historically, foetal calf serum, of 1 to 2 per cent volume of the media, has been used 
as a rich source of these complex protein requirements.  However, the composition of 
serum varies from lot to lot, introducing a significant variability in products 
manufactured from this source. 
 
     Minimum Essential Media (MEM) is the most widely used media and was 
originally developed for primary cell cultures.  It supports the growth of a broad 
spectrum of cells (including haematopoietic and bone marrow cells).  It serves as the 
basis for other modified media, such as DMEM. 
 
      Dulbecco’s Modified Eagle Media (DMEM) is a modification of MEM which has 
increased amino acids and vitamins and also contains non-essential amino acids, ferric 
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nitrate, and more glucose.   It is suited for a broad range of mammalian cells and can 
be used as a basic component of speciality media. 
 
     Nutrient Mixture F-12  (Ham’s Modification) has a higher level of amino acids, 
vitamins and trace elements.  It was developed for cell lines but is suitable also for 
primary cell cultures. 
 
3.2.2. Primary and secondary cell cultures 
     Primary cell cultures are cell cultures prepared directly from the tissues of an 
organism.  Thus, we have used dorsal root ganglia neurons harvested from rat to 
investigate the effect, if any, of xenon in attenuating their response to capsaicin.   
Such cultures suffer from several drawbacks, most notably, the damage which the 
cells sustain while being harvested and the effect on their normal functioning of their 
being dissociated from the other tissues with which they profoundly interact in vivo. 
 
        Secondary cell cultures describe the cultures obtained from propagating cells 
derived from tissue, which introduces the next most fundamental aspect of cell culture 
technique, namely, the process of growing cells in a confluent monolayer by 
providing them with anchorage to pass “start” in their cell cycle.   Dissociated cells 
plated on a dish in the presence of appropriate media adhere to the surface, spread out, 
and divide until a confluent monolayer is formed in which each cell is attached to the 
dish and contacts its neighbours on all sides.  At this stage, the cells stop dividing, 
thereby exhibiting “density-dependent inhibition of cell division” unless they are 
cancerous (“transformed”) cells which are not similarly restrained. Cells grown in 
vitro also generally exhibit “anchorage dependence of cell division” meaning that 
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they require to be able to adhere to the underlying plate surface in order to divide.  A 
suitable surface to which propagating cells may adhere is constituted by the plastic 
surface of the culture-dish or T75 flask. 
 
       Many biochemical procedures require the isolation of a specific population, or 
populations, of cells.  The required cells must be dissociated from their parent tissues 
and from other cell types.  Disruption of the extracellular matrix and intercellular 
junctions that hold the cells together is typically achieved by the use of proteolytic 
enzymes, such as trypsin and collagenase, or with agents, such as EDTA, that bind, or 
chelate, the Ca2+ on which cell-to-cell adhesion depends.  Large cells can be separated 
from small cells, and dense cells from light cells, by centrifugation.  Yet another 
technique is based on the tendency of some cell types to adhere strongly to glass or 
plastic, which allows them to be separated from cells that adhere less strongly.  A 
refinement of this latter technique relies upon the specific binding properties of 
antibodies.  Antibodies that bind specifically to the surface of only one cell type in a 
tissue can be coupled to various matrices – such as collagenase, polysaccharide beads, 
or plastic – to form an “affinity surface” to which only cells recognised by the 
antibodies will adhere.  The cells which are bound may then be recovered by gentle 
shaking, by treatment with trypsin to digest the proteins that mediate the adhesion, or, 
in the case of a digestible matrix (such as collagen), by degrading the matrix itself 
with enzymes, such as collagenase (Alberts et al., 1994). 
 
3.2.3. Propagation techniques 
     Cell culture propagation techniques, in which mammalian cells are propagated in 
vitro for experimental use, are among the most remarkable techniques of modern 
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biological science. When cells from normal mammalian tissues are cultured in 
standard conditions, their ability to propagate is confined to a limited number of 
division cycles – about 50 for typical cells derived from humans.  After this, they 
cease dividing in the process described as “cell senescence.”   Some cells are capable 
of avoiding cell senescence to divide indefinitely as “cell lines.”   These cells have 
undergone a genetic change that makes them effectively immortal.  They will 
proliferate indefinitely in appropriate conditions and can be propagated as a cell line.    
Cell lines can also be developed from cancer cells which do not exhibit anchorage 
dependence and which proliferate to a very much higher density in a culture dish.  
Normal cells may similarly be “transformed” to constitute “transformed cell lines” by 
using a chemical or virus to alter their genetic make-up.  The genetic uniformity of a 
cell line can be improved by cell cloning, in which a single cell is isolated and 
allowed to proliferate to form a large clone.  A “clone” is any such collection of cells 
that are all descendants of a single ancestor.   Such clones offer standardised cells 
which are ideal for comparative purposes over many experiments (Alberts et al., 
1994). 
 
      The major advantages of these cloned cells reside in the efficiency with which 
they may be produced when compared with primary cultures and the consistency and 
reproducibility of the results which can be obtained from their use.  The main 
disadvantage associated with the use of these cells is that these cells are atypical and 
their responses are not indicative of those of any other cell type.  Moreover, after 
repeated passaging their characteristics may change and become quite different from 
those found in the starting population. 
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3.2.4. HEK293 technology 
     The HEK293 cell line is a clone of standardised cells which has proved to be 
particularly accommodating for reliably expressing DNA which has been artificially 
introduced into the cell in a process called “transfection.”   The HEK293 cell line is 
derived from human embryonic kidney (HEK) cells which were transformed by 
exposing human embryonic kidney cells to sheared fragments of adenovirus type 5 
DNA (Graham et al., 1977);  and the human-viral junctions of integrated adenovirus 
type 5 DNA in HEK293 cells have been cloned and sequenced (Louis et al., 1997).  
Remarkably, it has been found that these cells express significant amounts of protein 
and mRNA for three of the four major neurofilament (NF) proteins (NF-M, NF-L, and 
alpha-internexin),  with, in addition, small amounts of NF-H, the fourth NF subunit.  
Subject to very few, apparently aberrant, exceptions, each of these NF proteins is 
found only in neurons.  Hence, the presence of all of these proteins in HEK 293 cells 
is highly suggestive that these cell lines belong to the neuronal lineage.  It has been 
suggested that the most likely explanation for this phenomenon is that Ad5 
preferentially transforms rare neuronal lineage cells present in human and rodent 
kidney cultures.  It has also been observed that the use of these cells as a non-neuronal 
control line in transfection studies is inappropriate given their many attributes of 
developing neurones and neuronal progenitor cells (Shaw et al., 2002). 
 
       HEK293 cells have limitations when employed as a model to examine the 
functioning of various cell types since they are essentially in a category of their own.  
However, they are highly efficient in expressing a reliable transient transfection.  
Moreover, they are relatively easy to manage and sustain in culture.  They are, 
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therefore, useful where the behaviour of the cell itself is not the subject of study, but 
rather the protein which is expressed by the transfected DNA.   Repeated passaging of 
these cells results in variations from their original characteristics.  Hence, in this 
laboratory we do not use these cells after they have been passaged 20 times. 
 
      An important variant of the HEK293 cell line is the HEK293T cell line which 
provides longer temporal expression of the desired gene product. 
 
3.2.5. Transfection 
     Transfection of animal cells typically involves opening transient pores in the cell 
plasma membrane to allow the uptake of material.  Genetic material (such as 
supercoiled plasmid DNA or siRNA constructs), or even proteins, such as antibodies, 
may be transfected.  Various proprietary transfection reagents, such as Lipofectamine, 
are widely used.  Lipofectamine 2000 is a cationic liposome based reagent that 
provides high transfection efficiency and high levels of transgene expression in a 
range of mammalian cell types in vitro using a simple protocol.  Optimum 
transfection efficiency and subsequent cell viability depend on a number of 
experimental variables, such as cell density, liposome and DNA concentrations, 
liposome-DNA complexing time, and the presence, or absence, of media components, 
such as antibiotics and serum  (Dalby et al., 2004). 
 
       Tansfections may be transient or stable.   Transient transfections do not require 
that the foreign DNA should be introduced into the nuclear genome of the host cell, 
with the result that the foreign DNA is lost at the later stage when the cells undergo 
mitosis.  A stable transfection requires that the trasfected gene should remain in the 
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genome of the cell transfected and its daughter cells. To achieve a stable transfection, 
another gene must be co-transfected which gives the host cells some selection 
advantage, such as resistance to a certain toxin into their genome.  Addition of the 
toxin, to which the transfected gene offers resistance, results in only those few cells 
being able to proliferate, while the others perish.  Repeated application of this 
selection procedure results in only the cells with a stable transfection remaining for 
further cultivation.  Geneticin, also known as G418, is a common toxin employed to 
produce stable transfection.   
 
3.2.6. Cloning DNA of hTRPV1 
     DNA may be cloned by first obtaining a fragment of DNA which contains the gene 
of interest.  In our experiments using HEK293 cells, this was hTRPV1.  This DNA is 
then inserted into the purified DNA genome of a self-replicating genetic element – 
generally a virus or a plasmid. Plasmids are self-replicating extra-chromosomal 
circular DNA molecules, distinct from the normal bacterial genome.  The terms 
"recombinant DNA technology," "DNA cloning," "molecular cloning," or "gene 
cloning" all refer to the same process: the transfer of a DNA fragment of interest from 
one organism to a self-replicating genetic element, such as a bacterial plasmid.   The 
DNA of interest can then be propagated in a foreign host cell.  
 
      To "clone a gene," a DNA fragment containing the gene of interest is isolated 
from chromosomal DNA using restriction enzymes and then united with a plasmid 
that has been cut with the same restriction enzymes. When the fragment of 
chromosomal DNA is joined with its cloning vector in the laboratory, it is called a 
"recombinant DNA molecule." Following introduction into suitable host cells, the 
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recombinant DNA can then be reproduced along with the host cell DNA. Plasmids 
can carry up to 20,000 bp of foreign DNA. Besides bacterial plasmids, some other 
cloning vectors include viruses, bacteria artificial chromosomes (BACs), and yeast 
artificial chromosomes (YACs). Cosmids are artificially constructed cloning vectors 
that carry up to 45 kb of foreign DNA and can be packaged in lambda phage particles 
for infection into E. coli cells. BACs utilize the naturally occurring F-factor plasmid 
found in E. coli to carry 100 to 300 kb DNA inserts. A YAC is a functional 
chromosome derived from yeast that can carry up to 1 MB of foreign DNA. Bacteria 
are most often used as the host cells for recombinant DNA molecules, but yeast and 
mammalian cells also are used (Human Genome Project Information, 2008). 
 
3.2.7. Protocols: generally 
      We employed HEK293T cells in the experiments which required cloned 
transformed cells.  HEK293T cells are stored in liquid nitrogen until required for 
experiments.  Hence, the first protocol describes the procedure for retrieving cells 
from liquid nitrogen for growth and propagation in a flask maintained in an incubator.  
Such cells multiply, and are then passaged so that certain of their number can be used 
for transfection, while the remainder are placed in storage in liquid nitrogen until 
required.  Hence, the protocol for passaging cells is followed by that for transfection 
and that for preparing the cells for storage in liquid nitrogen. 
 
      Additional protocols describe the preparation of culture media and of poly-dl- 
ornithine-coated cover-slips and, finally, the preparation of a clone of  hTRPV1.   
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3.2.7.1.     Retrieving cells from liquid nitrogen 
       Generally, spray equipment with enthanol before introducing it into the fume   
cabinet, taking care, however, not to contaminate any cells or medium with such 
ethanol. 
 
First Day 
1. Place 35 mL of culture medium into a 50 mL Falcon tube. 
2. Spray with ethanol and place the Falcon tube in an incubator at 37 degrees 
C. 
3. Remove a vial of HEK293T cells from liquid nitrogen using a full face 
visor and glove protection. 
4. Place the vial in 37 degrees C. water bath for 5–10 minutes, until 
completely thawed. 
5. Then spray the vial with 70 per cent ethanol and wipe it down  before 
placing it into the fume cupboard. 
6. Remove the cell suspension from the vial and place it in the Falcon tube. 
7. Then, add 10 mL culture media, drop by drop, for the first 1 mL volume.  
Slow addition of the culture media helps to reduce cell damage by slowing 
the environmental changes to which the cells must adjust. 
8. Centrifuge at 1,100 rcp for 5 minutes at 26 degrees C. 
9. Remove the supernatant, and gently tap the pellet left in the end of the 
tube. 
10. Add 15 mL of culture medium to re-suspend the pellet. 
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11. Transfer the contents of this Falcon tube to a T75 flask, and label with date 
and passage number. 
12. Place the flask in an incubator at 37 degrees C. in 5 per cent CO2  
overnight. 
 
Second Day 
1. Place 15 mL of culture medium in a 50 mL Falcon tube and then place the 
tube in a hot water bath to warm the medium to 37 degrees C. 
2. Check the flask under a microscope to ascertain whether cells have 
attached to the flask surface. 
3. Remove the existing medium in the flask and replace it with fresh 15 mL 
culture medium to remove DMSO present from the previous freezing 
process and to give the cells a further boost of nutrients to encourage 
growth. 
4. Return the flask to the incubator for 3 days. 
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3.2.7.2     Passaging of cells 
     All steps in this technique must be performed in a fume-cabinet in aseptic 
conditions. 
 
1. The fume-cabinet is cleaned. 
2. Place 35 mL of culture media in a 50 mL Falcon tube and warm the same to 
37 degrees C. 
3. Defrost 1 x trypsin with EDTA (previously prepared in 5 mL aliquots). 
4. Withdraw the flask with cells from incubation and remove the media 
therefrom. 
5. Put 2.5 mL trypsin into the flask gently. 
6. Wash the cells briefly (not more than 10 seconds) with this trypsin by rotating 
the flask 10 degrees either way. 
7. Remove the “wash” medium. 
8. Place 2.5 mL trypsin into the flask and incubate at 37 degrees C. until the cells 
appear to cease to adhere (which should be less than 5 minutes).  Confirm 
under the microscope that the cells are no longer adherent.  Tap the flask 
gently to dislodge the cells, if necessary. 
9. In the fume-cabinet, place 2.5 mL media into the flask and tip gently to 
dislodge the cells. 
10.  Remove the whole contents of the flask and place the same in a a 50 mL 
Falcon tube. 
11. Rinse out the flask with a further 2.5 mL of media and remove the contents of 
the flask into the Falcon tube. 
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12. Centrifuge for 5 minutes at 1,100 rcp (235 g.) at room temperature (26 degrees 
C.). 
13. Remove the supernatant, leaving a pellet behind. 
14. Tap the pellet and add 10 mL of fresh medium. Pippette up and down to 
disperse the cells in the fresh medium. 
15. Take a haemocytometer and put 10 uL of cell suspension into each of its two 
chambers. 
16. Count all viable cells in the centre grids under microscope.  (Note:  viable 
cells are those which possess a white halo.) 
17. Add the number of cells found in the two centre grids areas and then divide by 
2 to obtain the average number of cells per centre grids area. 
18. Each centre grids area takes 0.1 uL of cell suspension.  Therefore, one has 
obtained the average number of cells per  0.1 uL of cell suspension. 
19. Then multiply by 10,000 to give the number of cells per 1 mL of cell 
suspension. 
20. Each T75 flask should contain > 1.5 x 10(6) [1,500,000] cells and the amount 
in mL of cell suspension necessary to give this amount of cells must be 
calculated.  This calculation is 1,500,000 divided by the number of cells per 1 
mL of cell suspension. 
21. Put 15 mL of culture medium in a fresh T75 flask (less if a large amount of 
cell suspension is to be added as the total volume in the Flask should not 
exceed approx. 20 mL). 
22. Add the amount of cell suspension calculated to be necessary to comprise 
1,500,000 cells. 
23. Label the flask appropriately with cell type, passage number, and date. 
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3.2.7.3     Transfection and plating 
     The transfection procedure takes place over 2 days, as the cells require 24 hours to 
settle and begin to spread across the dish on their way to becoming a confluent 
monolayer in the dish. 
 
Day 1 
1. Take a 60 mL round dish. 
2. Warm 5 mL of culture medium and put in the dish. 
3. Add 1.5 million cells to the dish. 
4. Incubate overnight at 37 degrees C. 
 
Day 2 
1. Check that the cells in the dish are between 50 per cent to 90 per cent 
confluent and return the dish to the incubator. 
2. Prepare the following: 
On ice:  
a. DNA 
b. Lipofectamine 
c. Plus Reagent 
 Heat:  Warm 3 mL of DMEM. 
3. Take 2 x 1.5 mL eppendorf tubes within the fume cup-board and label 
them (+) and (LIPO), respectively. 
4. Add 290 uL DMEM to each of these tubes. 
5. Then, to the (+) tube add: 
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a. 10.71 uL hTRPV1 (140 ng/uL) 
b. 7.5 uL Plus Reagent (which is orange-labelled) 
6. Incubate the  (+) tube for 15 minutes at room temperature. 
7. Add to the (LIPO) tube, 11.5 uL Lipofectamine (which is green-labelled). 
8. After the (+) tube has been incubated for 15 minutes, add the contents of 
the (LIPO) tube to the (+) tube. 
9. Incubate the (+) tube for a further 15 minutes at room temperature. 
10. At the same time, remove the culture medium from the dish while leaving 
the cells therein. 
11. Then, immediately, add 2 mL of DMEM to the dish very gently, drop by 
drop, and leave to incubate for 15 minutes at room temperature. 
12. After the 15 minute incubation of the (+) tube, put the contents of this tube 
into the dish very gently. 
13. Incubate for 3 hours in the incubator at 37 degrees C. 
14. After the 3 hour incubation, add 5 mL of heated culture medium to the 
dish.  This stops the transfection which is now completed. 
15. The cells must now be plated. 
16. Take 4 plates (16 wells) and “poly-dl-ornithine-coated” cover-slips which 
have been prepared in advance.  (The plates should have their coverslips 
added before trypsin EDTA is added to the cells.) 
17. Defrost 1 x trysin with EDTA (which have been previously prepared in 5 
mL aliquots). 
18. Remove the media from the dish. 
19. Put 2.5 mL trypsin EDTA into the dish gently. 
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20. Wash the cells briefly (for not more than 10 seconds) with this trypsin 
EDTA by rotating the dish 10 degrees either way. 
21. Remove the “wash” medium. 
22. Place 2.5 mL trypsin EDTA into the dish and incubate for 5 minutes at 37 
degrees C.  Then confirm under the microscope that the cells are no longer 
adherent. 
23. Again, in the fume-cabinet, place 2.5 mL culture media into the dish and 
tip gently to dislodge the cells. 
24. Remove the 5 mL of solution in the dish and place the same in a Falcon 
tube. 
25. Rinse out the dish with a further 2.5 mL of media and remove the contents 
of the flask into the Falcon tube. 
26. Centrifuge for 5 minutes at 1,100 rcf (or 235 g.) at room temperatures (26 
degrees C.) 
27. Remove the supernatant, leaving a pellet behind. 
28. Tap the pellet and add 5 mL of fresh media.  Pippette up and down to 
disperse the cells from the pellet. 
29. Take a haemocytometer and put 10 uL of cell suspension into each of its 
two chambers. 
30. Count all viable cells in the centre grids under a microscope.  (Note:  
Viable cells are cells which possess a white halo.) 
31. Add the number of cells found in the two centre grids areas and then 
divide by 2 to obtain the average number of cells per centre grids area. 
32. Each centre grids area takes 0.1 uL of cell suspension.  Therefore, one has 
obtained the average number of cells per 0.1 uL of cell suspension. 
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33. Then, multiply by 10,000 to give the number of cells per 1 mL of cell 
suspension. 
34. Each well must contain a minimum of 300 uL of cell suspension in culture 
medium. 
35. Calculate on the basis of, say, 300 uL x 18 = 5,400 uL = 5.4 mL of culture 
medium in a Falcon tube.  (Although cells are required only for 16 wells, 
allow sufficient suspension for 18 cells by way of precaution). 
36. Each well must contain 25,000 cells in suspension.  Therefore, calculate 
the cells required to provide 18 wells with 25,000 cells (namely, 450,000 
cells). 
37. Then, remove from the previously prepared 5.4 mL of culture medium 
sufficient of the same to allow for the addition of the volume of cell 
suspension which is required to provide the 18 wells with 25,000 cells 
(i.e., 45,000 cells).  Next, add that volume of cell suspension to the 
remaining volume of culture media to give 5.4 mL cell suspension in 
culture media.  
38. Pipette cell suspension in culture media into each of the 16 wells. 
39. Label the wells appropriately with cell type, passage number, and date. 
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3.2.7.4.     Preparing cells for liquid nitrogen 
     After cells have been passaged, there will generally be many more cells available 
than are the required for transfection.   These cells can be preserved for future use by 
storing them in liquid nitrogen after having first prepared them appropriately for this 
purpose. 
 
1. Obtain: 
a. 35 mL of culture medium (heated to 37 degrees C.) 
b. 5 mL of trypsin EDTA. 
c. 2 cryovials. 
d. Freezing medium 
2. The freezing medium is comprised of: 
a. Culture medium (70 per cent by volume) 
b. DMSO (10 per cent by volume). 
c. Foetal calf serum (20 per cent by volume) 
3. Thus, to make 1 mL of freezing medium add: 
a. 0.7 mL of culture medium 
b. 0.1 mL of DMS0 
c. 0.2 mL of foetal calf serum. 
4. The amount of freezing medium required depends on the number of 
cryovials because each cryovial needs 1.5 mL of freezing medium. 
5. Obtain the cell suspension intended for preservation from the flask by 
using trypsin EDTA to dislodge the cells as in the process of passaging 
those cells. 
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6. Defrost 1 x trypsin with EDTA (previously prepared in 5 mL aliquots). 
7. Withdraw the flask with cells from incubation and remove the media 
therefrom. 
8. Put 2.5 mL trypsin EDTA into the flask very gently. 
9. Wash the cells briefly (for not more than 10 seconds) with this trypsin 
EDTA by rotating the flask 10 degrees either way. 
10. Remove the “wash” medium 
11. Place 2.5 mL trysin EDTA into the flask and incubate for 5 minutes at 37 
degrees C.   Then confirm under the microscope that the cells are no 
longer adherent.  Tap gently to dislodge the cells, if necessary. 
12. In the fume-cabinet, place 2.5 mL media into the flask and tip gently to 
dislodge the cells. 
13. Remove the whole contents of the flask and place the same in a Falcon 
tube. 
14. Rinse out the flask with a further 2.5 mL of media and remove the contents 
of the flask into the Falcon tube. 
15. Centrifuge for 5 minutes at 1,100 rcf (or 235 g.) at room temperature (26 
degrees C.) 
16. Remove the supernatant, leaving a pellet behind. 
17. Tap the pellet and add 10 mL of fresh media.  Use the pipette repeatedly 
on the contents of the Falcon tube to disperse the cells within the culture 
medium. 
18. Take a haemocytometer and put 10 uL of cell suspension into each of its 
two chambers. 
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19. Count all the viable cells in the centre grids under a microscope.  (Note:  
viable cells are cells which possess a white halo). 
20. Add the number of cells found in the two centre grids areas and then 
divide by 2  to obtain the average number of cells per centre grids area. 
21. Each centre grids area takes 0.1 uL of cell suspension.   Therefore, one has 
obtained the average number of cells per 0.1 uL of cell suspension. 
22. Then multiply by 10,000 to obtain the number of cells per 1 mL of cell 
suspension. 
23. Each cryovial must contain at least 4 x 10(6) and not more than 10 x 10(6) 
cells. 
24. Therefore, the amount in mL of cell suspension necessary to give this 
amount of cells (4 x 10(6)) must be calculated. 
25. Make a decision on the number of cryovials that it is intended to put into 
liquid nitrogen and the amount of cells that each cryovial should contain, 
having regard to the total amount available in the cell suspension. 
26. Calculate the volume of cell suspension necessary to provide the required 
number of cells for the cryovials required and put that volume of cell 
suspension into a Falcon tube. 
27. Centrifuge for 5 minutes at 1,100 rcf (or 235 g.) at room temperature (26 
degrees C.). 
28.  Remove the supernatant, leaving a pellet behind. 
29. Tap the pellet and now add the volume of freezing medium necessary to 
provide 1.5 mL of freezing medium per cryovial. 
30. Use the pipette repeatedly on the contents of the Falcon tube to disperse 
the cells within the freezing medium. 
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31. Add 1.5 mL of the cell suspension in the Freezing medium to each 
cryovial. 
32. Label each cryovial appropriately with cell type, passage number, date, 
and number of cells. 
33. Put the cryovials at: 
a. 4 degreees  C. for 20 minutes;  and then 
b. – 20 degrees C. for 15 minutes. 
34. Wrap each vial in cotton wool and place in – 80 degrees C. for two hours 
or overnight. 
35. Then place the vials in the liquid nitrogen container, ensuring that the vials 
are in vapour phase.  Note the basket and rack number and note details of 
the cells put down in the appropriate file. 
 
3.2.7.5.     Preparation of cell culture medium 
    In the fume-cabinet, in aseptic conditions, add to a 500 mL bottle of “Minimum 
Essential Medium” the following: 
 
1. Penicillin streptomycin solution 10 mL. 
2. L-Glutamine 5 mL 
3. “MEM Non-Essential Amino Acids”  5 mL 
4. Foetal bovine serum  50 mL. 
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3.2.7.6.     Preparation poly-dl-ornithine-coated cover-slips 
      Polyamino acids facilitate the attachment of cells and proteins to solid surfaces in 
biological applications. In cell cultures normal attachment, growth, and development 
of many cell types are dependent on attachment factors and extracellular matrix 
components. While some cells are able to synthesize these components, others require 
an exogenous source, particularly when grown in serum-free culture.  Sterile, cell 
culture-tested, polyamino acids facilitate attachment, cell spreading, growth, 
morphology, differentiation, and motility of cells.  In histochemical applications both 
polymers of D- and L-lysine are used to coat slides to promote attachment of cells.  
 
1. Obtain a batch of 100 cover-slips labelled “100 pcs Cover Glass 13 mm 
Borosillicate Glass. 
2. Put these in a 50 mL Falcon tube and place sufficient ethanol in the Falcon 
tube to cover them (15 mL). 
3. Rotate the Falcon tube in a rotating machine for 10 minutes. 
4. Remove the ethanol and replace with 25 mL of pure distilled water.   
5. Rotate the tube 10 times by hand. 
6. Repeat the pure distilled water wash and hand rotation two more times. 
7. Then place sufficient pure distilled water in a Falcon tube to reach the 15 
mL level  (including the volume occupied by the cover-slips). 
8. Defrost a vial of poly-dl-ornithine. 
9. Add 300 uL poly-dl-ornithine to the Falcon tube. 
10. Rotate, using the rotating machine, for at least 1 hour. 
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3.3. IMMUNOHISTOCHEMISTRY 
3.3.1. Introduction 
 
     Immunohistochemistry combines anatomical, immunological and biochemical 
phenomena to enable specific proteins to be identified by means of a specific 
antigen/antibody reaction tagged with a visible label.  This technique enables the 
distribution and localisation of specific proteins within a tissue to be visualised.  It 
involves staining the cells by means of antibodies against the target antigen.  This first 
antibody can be labelled but it is more common (and improves the visualisation) to 
use a second antibody directed against the first (an antiIgG). This second antibody is 
conjugated either with fluorochromes or appropriate enzymes or colourimetric 
reactions or gold beads (for electron microscopy) or with the biotin-avidin system so 
that the location of the primary antibody and, thus, the target antigen, can be 
recognised.  The term “immunohistochemistry” is frequently used interchangeably 
with “immunocytochemistry.”  Strictly, “immunochemistry” refers to the use of this 
technique in the context of tissues, rather than individual cells to which the term 
“immunocytochemistry” applies. Thus, immunohistochemisty is the demonstration of 
a target antigen in tissue, or in a cell, in situ by detecting specific antibody-antigen 
interactions where the antibody has been tagged with a visible label.   
 
     Immunocytochemistry has been described as a broad-based and powerful method 
for analyzing specific biochemical structures and sequences at the cellular level, 
allowing the study of multiple cellular compartments, including the cell body, axons 
and dendrites of neurons.  Even minute levels of protein can be visualised in cellular 
compartments and membranes.  At the same, there is a serious issue relating to the 
specificity of the process.  It can be quite difficult to prove target antigen specificity, 
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particularly in view of the potential for cross-reactivity.  Another disadvantage resides 
in the fact that, generally, immunocytochemistry is not quantitative.  There are a 
number of reasons for this including multiple epitopes, different affinities for different 
sizes and sequences of various protein versions, variable fixation, and variable tissue 
penetration by antisera (Stanley et al., 1995). 
 
3.3.2. Antibody staining 
     Antibodies are serum glycoproteins, known as immunoglobulins (Igs), which are 
secreted by terminally differentiated B cells (leukocytes). In the vertebrate immune 
system, antibodies are produced as a defence against foreign substances.  Antibodies 
may be used as biochemical tools to identify and locate specific cell components. Of 
the  five classes of antibodies, IgGs are the predominant class produced in the 
immune response.  Polyclonal antibodies can be made against any antigen by 
injecting the antigen (isolated cell constituent or molecule) into a host animal (e.g. 
goat, rabbit or mouse), harvesting the plasma, and removing clotting factors to 
produce serum containing the antibodies.  Animals produce a highly heterogeneous 
mixture of antibodies in response to challenge by a foreign antigen.  These different 
antibodies come from different antibody producing cells.  Polyclonal antibodies have 
an advantage over monoclonal antibodies in that they are more likely to identify 
multiple epitopes of the target protein.   An alternative is to use “monoclonal 
antibodies.” Monoclonal antibodies are produced by fusing spleen cells with  
myeloma cells and growing the resultant hybrids in tissue culture.  The hybrids are 
grown in a selective medium containing hypoxanthine and aminopterin (HAT), the 
original myeloma cells being unable to survive in this medium.  The hybrids are sub-
cultured to produce clones derived from individual hybrids and each clone produces a 
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single class of antibody.  Thus, monoclonal antibodies consist of a single molecular 
species whose cross-reactivity can be well characterised.  In contrast, conventional 
antisera consists of a heterogeneous population of antibodies of different molecular 
species showing complex cross-reactivity.  In addition, the characteristics of the 
antibody population in sera varies from bleed to bleed and from animal to animal and 
the supply of high-affinity specific antibodies is frequently exhausted after one, or 
two, years (Cuello et al., 1983). 
 
     Where a secondary antibody is used, it must be generated against the 
immunoglobulins of the primary antibody source, e.g., if the primary antibody is 
raised in rabbit, then the secondary antibody could goat anti-rabbit.  The optimal titer 
of both the primary and secondary antibody should be determined for each batch.  The 
proper working dilutions for every antibody must be optimised for the system in 
which it is being employed   The same system does not always work for every 
antibody.   The product data sheets may be used as a guide for dilution series starting 
points.  The optimal antibody dilution will be that which gives the strongest specific 
antigen staining with the lowest non-specific background. 
 
 
3.3.3. Fixatives to retain morphology of tissues and cells 
 
      For immunohistochemical analysis, it is essential that the morphology of the 
tissues and cells be retained and that the antigenic sites be accessible. Tissue blocks or 
tissue sections are typically immersed into a fixative solution. Fixation is necessary to 
prevent artifactual diffusion of soluble tissue components, to arrest enzymatic activity, 
to avoid decomposition of the structure, and to protect the tissue against the 
deleterious effects involved with the various stages of the immunohistochemical 
 158 
process. Fixatives help tissue preservation by preventing autolysis caused by 
lysosomal enzymes and to prevent any bacterial or fungal growth. At the same time, 
fixatives will often cross-link the tissue so that it can become difficult for the 
immunoassay reagents to penetrate the tissue.  Four variables must be considered in 
determining the optimal fixation conditions for immunohistochemical localisation, 
namely:  (i) preservation of tissue morphology;  (ii) immobilisation of the antigen;  
(iii) preservation of antigen immunoreactivity;  and (iv) adequate penetrability of 
tissue to the immunochemical reagents.  The optimal fixation conditions with respect 
to the first two variables usually involve rapid and complete fixation, whereas the 
optimal conditions for the second two variables are best achieved with the lowest 
possible degree of fixation.  Therefore, the most appropriate fixation conditions 
necessitate a compromise between competing considerations.  Well-defined 
localisation with a low intensity of staining reaction are normally the symptoms of 
excessive fixation, since fixation tends to lower immunoreactivity and penetrability of 
immunoreagents.  On the other hand, less than optimal fixation is usually associated 
with an intense reaction that is diffuse and poorly localised (Berod et al., 1981).  
 
     Formaldehyde-based fixatives stabilise tissues by reacting primarily with basic 
amino acids to form methylene cross-links. The number of methylene bridges formed 
depends on the concentration of formaldehyde, temperature, pH and time of exposure. 
Formaldehyde fixatives are relatively mild.  However, they are difficult to reverse 
(Puchtler & Meloan, 1984).  They are well tolerated by tissues and allow for good 
penetration. The disadvantages of using this type of fixative include shrinkage and 
distortion of the tissue and, therefore, the antigenic sites. Examples of formaldehyde-
based fixatives include Bouin’s solution and 10% phosphate buffered neutral 
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formalin. Formaldehyde is the most commonly used fixative in immuno-
histochemistry because of its high degree of tissue penetration and its good 
preservation on immunoreaction, compared to glutaraldehyde.  Formaldehyde fixation 
is highly pH dependent (Berod et al., 1981). 
 
     Glutaraldehyde is a dialdehyde that reacts with amino groups, sulfhydryl groups 
and possibly with aromatic ring structures. Fixatives containing glutaraldehyde are 
stronger cross-linkers of protein than formaldehyde. They penetrate tissue more 
slowly, causing extraction of soluble antigens and modification of the structure. 
Glutaraldehyde inhibits enzyme activity more than does formaldehyde, the inhibition 
increasing with the time in the fixative (Hopwood, 1967).  Tissues that have been 
fixed with a glutaraldehyde-based fixative must be treated before the immunoassay 
with inert amine-containing molecules because free, unsaturated aldehyde groups are 
available to covalently link amine-containing moieties such as antibodies. The most 
efficient aldehyde blockers are ethanolamine and lysine. Glutaraldehyde-based 
fixatives include 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M phosphate 
buffer and 5% glutaraldehyde in 0.1 M cacodylate  and 1% sodium metabisulphite, 
pH 7.5-7.8 (Pierce Protein Research Products, 2008).   
 
     Precipitating fixatives include ethanol, methanol and acetone. They precipitate 
large protein molecules and are good for cytological preservation. They result in poor 
penetration and possibly incomplete fixation. They are not good for electron 
microscope work because they cause tissue shrinkage. 
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3.3.4. Antigen retrieval 
     Fixation alters the tertiary structure of proteins (antigens) with the result that they 
may not be detected by specific antibodies.  Antigen retrieval agents reverse at least 
some of these changes and are particularly necessary when tissues are fixed in cross-
linking fixatives.  Approximately 85 per cent of antigens fixed in formalin require 
some type of antigen retrieval to optimise the immunoreaction.  However, polyclonal 
antibodies are more likely to detect antigens than monoclonal antibodies in the 
absence of antigen retrieval agents.  The two most common antigen retrieval 
techniques are enzymatic and heat-based, respectively (Ramos-Vara, 2005). 
 
3.3.5. Inhibition of endogenous tissue components 
     Tissues, being complex biological systems, can contain materials that react with 
the various reagents used to develop an immunohistochemical stain. Cellular 
components such as enzymes and the vitamin, biotin, can result in unwanted signals, 
falsely indicating the presence of the target antigen. The immunoperoxidase method 
of signal detection is commonly used for the immunostaining of cells and tissues. 
Final analysis of this staining method is complicated by the presence of endogenous 
peroxidase and “pseudoperoxidase” activity in the cells and tissues. Peroxidase reacts 
with hydrogen peroxide to reduce the diaminobenzidine (DAB) substrate or other 
peroxidase substrates, resulting in non-specific staining of the tissue or false positives. 
To determine if there is endogenous peroxidase activity, the fixed tissue should be 
reacted with a peroxidase substrate, such as DAB. Any coloured precipitate that forms 
in the tissue from this treatment indicates endogenous activity. If a tissue is rich in 
peroxidase activity, an alternative enzyme label, such as calf intestinal alkaline 
 161 
phosphatase (AP), can be used.  Several methods have been devised to inhibit or 
destroy endogenous peroxidase activity after tissue fixation. The most common 
methods are 3% H2O2, or H2O2 in methanol.  The activity of an antibody is not 
affected by the addition of this inhibitor.  To ensure that the peroxidase inhibitor does 
not affect immunoreactivity of the primary antibody, apply the inhibitor after the 
incubation with the primary antibody and before incubation with the peroxidase 
conjugate (Pierce Protein Research Products, 2008). 
  
3.3.6.  Blocking of non-specific sites 
      Blocking the reactive sites in tissues is essential for the development of an 
immunohistochemical reaction. Normal serum is the most popular blocking agent for 
immunohistochemical staining. The principle is that non-immune serum from the host 
species of the secondary antibody is applied to the tissue at the beginning of the 
procedure and will adhere to protein-binding sites either by non-specific adsorption or 
by binding of specific, but unwanted, serum antibodies to antigens in the tissue. If a 
direct technique is being performed, the blocking serum should be from the host 
species providing the primary antibody (Pierce Protein Research Products, 2008). 
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3.3.7. Avidin-biotin system 
     Avidin is a 68,000 molecular weight glycoprotein with an extraordinarily high 
affinity for the small molecular weight vitamin, biotin.  This affinity is more than one 
million times higher than that of antibody for most antigens.  Hence, the binding of 
avidin to biotin (unlike antibody-antigen interactions) is essentially irreversible.  In 
addition to this high affinity, the “Avidin/Biotin System” can be effectively exploited 
because avidin has four binding sites for biotin and most proteins (including 
antibodies and enzymes) can be conjugated with several molecules of biotin.  The first 
step in detecting a primary antibody is the addition of a biotinylated, affinity-purified 
secondary antibody.  The biotinylated secondary antibody can then be detected using: 
(i) a preformed macromolecular complex between avidin and biotinylated enzyme 
which still retains biotin-binding sites (the Vectastain ABC system); (ii) avidin 
covalently conjugated to enzymes;  or (iii) avidin acting as a bridge to biotinylated 
enzymes (Vector Laboratories, 2004).  
 
    The ABC system has several advantages.  It increases the enzyme label at the tissue 
antigen site and provides increased detection efficiency.  It requires less primary 
antibody and involves a short assay time.  Against this, some tissues may require 
blocking of endogenous biotin to avoid non-specific staining.  Moreover, the ABC 
complex is large, and may hinder tissue penetration in some applications.  If the 
avidin-biotin complex becomes too large to penetrate the tissue, an alternative method 
can be used, called the “labelled avidin-biotin (LAB)” method.  This employs an 
avidin-enzyme conjugate (or streptavidin-enzyme conjugate) to detect the bound 
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biotinylated-primary antibody on the tissue section. This smaller complex allows 
better tissue penetration (Pierce Protein Research Products, 2008).  
 
3.3.8. Colour of antigen-antibody reaction 
     The antigen-antibody reaction is not visible under the microscope unless a label is 
used.   Enzymes are the most commonly used labels, especially horseradish 
peroxidase and alkaline phosphatase.  Each enzyme has specific substrates required to 
produce a coloured precipitate. Thus, for horseradish peroxidase, 
3,3’diaminobenzidine tetrachloride (DAB) is the most commonly used chromogen, 
giving a brown colour.  It is insoluble in organic solvents, but is inappropriate when 
endogenous peroxidase activity is very high.   Several chromogens are used for 
alkaline phosphatase which is recommended for immunocytochemistry or cytological 
specimens.  The choice of counter-stain will depend mainly on the colour of the 
immune reaction.  The counter-stain must produce enough contrast to avoid confusion 
with the chromogen precipitate.  It should lightly stain the tissues, without interfering 
with the chromogen precipitate.  One of the most widely used is haemotoxylin which 
stains blue (Ramos-Vara, 2005). 
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3.3.9 Protocol – Immunohistochemistry (using DAB) 
Preparation of tissue 
1. After completion of the experimental protocol, the animals are perfused 
transcardially with 4 per cent paraformaldehyde. 
 2. The lumbar spinal cord is recovered from each animal and placed in a solution 
of 80 per cent sucrose dissolved in PBS until the tissue sinks. 
3.  The spinal cord is then  cut into 20 um sections.   
 
Day 1:  Application of primary antibody   
  
1. Place the sections in a bath and rinse three times (by bathing for 5 minutes 
for each rinse) with phosphate-buffered saline (PBS). 
2. Prepare a “blocking solution” using PBS + Triton X (0.3%) to which 
normal donkey serum has been added in the ratio 90:10.   
3. Apply the “blocking solution” and leave for 30 minutes.    
4. Surround the sections with 2 x 2 parafilm to create a “well” to hold the 
primary antibody. 
5. Prepare the primary antibody in PBS-Triton in the required concentration 
and then apply it to the sections.    
6. Place a cover-slip over the parafilm. 
7. Allow the sections to incubate in the primary antibody overnight at room 
temperature.  
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Day 2:  Application of secondary antibody   
 
1. After incubation overnight, rinse the sections in water to remove the cover-
slips.    
2. Then rinse the sections three times in PBS, by allowing them stand in fresh 
PBS for 5 minutes for each rinse.  
3. Prepare the secondary antibody in 1:200 PBS-Triton 
4. Apply the secondary antibody to the sections and allow them to incubate in 
it for 30 minutes at room temperature. 
5. Then prepare the ABC solution immediately in order to allow it to stand 
for 30 minutes before use.   
6. Rinse the incubated slides with PBS three times, using 5 minute rinses in 
PBS. 
7. Then rinse with  Tris (0.01 m or 0.05 m) 
8. Prepare DAB and apply. 
9. Wait for the change in colour. 
10. Terminate the reaction by applying Tris. 
11. Rinse with PBS once by allowing the slides to stand in the PBS for 5 
minutes. 
12. Then rinse with water.   
13. The sections are then dehydrated with ethanol (50%; 75%; 90%; 96%; 
absolute). 
14. Bathe in xylene for at least 1 hour, and keep in xylene until ready to 
mount. 
15.  Apply the mounting medium and then the cover-slips  
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3.4.  AGONIST-ACTIVATED COBALT UPTAKE 
3.4.1. Introduction 
     The agonist-activated cobalt uptake technique is a method of quantitatively 
analysing the extent of non-selective cation channel activation in neurons and other 
cells.   The cells are placed in cobalt in solution with the result that their extracellular 
environment includes divalent cobalt cations.  When the cation channels which are the 
subject of investigation are opened on being stimulated by an agonist, these 
extracellular cobalt ions are drawn by their concentration and electrical gradients 
within the cell where they may be caused to become precipitated by exposure to a 
solution of ammonium polysulphide.  The extent of the resulting intracellular staining 
offers a measure of the extent to which the ion channels in question have been 
activated by the agonist, or putative agonist.   The intracellular staining can be 
assessed visually, using a microscope, which is adequate where the technique is 
employed only to determine whether there has been agonist activation of the channels 
in question.  However, such visual assessment is inadequate where one seeks to 
investigate the existence, or otherwise, of gradations in staining referable to 
alterations of the conditions in which the agonist is applied.  Hence, the development 
of a computer programme which measures on an arbitrary scale the extent to which 
individual cells absorb light (i.e., are discoloured).  While the scale is arbitrary, it is, 
nevertheless, relative which is all that is required since the enquiry relates to the 
extent of comparative, rather than absolute, staining by precipitated cobalt ions.   
 
     This technique was developed by Pruss and colleagues (1991) who showed that 
activation of kainate receptors causes Co2+ influx into neurons, type-2 astrocytes, and 
 167 
O-2A progenitor cells.  Based on the pattern of responses to kainate, glutamate, and 
quisqualte, it was possible to discriminate between three functionally different 
kainate-activated ion channels (Pruss et al., 1991).  The technique has since been 
widely used to label neurons (Nagy et al., 1993; Lorusso et al., 1998;  Singh Tahim et 
al., 2005).    
 
      The TRPV1 ion channel is potently activated by capsaicin which is typically 
employed as an agonist to activate this channel.    Hence, the extent of capsaicin 
activation of these ion channels in the presence, and absence, of various substances 
can be assessed using  this technique. The standard protocol for cobalt-labelling 
involves rinsing the cells twice for 2 minutes in a normal buffer followed by 
incubation for 5 minutes of the cells in cobalt buffer, to which there has previously 
been added, sufficient capsaicin to allow for activation by capsaicin (of the required 
concentration) of TRPV1 ion channels expressed by the cells.  The result is that the 
capsaicin, at the required concentration, activates TRPV1 ion channels expressed in 
the cells in the presence of extracellular cobalt ions in solution.  These cobalt ions 
thereby gain ingress to the cells, via the opened TRPV1 ion channel pores, where they 
discolour the cytoplasm when they are precipitated in the presence of ammonium 
polysulphide.  The cells so discoloured are usually referred to as having been 
"labelled" as TRPV1-activated cells.  The precipitation is achieved after a brief 
rinsing of the cells in standard buffer followed by a 2 minute incubation in 0.12% 
ammonium polysulphide (Sigma).   
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     The extent to which TRPV1 ion channels are activated when challenged with 
different concentrations of capsaicin can be determined by examining the uptake of 
cobalt by individual cells as evidenced by the discolouration of the cells when 
visualised by a light microscope attached to a CCD camera (Leica) and a PC running 
the QWin software package (Leitz, Wetzlar, Germany). Following background 
subtraction, the area of the cells and their optical density, measured on an arbitrary 
scale between 0 and 255, are measured in 100-150 randomly systematically chosen 
neurons on each coverslip. With these settings, greater optical intensity values 
represent light, labelled cells, while smaller optical intensity values represent dark, 
non-labelled cells.  
 
     The main concerns with the use of the cobalt uptake technique arise from the fact 
that the extracellular solution is not a physiological solution.  In particular, it does not 
comprise Ca2+; and, moreover, the concentration of sucrose in the buffer creates an 
hypertonic extracellular solution.   Ca2+ is excluded from the buffer to prevent these 
ions from competing with Co2+ for entry into the cell via TRPV1 ion channels, while 
the amount of sucrose employed has been found necessary to maintain the cells in the 
buffer in a healthy condition.  Nevertheless, these concerns are misplaced in the 
context of the purpose for which this technique has been employed in the present 
experiments.   First, the absence of Ca2+ in the extracellular solution would be 
important if the objective of the technique were to measure the effects of ingress of 
Ca2+ into the cell.  However, the purpose of the technique is to assess the relative 
ingress of Co2+ ions as evidenced by staining of the cells as a relative measure of 
activation of TRPV1.   Second, an apparently more substantial objection is that the 
composition of the extracellular solution is such as to result in its gaining entry into 
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the cell along its concentration gradient.  While this occurs to some extent, it does not 
result in bursting of the cells because when the cells are ultimately visualised under 
the microscope, there is no evidence of cell lysis – a finding which has been 
consistently made in all of the experiments performed in this laboratory.  Moreover, 
we have specifically compared the diameter of capsaicin-responding cells after cobalt 
uptake with the diameter of similar cells taken from DRG ganglia maintained in 
physiological solution and found no difference in the diameters of the respective cell 
populations.    The final objection is that the nature of the extracellular buffer may be 
such as to activate mechanoreceptors resulting in ingress of   Co2+ via these channels 
when thus activated.  However, this objection cannot stand with the fact that the 
cobalt staining is abolished in the presence of a capsaicin antagonist and does not 
occur in TRPV1-null mice.  In the result, this technique is cheap, efficient, and 
entirely suitable for the limited purpose for which it has been employed in our 
experiments.   
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3.4.2. Preparation of buffers 
3.4.2.1.      Standard (Normal) Buffer 
        Standard (normal) buffer is prepared by adding to 1 L of distilled water:  NaCl: 
3.358 g;  KCL:  0.3725 g;  HEPES  2.833 g;  glucose:  2.16 g;  MgCl2:  0.4066;  
sucrose:  47.5797 g.   The pH should be 7.4.   Bring the buffer to pH 7.4 by the 
addition thereto of sufficient NaOH to raise it to 7.3 on the pH meter after which it 
will increase of its own accord to 7.4. 
 
3.4.2.2.      Cobalt buffer 
      The “cobalt buffer” is prepared by adding 1.2 g CoCl2 to 1 L of the previously 
prepared standard (normal) buffer.    
 
3.4.3. Agonist: capsaicin 
      Stock capsaicin (Tocris, Bristol, UK) is diluted in H2O and DMSO (50:50) to 
provide several capsaicin concentrations, e.g.:  10 nM; 30nM;  100 nM; 300 nM;  and 
1 uM.  Previous experiments in this laboratory have demonstrated that DMSO alone, 
at concentrations in excess of 1:500, is capable of activating TRPV1 ion channels.  
Hence, the importance of limiting the concentration of DMSO employed.  The DMSO 
is necessary because capsaicin is highly hydrophilic and cannot be added to water 
alone.  Thus, it is added to DMSO and water in which it dissolves. 
 
 171 
       To confirm that DMSO is not participating in activation of TRPV1 ion channels, 
but is merely acting as a vehicle for delivery of the capsaicin to those receptors, 
DMSO is added to the standard cobalt chloride buffer (the “vehicle control”).  
 
3.4.4. Agonist-activated cobalt uptake protocol 
 
1. Pre-heat a precision incubator to 37 degrees C.  
2. Pre-heat to 37 degrees C. Falcon tubes comprising standard buffer and 
cobalt buffer, respectively. 
3. Obtain several small vials, the number depending on the number of 
different dilutions of capsaicin (or other variations) to be employed in the 
experiment.  An additional vial will serve as the “without capsaicin”  
control. 
4. Put 2 mL of cobalt buffer in each of the small vials. 
5. Put 1 uL  of each capsaicin dilution in all, except one, of these vials. 
6. Place all the vials in the precision incubator at 37 degree C. 
7. Label appropriately the wells assigned to the various concentrations of 
capsaicin employed, plus the control application of buffer. 
8. Then place a cover-slip containing cells in each of these wells. 
9. Rinse the cells on their cover-slip in each well twice with incubated 
standard buffer by putting 0.5 mL of incubated standard buffer into each 
well.  Remove the buffer using a pipette, and rinse again using the 
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incubated standard buffer.  Then, pipette out the added buffer to complete 
the second rinse. 
10. Now, put more incubated buffer in each well and incubate the cells in this 
buffer for 5 minutes at 37 degrees C., after which remove this buffer. 
11. Put 500 uL of each concentration of capsaicin in all of the wells except 
that for control to which should be added instead 500 uL standard buffer. 
12. Incubate for 5 minutes at 37 degrees C. 
13. In the fume-cabinet, add 60 uL of ammonium polysulphide to 5 mL of 
incubated buffer. 
14. Terminate the incubation after 5 minutes and remove the solutions from 
the wells. 
15. Wash each twice with standard buffer (which has not been incubated 
beforehand.) 
16. After the second wash, put ammonium polysulphide on the cover-slips and 
incubate at room temperature for 2 minutes, before removing the 
ammonium polysulphide. 
17. Apply 70 per cent ethanol to the coverslips to fix the tissue. 
18. Use glycerol to mount the cover-slips on slides. 
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3.4.5. Image analysis protocol 
 
1. Run Leica  QWin V3 programme on computer. 
2. Switch on camera control. 
3. Adjust shutters on the microscope.  Left to middle.  Right to out. 
4. Condenser to “H”, Filter to “1” 
5. Use maximum objective on the microscope. 
6. Click “Eye” for live image. 
7. Click “Mono”. 
8. Capture image of “empty field”, i.e., no slide. 
9. Go to “Measure” and, then, “Measure Interactive”. 
10. Then draw several areas and check grey level values. 
11. Set optical intensity of background grey level to above 200 and less than 250.. 
12. To obtain this optical intensity, return to “live image”, then reduce/increase 
light from the micorscope, or alter “exposure time” on the camera control.  
Then, capture image and measure again. 
13.  When the requited optical intensity is obtained, press “Subtract (Sub)” button 
on Function Keys of the cameral control box. 
14. Next, place a slide in the microscope and adjust the light to obtain the detial of 
the images. 
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15. Then, “capture image”, save as “---“, and return to “live image”. 
16. Obtain from 150 to 250 images from each cover-slip. 
17. After all the images of a given cover-slip have been collected, copy the same 
to the Excel file as follows: 
a. in the window entitled “Manual Results”, got to “Edit” and click 
“Copy”; 
b. Then go to “Desk Top,” open Excel and in any column click “Paste” 
and then “Save”. 
18. Before taking images of the next cover-slip, click on “Reset” in the “Measure 
Interactive” window to eliminate previous data. 
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3.5.  ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
3.5.1. Introduction 
      Enzyme-linked immunosorbent assay (ELISA) is a plate-based assay employed to 
search for the presence, and quantify the amount, of peptides, proteins, antibodies or 
hormones.  This technology involves the antigen being immobilised to a solid surface 
whereupon it is complexed with an antibody linked to an enzyme.  The conjugated 
enzyme activity is measured by incubation with a substrate to produce a measurable 
product.  ELISAs are typically carried out in a 96-well polystyrene plate which can 
passively bind antibodies and proteins.  Horeseradish peroxidise (HRP) and alkaline 
phosphatase (AP) are the enzyme labels which are usually employed.  When the 
ELISA is performed with an HRP or AP conjugate, there is a large selection of 
substrates available.  The assay sensitivity required and the device available for signal 
detection (spectrophotometer, fluorometer or luminometer) will determine the choice 
of substrate (Thermo Scientific Proteomics, 2009). 
 
3.5.2. Sandwich assay 
      Immobilization of the target antigen can be achieved by direct adsorption to the 
assay plated.  Alternatively, the target antigen can be immobilised using a “capture 
antibody” that has been attached to the plate.  The target antigen is then detected using 
a labelled primary antibody or using a labelled secondary antibody.  The so-called 
“sandwich assay” is the most effective ELISA assay type.  Here, the target antigen is 
bound between two primary antibodies – the capture antibody and the detection 
antibody to provide an assay which is both sensitive and robust.  In a sandwich 
ELISA, it is essential that the secondary antibody should be specific for the detection 
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of the primary antibody only and not for the capture antibody.  Generally, this is 
achieved by using capture and primary antibodies from different host species. 
(Thermo Scientific Proteomics, 2009). 
 
3.5.3. ELISA procedure 
 3.5.3.1.     Coating the well with capture antibody   
       An assay microplate is chosen which has a minimum protein-binding capacity of 
400 ng/cm2 and a coefficient of variation value of protein binding which is < 5 per 
cent to limit deviation in values that should be identical in the assay results between 
wells and plates (Thermo Scientific Proteomics, 2009). Clear polystyrene flat bottom 
plates are used for colorimetric signals, while black or white opaque plates are used 
for fluorescent and chemiluminescent signals.  Plate-coating with the relevant 
antibody is achieved through passive adsorption of the protein to the plastic of the 
assay microplate as a result of hydrophobic interactions between the plastic and non-
polar protein residues. The most common method of coating plates involves adding a 
2 – 10 ug/ml solution of protein dissolved in an alkaline buffer such as phosphate-
buffered saline (pH 7.4) or carbonate-bicarbonate buffer (pH 9.4).  The plate is left to 
incubate for several hours to overnight at 4 – 37 degrees C.  Then, after removing the 
coating solution, blocking buffer is added to ensure that all remaining available 
binding surfaces of the plastic well are covered.  Some proteins, especially antibodies, 
are best coated on plates at a concentration lower than the maximum binding capacity 
in order to prevent non-specific binding in later steps by a phenomenon called 
“hooking.”  “Hooking” results from proteins getting trapped between the coating 
proteins which prevents effective washing and removal of non-bound proteins.  When 
hooking non-specifically traps detection primary and secondary antibodies, high 
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background signal results in reducing the signal to noise ratio and thus the sensitivity 
of an assay (Thermo Scientific Proteomics, 2009). 
 
      Either monoclonal or polyclonal antibodies can be used as the capture and 
detection antibodies in sandwich ELISA systems.  Monoclonal antibodies have an 
inherent mono-specificity toward a single epitope which provides for precision in 
both detection and quantitation of small differences in antigen.  However, these 
antibodies are very expensive.  The design of a sandwich ELISA must take account of 
the fact that the capture and detection antibodies must recognise two different non-
overlapping epitopes.  When the antigen binds to the capture antibody, the epitope 
recognised by the detection antibody must not be obscured or altered.  Capture and 
detection antibodies that do no interfere with one another and can bind simultaneously 
are called “matched pairs” and are suitable for developing a sandwich ELISA   
(Thermo Scientific Proteomics, 2009).  The strength of the “matched pair” in capture 
and detection of the analyte is the most important single factor in the success of the 
ELISA (Millipore, 2009).   
 
3.5.3.2.     Blocking buffer 
         A “blocking buffer” is a solution of irrelevant protein, mixture of proteins, or 
other compound, that passively adsorbs to binding surfaces on the plate which are not 
already bound with capture antibody.  The most important consideration when 
choosing a blocking buffer is the signal:noise ratio, which is measured as the signal 
obtained with a sample containing the target analyte as compared to that obtained 
with a sample without the target analyte.  The objective is to determine the highest 
signal:noise ratio.  Failure to use sufficient blocker will result in excessive 
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background and a reduced signal:noise ratio, while using too high a concentration of 
blocker may mask antibody-antigen interactions, or inhibit the enzyme, again causing 
a reduction in the signal:noise ratio.  Serial testing is necessary to ascertain the most 
effective blocking buffer (Thermo Scientific Proteomics, 2009). 
 
3.5.3.3.     Washes 
       Washes must be performed between each step of the ELISA.  These washing 
steps are necessary to remove non-bound reagents and to decrease background, 
thereby increasing the signal:noise ratio. Inadequate washing allows high background, 
while too much washing may result in decreased sensitivity caused by elution of the 
antibody and/or antigen from the well.  Washing is done in a physiological buffer 
such as Tris-buffered saline (TBS) or phosphate-buffered saline (PBS) without any 
additives.   A detergent such as 0.05 per cent Tween-20 may be added to the buffer to 
help to remove non-specifically bound material. (Thermo Scientific Proteomics, 
2009). 
 
3.5.3.4.  Substrates for detection 
    The last stage in all ELISA procedures is the detection.  Unless a radioactive or 
fluorescent tag is used, this requires the use of an enzyme substrate. The enzyme 
converts the substrate to a detectable product.  In a properly constructed ELISA, the 
intensity of the signal produced when the substrate is added is directly proportional to 
the amount of antigen captured in the plate and bound by the detection reagents.  
Enzyme-conjugated antibodies (especially those involving horseradish peroxidase) 
offer the most flexibility in detection because of the variety of substrates available for 
chromogenic, chemifluorescent and chemiluminescent imaging (Thermo Scientific 
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Proteomics, 2009).  Popular enzymes  are those that convert a colourless substrate to a 
colour product, e.g., pnitrophenylphosphate (pNPP), which is converted to the yellow 
p-nitrophenol by alkaline phosphatase.  Substrates used with peroxidase include 2,2’-
azo-b9s(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS), which yields a green colour 
(Millipore, 2009) 
 
     Apart from individually constructing an ELISA system from first principles, 
complete kits are available for the detection of specific cytokines and other targets, 
such as interferon gamma (IFN gamma) and interleukin 6 (IL-6). 
 
3.5.4. Protocol for sandwich ELISA (Millipore, 2009) 
1. Before the assay, both antibody preparations should be purified and one must be 
labelled.  
2. For most applications, a polyvinylchloride (PVC) microtiter plate is best; 
however, consult manufacturer guidelines to determine the most appropriate type 
of plate for protein binding.  
3. Bind the unlabeled antibody to the bottom of each well by adding approximately 
50 µL of antibody solution to each well (20 µg/mL in PBS). PVC will bind 
approximately 100 ng/well (300 ng/cm2). The amount of antibody used will 
depend on the individual assay, but if maximal binding is required, use at least 1 
µg/well. This is well above the capacity of the well, but the binding will occur 
more rapidly, and the binding solution can be saved and used again.  
4.    Incubate the plate overnight at 4°C to allow complete binding.  
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5. Wash the wells twice with PBS. A 500 mL squirt bottle is convenient. The 
antibody solution washes can be removed by flicking the plate over a suitable 
container.  
6.   The remaining sites for protein binding on the microtiter plate must be saturated 
by incubating with blocking buffer. Fill the wells to the top with 3% BSA/PBS 
with 0.02% sodium azide. Incubate for 2 hrs. to overnight in a humid atmosphere 
at room temperature.  Note: Sodium azide is an inhibitor of horseradish 
peroxidase. Do not include sodium azide in buffers or wash solutions if an HRP-
labelled antibody will be used for detection. 
 
7.   Wash wells twice with PBS.  
 
8.   Add 50 µL of the antigen solution to the wells (the antigen solution should be                             
titrated). All dilutions should be done in the blocking buffer (3% BSA/PBS). 
Incubate for at least 2 hrs. at room temperature in a humid atmosphere.  
9.   Wash the plate four times with PBS.  
10.  Add the labelled second antibody. The amount to be added can be determined in    
preliminary experiments. For accurate quantitation, the second antibody should be 
used in excess. All dilutions should be done in the blocking buffer.  
 
11.  Incubate for 2 hrs. or more at room temperature in a humid atmosphere.  
12.  Wash with several changes of PBS.  
13.  Add substrate as indicated by manufacturer. After suggested incubation time has 
elapsed, optical densities at target wavelengths can be measured on an ELISA 
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plate reader. Note: Some enzyme substrates are considered hazardous, due to 
potential carcinogenicity. Handle with care and refer to Material Safety Data 
Sheets for proper handling precautions.  
 
14.  For quantitative results, compare signal of unknown samples against those of a 
standard curve. Standards must be run with each assay to ensure accuracy. 
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 Figure 1 Images of sections from skin 
Figure 2 Photomicrographs showing spinal dorsal horn of wild  
type and TRPV1 knock-out (KO) animals 
 
Figure 3 Bar charts showing average number of pERK1/2  
immunolabelled neurons per section  
 
 
NOTE:   CERTAIN OF THE EXPERIMENTS DESCRIBED IN THIS CHAPTER WERE 
PERFORMED BY MR. CHIN WING KO, UNDER SUPERVISION, WHILE A STUDENT IN 
THIS DEPARTMENT FOR THE DEGREE OF MASTER OF RESEARCH (M.RES.). 
 184 
4.1 INTRODUCTION 
      Pain resulting from severe burn injury is one of the most excruciating pain 
sensations that can be experienced and the absence of consistently effective analgesics 
for its treatment renders its clinical management unsatisfactory (Arturson, 1996; 
Patterson et al., 2004).  Severe burn injury causes major tissue damage and the 
attempts of the body to defend against infection and to effect repair of injured tissues 
generate a massive inflammatory response.  This inflammatory response induces the 
formation and release of inflammatory mediators (Arturson, 1996).  The resulting 
excitation of a sub-population of nociceptive primary sensory neurons is responsible 
for initiating, and maintaining, the sensation of peripheral inflammatory pain. We 
hypothesised that severe burn injury results in sustained activation of ERK1/2 
(pERK1/2) and that activation of the transient receptor potential vanilloid type 1 
receptor (TRPV1) mediates, in part at least, this effect. 
 
       TRPV1 is a ligand-gated, non-selective, cationic channel (Caterina et al., 1999; 
Heyman & Rang, 1985; Marsh et al., 1987; Tominaga et al., 1998) which is known to 
play an important role in several types of heat-induced hyperalgesia.  About 40 per 
cent of the total neuronal population of primary sensory neurons express TRPV1 and 
the vast majority of these are non-myelinated, small diameter, nociceptive fibres 
innervating many tissues (Avelino et al., 2002;  Dinis et al., 2004; Guo et al., 1999; 
Sato et al., 2005). Heat hyperalgesia secondary to inflammatory tissue injury fails to 
develop in TRPV1 null mice as in wild type mice in several models of thermal 
hyperalgesia, including that induced by carrigeenan, mustard oil, and complete 
Freund’s adjuvant (Caterina et al., 2000; Davis et al., 2000), suggesting that TRPV1 is 
an essential component in the development of pathological thermal hyperalgesia 
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resulting from peripheral inflammation (Pogatzki-Zahn et al., 2005).  The 
development of thermal hyperalgesia following inflammation involves an increased 
level of TRPV1 expression (Amaya et al., 2004; Kasama et al., 2007; McNaughton, 
2005;  Stein et al., 2006).  It also involves the sensitization of existing TRPV1 
channels by inflammatory agents (Chuang 2001; Vellani et al., 2006; Zhang et al., 
2008;  Zhu and Oxford, 2007).  There is evidence that TRPV1 may be implicated in 
severe burn injury-induced pain.  Immersion of one hind-paw of wild type mouse into 
51 degrees C water for 15 seconds under brief ether anaesthesia induces thermal and 
mechanical hyperalgesia, manifested as a fall in heat and mechanonociceptive 
thresholds, which is reduced in TRPV1 null mice (Bolcskei et al., 2005).  TRPV1 also 
suggests itself as being peculiarly relevant in the context of the spontaneous on-going 
pain found in burn injury-induced inflammation because of its ability, when sensitized 
by various inflammatory agents, to be rendered spontaneously active by body 
temperature alone (refs: Nagy et al., 2008;  Nagy et al., 2009).   
 
     To investigate the role of TRPV1 in mediating the pain sensations associated with 
severe burn injury, we have developed a rodent model of second degree, partial 
thickness, burn injury by inducing a scalding-type injury, occasioned by immersing 
one of the animals hind-limbs in water heated to 60 degrees C. for two minutes (under 
urethane anaesthesia).  Activation by phosphorylation of extracellular signal-regulated 
protein kinase 1/2 (ERK1/2) in spinal dorsal horn neurons is a recognised marker of 
spinal nociceptive processing  (Ji et al., 1999).  Hence, to elicit the extent to which 
TRPV1 is implicated in burn injury-induced nociception, we compared 
phosphoylation of ERK1/2 (pERK1/2) in spinal dorsal horn neurons for this model of 
scalding-type burn injury in TRPV1 null mice and in wild-type mice.     
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4.2.  MATERIALS AND METHODS 
 
4.2.1 Animals 
    All experiments were performed in accordance with the requirements of the 
Animals (Scientific Procedures) Act, 1986 (U.K.) and adhered to the guidelines of the 
Committee for Research and Ethical Issues of IASP published in PAIN®, 16 (1983) 
109-110.   In addition, the use of the animals for these experiments was approved by 
the Animal Subjects Review Board of the University of Porto, Porto, Portugal. All 
efforts were made to minimise both the number of animals employed in these 
experiments and any possible suffering of these animals. 
 
      Male and female C57BL/6J wild type mice (Charles River Laboratories), and 
B6.129X1-Trpv1/J mice lacking the TRPV1-encoding gene, weighing from 15.0 g to 
29.0 g, were used in these experiments. Animals were housed in the veterinary facility 
of São João Hospital (Porto, Portugal) and kept in a 12 hours day and night cycle with 
free access to food and water.  
 
4.2.2.  Experimental groups 
     Each experiment was performed using two groups of animals comprising four wild 
type (WT) and four TRPV1-null “knock out” (KO) mice, respectively.  The animals 
in all groups were anaesthetised using an intraperitoneal injection of urethane 
(0.02mg/g, Sigma).  Animals were constantly monitored to ensure that they remained 
deeply anaesthetised during the course of the experiment. In total, 28 wild type and 28 
TRPV1 null mice were employed in these experiments. 
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     A wild type group and a KO group were each subjected to one of seven 
experimental protocols as follows:  (1) One hour survival after urethane anaesthesia 
and without any burn injury; (2) Urethane anaesthesia followed by insertion for two 
minutes of the right hind-limb below the knee into 37ºC water with survival for one 
hour;  (3) Noxious thermal stimulus after urethane anaesthesia comprising insertion 
for one second of the right hind-limb below the knee into 60ºC water with survival for 
one hour; (4) Burn injury after urethane anaesthesia comprising insertion for two 
minutes of the right hind-limb below the knee into 60ºC water with survival for five 
minutes;  (5) Burn injury after urethane anaesthesia comprising insertion for two 
minutes of the right hind-limb below the knee into 60ºC water with survival for one 
hour;  (6) Burn injury after urethane anaesthesia comprising insertion for two minutes 
of the right hind-limb below the knee into 60ºC water with survival for three hours;  
and (7) Burn injury after urethane anaesthesia comprising insertion for two minutes of 
the right hind-limb below the knee into 60ºC water with survival for 6 hours.  In all 
cases, the animals were constantly monitored throughout the experiment and were 
maintained unconscious under anaesthesia throughout the entire duration of the 
experiment by repeated i.p. injections of urethane, as required. 
 
4.2.3 Tissue preparation 
     After the specified survival period, the animals were terminally anaesthetised with 
urethane and were then perfused through the aorta with calcium-free Tyrode solution 
followed by 4% paraformaldehyde in 0.01 M phosphate buffered saline (PBS, pH 7.5) 
for 15 minutes. Heparin (LEO Pharma A/S, Denmark) was injected into the left 
ventricle before the perfusion to prevent blood clotting. The spinal cord and the skin 
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from the right lower hind-limb of each animal were carefully dissected and immersed 
in 4% paraformaldehyde for 4 hours at 4ºC. These tissues were then placed in 30% 
sucrose in 0.1M PBS until saturated.  
 
     The L4-L5 lumbar segments of the spinal cord were in each case identified and 
dissected out.  The vental aspect  of the contralateral side of each spinal cord block 
was identified and marked by a shallow incision.   The tissue blocks were then 
embedded in OCT embedding medium (VWR, West Chester, PA) and 20µm 
transverse sections were cut on a cryostat.  Sections were thaw-mounted on Superfrost 
Plus microscope slides.  
 
4.2.4. Immunohistochemistry 
     The sections were first washed in PBS and incubated in PBS containing 0.3% 
Triton X (PBST) for 10 minutes.  The endogenous peroxidase activity was quenched 
by incubating the section in 0.3% H2O2. Sections were then placed in 10% normal 
donkey serum (NDS) for 25 minutes. The primary antibody was anti-phospho 
extracellular signal-regulated protein kinase 1/2 (pERK1/2) raised in rabbit against the 
residues surrounding T202/Y204 of pERK1/2 (1:1000, Neuromics). The sections 
were incubated in the primary antibody overnight.  Following washes in PBS, the 
sections were incubated with biotin-conjugated donkey anti-rabbit IgG (1:800; 
Jackson Immunoresearch) for 2 hours. The immunoreaction was visualised using the 
Vectastain Elite and IMPACT DAB kits (Vector). The slides were then dehydrated in 
ethanol, cleaned in xylene and covered by depex polystyrene. All the washes and 
dilutions were performed at room temperature in PBST, with the addition of 0.3% 
NDS for the dilution of the primary antibody. 
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4.2.5. Histopathological analysis  
      Skin tissue from the hind-paws exposed to hot water were embedded in paraffin, 
and sections were cut with a Reichert microtome at a thickness of 10 um. After 
deparaffination, the sections were stained with hematoxylin and eosin and 
coverslipped. Photographs were taken with a Nikon Eclipse 800 microscope  with a 
Spot RT Slider digital camera (Diagnostic Instrument Inc., Sterling Heights, MI) and 
Spot 3.5.9.1. software (Diagnostic Instrument Inc.). 
  
4.2.6. Data analysis and statistics 
      Four non-consecutive sections were randomly taken from the spinal cords of each 
experimental group for analysis.  These slides were then analysed using a Leica 
microscope.  Cells expressing pERK1/2 were identified at x 40 magnification in both 
the ipsilateral, and contralateral, sides of the spinal cord.  The average number of 
pERK1/2-expressing cells over the four sections were then calculated for each side of 
the spinal cord. The ipsilateral and contralateral means (±SEM) for each group were 
calculated. Differences in the number of pERK1/2-expressing neurons between the 
different experimental groups were analysed using one way ANOVA.  Whether 
differences found were significant was established using Tukey’s post-hoc test. 
Differences were regarded significant at p<0.05.  
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4.3. RESULTS 
4.3.1. Histopathology of skin 
     The hind-limb skin tissue burned by immersion in scalding water for 2 minutes at 
60 degrees C showed major pathological signs not found in normal tissue from naive 
animals (Figure 1).  The epidermis of this burn-injured tissue was no longer adherent 
to the dermis, having become detached or lost.  The dermis itself remained adherent to 
the underlying sub-cutaneous connective tissue but was substantially disrupted.  It 
was oedematous, with its blood-vessels dilated or destroyed (Figure 1b).  These 
features were consistent with severe second degree, partial thickness deep burn injury.  
 
 
Figure 1. 
Typical images of sections cut from control skin (A) and skin subjected to 120 seconds 
immersion into 60ºC water (B). Both sections are stained with hematoxylin eosin. 
Note that, while in the control section the structure of the skin is easily visible, that 
structure is severely damaged in the section cut from the burn-injured skin. The layers 
of the epithelium are no longer recognisable, and the vessels are severely diluted.  
 
A 
B 
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4.3.2. General features of pERK1/2-expression in the spinal cord  
      pERK1/2-immunopositivity, where found, could be observed in the cytoplasm 
and/or in the nucleus of neurons.  In sections from animals of experimental groups 
(4), (5), (6) and (7), which were exposed to limb immersion in 60 degrees C. water for 
two minutes, the pERK1/2-immunopositive cells in the ipsilateral side of the spinal 
cord were predominantly found in the superficial laminae of the dorsal horn on that 
side, but were also seen in the deep dorsal horn.  With increasing survival time after 
such burn injury, the distribution of labelled neurons altered in the ipsilateral spinal 
cord with an increasing number of labelled neurons being found in the deeper dorsal 
horn on that side, while an increasing number of labelled neurons were also observed 
in the dorsal horn of the contralateral side.    
 
 
4.3.3. Experimental groups 1:  no stimulus (naive animals) 
     Naive, anaesthetized, WT mice exhibited pERK1/2-expressing cells only 
extremely rarely in the dorsal horn on either side of the spinal cord (0.9±0.4 
ipsilateral; 0.7±0.3 contralateral; n = 3).  Similarly, only extremely few pERK1/2-
immunopositive neurons were found in the dorsal horn on either side of the KO 
animals (0.7±0.7 ipsilateral; 0.5±0.5 contralateral; n =3).  No significant difference 
was found between the combined number of pERK1/2-labelled neurons found on both 
sides of the spinal cord as between WT and KO mice.  Furthermore, no significant 
difference was found when the number of labelled in the corresponding sides of the 
spinal cords of WT and KO animals were compared. 
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Figure 2. 
Illustrative photomicrographs spinal dorsal horn of wild type (WT) and TRPV1 
knock-out (KO) animals. Naive animals (A and B) and burn-injured animals with 
different survival times (C-J). 
Only occasional isolated pERK1/2 immunopositive neurons are found in sections of 
either WT or KO naive animals (A and B), but sections of all burn-injured animals 
consistently express pERK1/2 immunopositive neurons in the spinal dorsal horn 
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. 
(C and D) Severe burn injury (short survival time) in WT and KO mice. The 
ipsilateral dorsal horn sections shown here exhibit pERK1/2 immunolabelled neurons 
and neuropil in lamina I and outer lamina II. No significant difference is observed in 
pERK1/2 immunolabelling between the WT and KO animals. 
(E and F) Severe burn injury (1 hour survival time) in WT and KO mice. The 
ipsilateral dorsal horn sections shown here exhibit substantially similar pERK1/2 
immunoreactivity to that found at the short survival time. No difference is observed in 
pERK1/2 immunolabelling between the WT and KO animals. 
(G to J) Severe burn injury (6 hours survival time) in WT and KO mice. At 3 hours 
and 6 hours survival time, the number of neurons labelled in the ipsilateral dorsal 
horn (G and H) exceeds that found at 1 hour survival time, although the number of 
such labelled neurons has diminished by 6 hours from the number observed at 3 
hours, while their distribution has also altered. At 3 hours and 6 hours survival time, 
pERK1/2 labelling is found on the contralateral side of the dorsal horn (I and J), to 
an extent which was not present at 1 hour survival time. Interestingly, the distribution 
of the labelled neurons on the contralateral side differs markedly from that of the 
labelled neurons on the ipsilateral side and, moreover, the intensity of the staining is 
frequently less than that seen on labelled neurons on the ipsilateral side. 
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Figure 3. 
Average number of pERK1/2 immunolabelled neurons per section in the ipsilateral 
and contralateral sides of the spinal dorsal horn of wild type (WT) and TRPV1 knock-
out (KO) mice.  
(A) The number of pERK1/2 immunopositive neurons in conditions not involving 
severe burn injury.  
(B) The number of pERK1/2 immunopositive neurons in conditions involving severe 
burn injury.  
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Note that the number of immunopositive neurons is significantly increased on the 
ipsilateral side at 5 minutes to 6 hours survival times. Note also that at 3 hours to 6 
hours survival times, pERK1/2 immunolabelled neurons are also expressed on the 
contralateral side of the spinal dorsal horn. By 6 hours, the number of labelled 
neurons is beginning to diminish in both ipsilateral and contralateral sides. Note that 
there is no significant difference between the extent of the immunolabelling between 
the ipsilateral and contralateral sides at both 3 hours and 6 hours survival times. 
Note also that there is no significant difference in the number of labelled neurons 
between the wild type and TRPV1 knock-out mice in any experimental group. 
 
 
4.3.4. Experimental groups 2:  non-noxious stimulus  
     Immersion of hind-limbs of WT and KO animals in 37 degrees C. water for 2 
minutes resulted in few pERK1/2-immunopositive neurons being observed in any side 
of the dorsal horn of both WT and KO mice (3.5±1.4 ipsilateral, and 2.7±1.4 
contralateral, in WT (n =3); 0.9±0.8 ipsilateral, 0.3±0.1 contralateral, in KO (n=4)).  
The number of pERK1/2-expressing cells was not significantly different as between 
the ipsilateral side and the contralateral side of either the WT or KO mice.  No 
significant difference was found between the number of labelled cells found in the 
same sides of the WT and KO animals. Consistent with previous findings that 
innocuous stimuli do not evoke pERK expression in the dorsal horn of the spinal cord 
(Ji et al., 1999), no significant difference was found between the number of labelled 
neurons observed in the same sides of the spinal cords of naive, anaesthetized, 
animals and of animals which had had a limb immersed in 37ºC water.  
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4.3.5. Experimental groups 3:  momentary noxious heat stimulus  
(1 hour survival time) 
     Immersion of the lower hind-paw into 60ºC water for 1 second with a survival time 
of 1 hour resulted in few pERK1/2-immunoreactive neurons being observed in either 
side of the dorsal horn of spinal cords of both WT (2±1.1 ipsilateral; 0.5±0.4 
contralateral; n =4) and KO mice (1.7 ±0.9 ipsilateral; 0.8 ±0.4 contralateral; n =3).  
No significant difference was found in the number of labelled neurons as between the 
two sides of the spinal cord in either WT or KO mice. Furthermore, there was no 
significant difference found in the number of pERK1/2-expressing neurons in the 
same sides of the spinal cords of the WT and KO mice. Moreover, the number of 
labelled  neurons in both WT and KO animals in any side of their spinal cord did not 
differ significantly from the number found in any side of the spinal cords of WT and 
KO animals which had received no stimulus at all (experimental groups (1)), or 
received an innocuous stimulus (experimental groups (2)).  
 
4.3.6. Experimental groups 4:  severe burn injury (short survival time) 
     Immersing the lower hind-limbs into 60ºC water for 2 minutes followed by a 5 
minute survival time resulted in a major increase in pERK1/2-immunoreactivity in the 
dorsal horn of the ipsilateral side of the spinal cord of WT mice, but had little effect 
on the dorsal horn of the contralateral side.  The average number of pERK1/2-
immunolabelled cells in the ipsilateral side and contralateral side of WT mice was 
25.1±4.8, (n=4) and 1.6±0.6 (n =4), respectively.  In the  ipsilateral side of the dorsal 
horn of WT animals, the great majority of the pERK1/2-immunopositive neurons 
were distributed in the medial part of the dorsal horn. The difference in the number of 
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pERK1/2-expressing cells as between the two sides of the dorsal horn in these 
animals was highly significant.  
 
     The number of pERK1/2-expressing neurons in the ipsilateral side of these WT 
animals was significantly higher than the number of such neurons found in the 
ipsilateral side of animals in the preceding experimental groups.  On the other hand, 
there was no significant difference found between the number of pERK-expressing 
neurons on the contralateral side of WT animals in these and in the preceding 
experimental groups.  
 
      There was a major difference in pERK1/2-immunoreactivity as between the 
ipsilteral and contralateral sides of the spinal cords of the KO mice in these 
experiments.   While the average number of pERK1/2-immunolabelled cells on the 
ipsilateral side of the dorsal horn of these animals was 16.1±0.8 (n=3), it was 0.3 ±0.1 
in the contralateral side (n =3).   The great majority of the pERK1/2-immunolabelled 
neurons were found in the medial part of the ipsilateral dorsal horn.  The difference 
between the numbers of labelled neurons found in the ipsilateral and contralateral 
sides of the spinal cords was significant.  
 
     Comparison of the number of labelled neurons found in the ipsilateral side of the 
spinal cord in WT and KO animals showed an ~36% reduction in KO mice which 
difference was significant. The difference in the average number of labelled neurons 
in the contralateral side of the dorsal horn of the WT and KO mice, however, was not 
significant. The average number of labelled neurons in the ipsilateral spinal cord of 
KO mice was significantly higher than that in the ipsilateral side of the dorsal horn in 
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animals in the preceding experimental groups.  However, the present experimental 
protocol did not evoke significant change in the number of neurons labelled in the 
contralateral side of these WT and KO animals, respectively, when compared to the 
contralateral sides of corresponding animals in the preceding experimental groups.   
 
4.3.7. Experimental groups 5:  severe burn injury (1 hour survival time) 
      Immersion of the lower hind-limb into 60ºC water for 2 minutes  followed by 1 
hour survival time also produced a substantial difference in pERK1/2-
immunoreactivity between the ipsilateral and contralateral sides of the spinal cord in 
WT mice. While the average number of pERK1/2-immunolabelled neurons found on 
the ipsilateral dorsal horn was 19±1.3 (n=4), it was 2.9±1.7 (n=4) on the contralateral 
dorsal horn.  The great majority of the labelled neurons in the ipsilateral dorsal horn 
were distributed in its medial part. The difference in the number of pERK1/2-
immunoreactive cells between the two sides of the spinal cord in these animals was 
significant.  Furthermore, increasing the duration of survival time following burn 
injury did not produce any significant change in the number of labelled neurons in the 
ipsilateral side of the dorsal horn of WT mice. The number of labelled neurons on the 
contralateral dorsal horn was not significantly different from the number found in the 
contralateral dorsal horn of WT animals in the preceding experimental groups. 
 
     In the KO animals in this experiment, pERK1/2-immunoreactivity was 
significantly greater in the ipsilateral side of the dorsal horn than in the contralateral 
dorsal horn.  While the average number of labelled cells in the ipsilateral side of the 
spinal cord was 16.3±1 (n=4), it was 3.5±0.4 on the contralateral side (n=4).  
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      The number of labelled neurons on the ipsilateral side of the dorsal horn in KO 
animals was significantly greater than the number found in the same side of the dorsal 
horn of KO animals in the first three experimental groups.  However,  the number of 
pERK1/2-immunopositive neurons on the ipsilateral side of the dorsal horn in KO 
animals  did not differ significantly from that found either in WT animals which had 
received the same treatment or in the KO mice which had had their lower limbs 
immersed into 60ºC water followed by 5-minute survival (experimental groups no. 4). 
The number of labelled neurons found in the contralateral dorsal horn did not differ 
significantly from the number of such neurons found in the contralateral side of the 
spinal cord of animals of any other treatment groups.  
 
4.3.8. Experimental groups 6: severe burn injury (3 hours  survival time) 
    At 3 hours after severe burn injury, the number of neurons which were stained for 
ERK activation in both KO and WT mice had substantially increased when compared 
with the number of neurons stained for such activation at 1 hour after such injury.  
Remarkably, at this later time, in both TRPV1-null and wild-type mice, the 
contralateral side of the dorsal horn now exhibited a substantial number of p-ERK-
immunopositive neurons, sometimes matching, or exceeding, the number of neurons 
stained for ERK activation on the ipsilateral side.  Interestingly, the distribution of the 
labelled neurons on the contralateral side differed markedly from that of the labelled 
neurons on the ipsilateral side and, moreover, the intensity of the staining was 
frequently less than that seen on labelled neurons on the ipsilateral side.  
 
     Here, again, we found no significant difference between the number of neurons on 
either side of the spinal cord labelled for ERK1/2 activation in TRPV1 knock-out 
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mice when compared with the number so labelled in the corresponding sides in wild-
type mice.  Thus, the average number of p-ERK1/2 immunopositive neurons in the 
ipsilateral dorsal horn of WT mice was 31.2 +/- 2.1 (n = 3), while the average number 
of neurons stained on the contralteral dorsal horn was 28.5 +/- 1.4 (n = 3).  In the case 
of KO mice, the average number of neurons stained on the ipsilateral dorsal horn of 
such mice was 33.1 +/- 2.9 (n = 3), while the average number of neurons stained on 
the contralateral dorsal horn was 29.9 +/- 3.9 (n = 3).  No significant difference was 
found between the number of neurons stained for ERK1/2 activation when the same 
sides were compared in knock-out and wild-type mice, respectively.    
 
4.3.9. Experimental groups 7: severe burn injury (6  hours survival time) 
    At 6 hours after severe burn injury, we found no alteration in the expression of p-
ERK1/2 immunopositive neurons from that at three hours, as previously discussed, 
except that at this juncture it was apparent that there was a reduction in the extent of 
the labelling in both the ipsilateral and contralateral sides of the dorsal horn which 
was found in both TRPV1-null and wild-type mice.   
 
     We found no significant difference between the number of neurons on either side 
of the spinal cord labelled for ERK1/2 activation in TRPV1 KO mice when compared 
with the number so labelled on the corresponding sides in WT mice.  Thus, the 
average number of p-ERK1/2 immunopositive neurons in the ipsilateral dorsal horn of 
WT mice was 22.1 +/- 2.6 (n = 3), while the average number of neurons stained on 
the contralateral dorsal horn was 19.9 +/- 3.1 (n = 3).   In the case of  KO mice, the 
average number of neurons stained on the ipsilateral dorsal horn of such mice was 
19.4 (n = 2), while the average number of neurons stained on the contralateral dorsal 
 201 
horn was 20.4 (n =  2).  No significant difference was found between the number of 
neurons stained for ERK1/2 activation when the same sides were compared in KO 
and WT mice, respectively.    
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4.4. DISCUSSION 
 
4.4.1. Experimental design 
           Histologically verifiable second degree burn injury was induced in mouse by 
exposing a lower hind-paw to hot water at 60 degrees C. for two minutes (under 
urethane anaesthesia).  Using this model of scalding-type burn injury and DAB-
labelling, we have compared the extent of the activation by such burn injury of 
ERK1/2 in the dorsal horn of the spinal cord of wild-type, and TRPV1 null, mice, 
respectively.  At all of the post-injury time points beyond 5 minutes which we 
measured (1 hour; 3 hours; and 6 hours), no significant difference was found in the 
extent of ERK1/2 activation (pERK1/2) in the ispilateral dorsal horn between wild-
type, and TRPV1 null, mice, respectively,  
 
        Ethical, and, indeed, in the United Kingdom, legal, considerations, dictate that 
animals must be deeply anaesthetised while subjected to this scalding-type burn 
injury.  Hence, behavioural assessment of the effect of this type of injury is not 
possible and reliance must be placed instead on a surrogate marker of nociception.  
Activation of spinal ERK1/2 is a recognised marker of spinal nociceptive processing.  
Ji and colleagues (1999) showed that peripheral capsaicin injection into the left hind-
paw of rat activates ERK1/2 by phosphorylation (pERK1/2) in dorsal horn spinal cord 
neurons and induces pain-related behaviour in the animal (Ji et al., 1999).  There is 
also compelling evidence that activation of ERK1/2 is found in many inflammatory 
conditions in the somatosensory system (Cruz et al., 2005a; Cruz et al., 2005b; Karim 
et al., 2006;  Seino et al., 2006;  Tsuda et al., 2007).    In accord, we found that both 
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non-noxious stimulation of the lower hind-paw and momentary noxious stimulation of 
the lower hind-paw each failed to evoke ERK1/2 activation.  However, sustained 
noxious stimulation of the same part over 2 minutes, which resulted in severe tissue 
injury, resulted in substantial ERK1/2 activation within 5 minutes of the injury being 
sustained. 
 
4.4.2. Involvement of TRPV2 
     The extent to which ERK1/2 was activated in the ipsilateral dorsal horn at five 
minutes after sustained noxious scalding-type injury was significantly greater in wild-
type animals when compared to TRPV1 null animals.  This difference in the level of 
ERK1/2 activation in wild-type mice, when compared with knock-out mice, can be 
attributed to the contribution to the excitation of primary sensory afferents made by 
TRPV1 present in the wild-type animals.   However, there was also an increase in 
pERK in the ipsilateral dorsal horn of knock out animals, albeit that it was 
significantly less than the increase found in wild-type animals.  One may speculate 
that this (lesser) increase in ERK1/2 activation in the knock-out animals was at least 
contributed to by activation of TRPV2 ion channels by the noxious heat stimulus.  
The transient receptor potential vanilloid receptor type 2 (TRPV2) is a non-selective 
cation channel, expressed primarily in myelinated afferents,  which is activated in 
mouse and rat by temperatures in excess of ~ 52 degrees C (Ahluwahlia et al., 2002; 
Lewinter et al., 2004; Ma, 2001; Neeper et al., 2007;  Patapoutian et al., 2003].  
TRPV2 in rat dorsal root ganglion cells appears to contribute to peripheral 
sensitization during inflammation and to be important in mediating pain 
hypersensitivity to noxious high temperature stimuli (Shimosato et al., 2005).  Given 
that there is increasing evidence of a role for TRPV2 in mediating high-threshold heat 
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responses in a sub-population of mammalian sensory neurons (Leffler et al., 2007;  
Qin et al., 2008), one may also speculate that TRPV2 may also be involved in 
mediating the pain occasioned by momentary exposure to scalding water (which fails 
to manifest itself in significant ERK1/2 activation).  The pain sensation induced by 
such noxious stimulus is almost instantaneous, which is essential if the animal is to 
protect itself by promptly withdrawing its limb from the source of danger.   This 
suggests the involvement in this phenomenon of myelinated nociceptive afferents 
which have the capacity for ultra-fast conduction of the pain signal, with the murine 
TRPV2 being the most obvious receptor capable of facilitating this response.   
 
4.4.3. TRPV1 redundant except in period immediately after injury 
        While TRPV1 clearly had an effect in activating ERK1/2 in neurones of the 
ipsilateral dorsal horn at five minutes after burn injury,  this effect of TRPV1 was not 
maintained and was absent when ERK1/2 activation was assessed at 1 hour, 3 hours, 
and 6 hours, after the scalding-type injury was sustained.   We suggest that these 
findings can reasonably be interpreted as showing that the nociceptive response to this 
scalding-type burn injury in mouse is not dependent on activation of TRPV1 except in 
the period immediately after the injury is sustained and certainly ending within 1 hour 
after injury.  
 
       The conclusion that TRPV1 is not essential for the maintenance of the 
inflammatory nociceptive response occasioned by scalding-type burn injury raises an 
important question relating to whether the search for new analgesic agents ought to be 
focused upon attempts to neutralize the actions of various ion channels as opposed to 
eliminating, or at least reducing, the availability of inflammatory agents, as such.  A 
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multiplicity of agents released in inflammation contribute to alter the firing pattern of 
nociceptive primary sensory neurons, including bradykinin, eicosanoids, nerve growth 
factor (NGF), artemin, glial cell line-derived neurotrophic factor (GDNF), serotonin, 
histamine, anandamide, adenosine 5’triphosphate (ATP), and cations, especially 
protons.  These inflammatory agents act directly on their own receptors found on 
primary afferents (in respect of which they are specific ligands) to contribute to 
excitation of these neurones (Nagy and Rice, 2002).  In addition, certain of these 
inflammatory agents also activate ion channels found on these neurons, or affect the 
sensitivity and expression of these ion channels.  Present evidence suggests that the 
most important of these ionotropic receptors affected by these agents are TRPV1 
(Ahern et al., 2005; Amaya et al., 2004; Avelino et al., 2002;  Bolcskei et al., 2005; 
Caterina et al., 1999, 2000;   Chuang et al., 2001;  Davis et al., 2000; Dinis et al., 
2004;  Guo et al., 1999;  Ji et al., 1999;  Jordt et al., 2000;  Kasama et al., 2007;  
McNaughton, 2005;  Pogatzki-Zahn et al., 2005; Ryu et al., 2003;  Sato et al., 2005;  
Stein et al., 2006; Sugiura et al., 2002,  2007;  Tominaga et al., 1998;  Vellani et al., 
2006; Zhang et al., 2008; Zhu and Oxford, 2007), TRPA1 (Andersson et al., 2008;  
Bandell et al., 2004; Chao et al., 2008;  Doerner et al., 2007; Jordt et al., 2004; 
Kobayashi et al., 2005; Taylor-Clark et al., 2008), TRPV4 (Alessandri-Haber et al., 
2005, 2006, 2008; Liedtke, 2005; Suzuki et al., 2003a, 2003b), and ASIC  (Babini et 
al., 2002; Bassler et al., 2001; Smith et al., 2007; Sugiura et al., 2005; Waldmann et 
al., 1997;  Zhang et al., 2006) ion channels.  Our findings suggest that, in the model of 
scalding-type burn injury which we employed, TRPV1 is an unnecessary “fifth-
wheel” on the carriage mediating the effects of these inflammagens, except in the 
period immediately after the injury is sustained and certainly ending within 1 hour 
after injury.     
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     It has yet to be shown that alteration of the functioning of any single ion channel 
type – whether TRPV1, TRPA1, TRPV4 or the ASICs – may  effect the outcome in 
terms of neuronal excitation and resulting pain sensation in the context of 
inflammation.   It has been shown that altered function of Na+ channels contributes to 
the increased hyper-excitability of primary afferent neurons in certain pathological 
pain states and the Nav1.9 sub-unit has been implicated in mediating inflammatory 
pain sensations (Amaya et al., 2006;  Priest et al., 2005).  It has also been shown that 
individual inflammagens may, conjointly, produce an effect which they are 
individually incapable of mediating. Thus, bradykinin, ATP, histamine, PGE2, and 
noradrenaline, when applied separately at maximal concentrations, all fail to modulate 
Nav1.9 current;  but,  when applied conjointly as a soup of inflammatory mediators, 
they rapidly potentiate Nav1.9 channel activity, generating sub-threshold 
amplification and increased excitability (Maingret et al., 2008).   Again, Levine and 
colleagues (2008) have shown that the level of the pro-inflammatory cytokine, 
interleukin-6 (IL6), is increased following a partial-thickness burn injury in rat and 
that spinal intrathecal injection of oligodeoxynucleotides antisense for gp130, a 
receptor subunit shared by members of the IL-6 family of cytokines, attenuates both 
burn-induced, and intrademeral IL-6-induced, mechanical hyperalgesia, as does 
intradermal injection of anti-IL-6 function blocking antibodies (Summer et al., 2008).  
The findings in these studies may have profound clinical implications because they 
suggest that, in certain pain states at least, an intervention which successfully prevents 
the contribution to neuronal excitation of certain only of the inflammagens may result 
in a significant analgesic effect. At the same, our findings suggest that there is 
redundancy, at least as regards TRPV1, in the complex of receptors (ionotropic and 
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G-protein coupled) which mediate the effects of these inflammagens so that, except in 
the initial aftermath of such burn injury, the resulting sensation of pain is not 
dependent on activation of TRPV1.   If this should also be the case in humans, then it 
would appear that, in the context of certain types of burn injuries at least, resources 
ought to directed toward attempting to eliminate, or reduce, the availability of 
inflammatory agents rather than attempting to modulate the activity of TRPV1 to 
induce analgesia. 
 
4.4.4. Contralateral responses to unilateral inflammatory lesions      
     Our finding that, at 3 hours after severe scalding-type burn injury, the number of 
neurons which were stained for ERK1/2 activation in both knock-out, and wild-type, 
mice had substantially increased when compared with the number of neurons stained 
for such activation at 1 hour after such injury, is consistent with a delay being 
necessary before inflammatory agents may mediate their effects through certain of 
their receptors.   Our further finding that at this later time, in both TRPV1-null and 
wild-type mice, the contralateral side of the spinal cord now exhibited a substantial 
number of p-ERK1/2-immunopositive neurons remains intriguing, notwithstanding 
that the phenomenon of hyperalgesia developing in the hindpaw contralateral to a heat 
injury has long been noted (Coderre and Melzack; Polgar et al., 1998).  Interestingly, 
the distribution of the labelled neurons on the contralateral side differed markedly 
from that of the labelled neurons on the ipsilateral side and, moreover, the intensity of 
the staining was frequently less than that seen on labelled neurons on the ipsilateral 
side.  Contralateral responses to unilateral inflammatory lesions are not unknown 
(Coderre and Melzack, 1991;  Koltzenburg et al., 1999;  Polgar et al., 1998; Shenker 
et al., 2003). One may speculate that this labelling is caused, or contributed to, by an 
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action of descending fibres on these contralateral dorsal horn neurons since the 
concept of supraspinal pronociceptive modulation of pain is now well recognised 
(Lima et al., 2002; Tavares and Lima, 2007).  In addition, or in the alternative, this 
labelling may result from cross-communication between opposite dorsal horn neurons 
(Coderre and Melzack, 1991; Shenker et al., 2003).  In any event, the activation of 
ERK1/2 on both sides of the dorsal horn discloses a process in which spinal neurons 
are driving inflammatory nociceptive activity after the excitatory effect of peripheral 
inflammagens has abated in primary sensory afferents. 
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5.1.  INTRODUCTION 
      In primary sensory neurons the membrane currents generated by neuronal ion 
channels, such as TRPV1, affect neuronal firing patterns to constitute, and initiate, the 
electrical transfer to the brain of, an integrated picture of pain-inducing stimuli.  The 
transfer of signals which relay this information from primary sensory neurons to the 
spinal cord is mediated by the release of neurotransmitter substances by these neurons 
where they synapse with second-order afferent neurons in the spinal cord.  
Nociceptive fibres terminate in the superficial layers of the dorsal horn, forming 
synaptic connections with transmission neurons running to the thalamus and other 
nuclei in the brain and brain-stem. Primary sensory neurons release glutamate (fast 
transmitter) and various peptides, especially substance P and calcitonin gene-related 
peptide (CGRP), which act as slow transmitters, at their central terminals in the spinal 
cord to mediate nociceptive signals.  In addition, these neurons may, in conditions of 
neurogenic inflammation, discharge CGRP and substance P at peripheral terminals 
which results in further increased neuronal excitation and pain. 
 
 Acute activation of TRPV1 in primary sensory neurons results in a short-
lasting burning pain sensation. However, sustained TRPV1 activation in those 
neurones resulting from inflammation of peripheral tissues leads to the development 
of heat hyperalgesia and visceral hyper-reflexia (Caterina et al., 2000; Davis et al., 
2000; Charrua et al., 2007). Activation of TRPV1 ion channels results in 
neurotransmitter release, including CGRP (Sauer et al., 1999).  CGRP release by 
primary sensory neurons is commonly regarded as a marker of substance P release 
also (Gibbins et al., 1985).  However, the difficulty in its use as a marker for TRPV1 
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activation resides in the fact that CRGRP release is ultimately the result of electrical 
activity in the cell which may be the result of the activation of receptors other than 
TRPV1.  Moreover, in rat, CGRP is expressed by all types of primary afferents 
(MCarthy & Lawson, 1990; Lawson & McCarthy, 1996).  In addition, CGRP 
expression may also be affected by nerve injury which is an inevitable consequence of  
DRG culture preparations (Honore et al., 2000).   
 
Xenon is an inert gas which binds to a remarkable range of proteins, including 
ion channels, such as the ionotropic N-methyl-D-aspartate (NMDA) receptor for 
glutamate, as well as certain non-NMDA receptors (Franks et al., 1998;  Gruss et al., 
2004; Dinse et al, 2005;  Dickinson et al, 2007; Salmi et al., 2008).  Research into the 
mechanism of action of xenon has focused, almost exclusively, on its role as a general 
anaesthetic. However, in addition to its potent anaesthetic effect, xenon, in sub-
anaesthetic doses, provides analgesia (Yagi et al., 1995;  Petersen Felix et al, 1998). 
Such xenon-induced analgesia is believed to be mediated, at least in part, through 
inhibition of spinal nociceptive processing by way of reducing noxious stimulation-
evoked spiking activity and long term potentiation in spinal cord neurons (Utsumi et 
al., 1997; Benrath et al., 2007; Watanabe et al., 2004).   It appears likely that xenon-
induced reduction of spinal nociceptive processing is not mediated solely through 
inhibition of NMDA receptor activity. All components of spinal cord ventral root 
potentials (VRPs) evoked by stimulation of primary afferents are reduced by xenon 
(Watanabe et al., 2004). Individual components of these VRPs are dependent on one, 
or other, of NMDA receptors, non-NMDA receptors, or tachykinin receptors (Nagy et 
al., 1994; Nagy & Woolf, 1996; Thompson et al., 1994). Hence, an inhibitory effect 
of xenon on VRPs may result from xenon’s action on these receptors in the spinal 
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cord and, in addition, or in the alternative, from xenon’s effect on one, or more, 
receptor types on primary nociceptive neurons resulting in reduced nociceptive input 
into the spinal dorsal horn.  
 
Previous studies have shown that xenon reduces pain-related behaviour 
evoked by formalin injection, which induces an inflammatory reaction in tissues 
(Fukuda et al., 2002; Ma et al., 2004). Recently, it has been shown that the formalin 
injection-evoked pain-related behaviour is reduced by TRPV1 antagonists (Garcia-
Martinez et al., 2006; Tang et al., 2007). These data suggest that, if xenon indeed 
reduces the nociceptive input into the spinal dorsal horn, that reduction could be 
mediated – at least in part – by an inhibitory effect on TRPV1. Accordingly, this work 
was designed to determine the effect of xenon on TRPV1 activity by studying 
TRPV1-mediated responses in primary sensory neurons, TRPV1-expressing human 
embryonic kidney 293 (HEK293) cells, and by capsaicin-injection-evoked activation 
of spinal dorsal horn neurons. 
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5.2. MATERIALS AND METHODS 
 
5.2.1.  Animals 
All procedures were performed in accordance with the requirements of the UK 
Animals (Scientific Procedures) Act, 1986. All together, 23 female Sprague Dawley 
rats (each ~100 g in weight) were used in this study. The animals were kept at 12 
hours light-dark cycles at controlled temperature and humidity, with food and water 
ad libitum. 
 
5.2.2. Capsaicin injection-induced expression of phosphorylated extracellular                                                                                                              
signal regulated kinase 1/2  
Sixteen female Sprague Dawley rats were randomly assigned to four groups. 
Xenon (80%) and oxygen (20%) was administered as a mixture at atmospheric 
pressure to the animals from two of these groups in a sealed Perspex chamber. The 
flow-rate of the gas mixture through the chamber was 2.1 l/minute, while the chamber 
itself had a volume of 3 l.  After exposure to the xenon/oxygen mixture for 15 
minutes, the animals in one of these groups received a subcutaneous injection of 
capsaicin (3mg/ml dissolved in 10% Tween 80; 25 µl) into the right hind-paw. The 
other xenon-treated group of animals were injected with the vehicle (10% Tween 80; 
25 µl). The remaining two groups of animals were anaesthetised with sodium 
pentobarbital (60 mg/kg, i.p.), after which one group was injected with capsaicin, 
while the other group was injected with vehicle. Following 5 minute survival under 
anaesthesia, all animals were perfused transcardially with saline followed by 4% 
paraformaldehyde. The lumbar spinal cord was removed and placed into the same 
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fixative for an additional 4 hours. Tissues were then put into 30% sucrose until they 
sank. The ventral horn of the L4-L5 segments was labelled by a shallow longitudinal 
cut on the left side. Then, 20 µm transverse sections were cut on a crysostat and thaw-
mounted on Superfrost Plus microscope slides (VWR, West Chester, PA). Sections 
were air dried overnight and stored at -20℃ until required. 
 
The effect of xenon on subcutaneous capsaicin injection-evoked activation of 
spinal cord neurons was assessed by studying the number of cells expressing 
phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2) in the dorsal horn 
of the spinal cord (Ji et al., 1999). Spinal cord sections were washed in 0.01M 
phosphate-buffered saline (PBS) and incubated in PBS containing 0.3% Triton X 
(PBST) for 10 minutes followed by incubation of the sections in 10% normal donkey 
serum (NDS, Jackson Labs, USA) in PBST for 20 minutes. Following brief washes in 
PBST containing 1% NDS, sections were incubated in a polyclonal primary antibody 
raised in rabbit against the residues surrounding T202/Y204 of pERK1/2 (1:700; 
Neuromics, USA) overnight. The immunoreaction was visualized by incubation with 
donkey anti-rabbit IgG conjugated to fluorescein isothiocyanate (1:500; Jackson Labs, 
USA) for 2 hours. Sections were covered by glass coverslips using Vectashield 
(Vector, UK). All the washes and incubations were done at room temperature in 
PBST.   
 
Spinal cord sections were analysed in a Leica epifluorescent microscope. 
Immunopositive neurons with clearly visible perikarya were manually counted on 
both the ipsi- and contra-lateral dorsal horn in every second of 10 adjacent sections. 
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5.2.3. Preparation of cultured primary sensory neurons 
Rats were terminally anaesthetised by Enflourane (Abbott, Maidenhead, UK) 
and their dorsal root ganglia (DRG) from the first cervical to the first sacral segments 
were dissected out and maintained in culture medium (Ham's nutrient F12 
(Invitrogen, UK), supplemented with 1 ml L-glutamine (Invitrogen, UK); 50 IU/ml 
penicillin (Invitrogen, UK); 50 µg/ml streptomycin (Invitrogen, UK); and 4% Ultroser 
G (Pall BioPharmaceuticals, France)). Ganglia were incubated in collagenase (2000 
U/ml, Sigma) for 3 hours at 37ºC in an atmosphere of 95% air and 5% CO2. 
Following washes in the supplemented medium, the ganglia were triturated through a 
fire-polished Pasteur pipette, before being re-suspended and plated on poly-DL-
ornithine-coated glass coverslips. The cells were then kept at 37°C in an atmosphere 
of 95% air and 5% CO2 for 2 days in the presence of nerve growth factor (NGF, 50 
ng/ml, Promega, UK). Each animal provided one culture. We then used the cobalt 
uptake technique, infra, to assess the effect of xenon on TRPV1 activity.  
 
5.2.4. Preparation of HEK293 cells transiently transfected with human TRPV1 
HEK293 cells were maintained and propagated using standard procedures. 
Briefly, cells were grown as monolayers in minimum essential medium (MEM, 
Invitrogen, UK) containing 10% foetal bovine serum (Invitrogen, UK), 2 mM L-
glutamine (Invitrogen, UK), penicillin (5,000 IU/ml, Invitrogen, UK), streptomycin (5 
mg/ml, Invitrogen, UK) and MEM non-essential amino acids (Invitrogen, UK) in an 
atmosphere of 95% air and 5% CO2 at 37ºC. Cells were harvested every 3-4 days, 
using trypsin-EDTA. Only cells with a passage number lower than 22 were used in 
this study. Sub-confluent HEK cells were transiently transfected with human TRPV1 
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(hTRPV1) using Plus Reagent and Lipofectamine (Invitrogen, UK). The hTRPV1 was 
cloned in a pcDNA3.1/V5-His-TOPO vector (Invitrogen, UK). Transfected cells were 
plated onto 13 mm coverslips coated with poly-DL-ornithine (Sigma, UK) in 25,000 
cells/cm2 density and cultured in the growth media for 1 to 4 days. We then used the 
cobalt uptake technique to assess the effect of xenon on TRPV1 activity. 
 
5.2.5 Cobalt uptake 
The cobalt uptake experiments were performed as described previously28-29. 
Briefly, cultured primary sensory neurones, or HEK293 cells attached to their 
coverslips, were washed in buffer A (in mM: NaCl, 57.5; KCl, 5; MgCl2, 2; HEPES, 
10; glucose, 12; sucrose, 139; at pH 7.4) twice for 2 minutes. Then, cells were pre-
incubated in buffer A saturated with a mixture of 75% nitrogen and 25% oxygen 
(control) or 75% xenon and 25% oxygen.  
 
The first experiment with primary sensory neurons was done at room 
temperature. The pre-incubation of cells in this experiment lasted for 15 minutes and 
was performed with buffer A that had been bubbled through with either of the gas 
mixtures for 15 minutes. The pre-incubation was done in four-well plates which were 
covered by parafilm in order to prevent the escape of the gases. Buffer A was changed 
for cobalt-uptake buffer (buffer A+5mM CoCl2) that had been bubbled through the 
appropriate gas mixture for 15 minutes and contained or lacked capsaicin (100nM or 
1µM; stock dissolved in DMSO; Tocris, UK). Incubation of the cells in the cobalt-
uptake buffer lasted for 5 minutes in four well plates covered by parafilm. 
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In a subsequent experiment, in order to try to improve xenon delivery, the pre-
incubation of primary sensory neurons was done in an air-tight chamber filled with 
either of the gas mixtures. Buffer A was saturated by exposing it to the gases in the 
chamber for 45 minutes before the pre-incubation. The flow-rate of the gas mixtures 
through the chamber was adjusted to 2.1 l/minute both during the buffer saturation 
and pre-incubation, while the chamber itself had a volume of 3 l. The pre-incubation 
time was 15, 30, or 60 minutes. The cobalt-uptake buffer that had been saturated also 
by exposing it to the gases for 45 minutes in the chamber and contained or lacked 
capsaicin (500nM) was put onto the neurons for 5 minutes. The temperature within 
the chamber throughout the experiment was maintained at 37ºC. 
 
Having regard to the results obtained on primary sensory neurons, the pre-
incubation of the HEK293 cells lasted for 45 minutes in the chamber with buffer A 
that had been previously saturated with the appropriate gas mixture in the chamber for 
45 minutes. Incubation of the cells in the cobalt-uptake buffer that had also been 
saturated in the chamber by the appropriate gasses for 45 minutes either with, or 
without, capsaicin (10nM-1µM) lasted for 5 minutes.  
 
Following the removal of the cobalt-uptake buffer both primary sensory 
neurons and HEK293 cells were washed briefly in buffer A at room temperature or 
37ºC. Cells were then transferred into 0.4% mercaptoethanol in buffer A for 2 
minutes, then into 70% ethanol for 30 minutes, and mounted on glass slides using 
glycerol. Analysis of the cobalt labelling was carried out as described previously28-29. 
Briefly, the optical intensities of more than 100 systematically randomly chosen cells 
were measured on each coverslip by a Leica light microscope attached to a CCD 
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camera and a PC running the QWin software package (Leica). The distributions of the 
optical intensities found on each cover-slip were then fitted by normal distributions. 
The cut of intensity distinguishing between responding and non-responding cells was 
established as the 95% confidence interval of the normal distribution fitting the 
intensities of the labelled cells (Figure 1).  
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Figure 1. 
 
Analysis of cobalt uptake experiments. Following the measurement of the optical 
intensity of at least 100 cells chosen randomly systematically, the distribution of the 
optical intensities were generated. The distributions were fitted with Guassian curves. 
(A) and (B) show typical distributions of optical intensities from two cover-slips 
containing cultured DRG neurons.  
(A) shows the optical intensities of cells which were incubated in cobalt without 
capsaicin.  
(B)  shows the distribution of optical intensities which were incubated in cobalt in 
the presence of capsaicin.  
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Note that, while in the control conditions (A), the cells formed two groups regarding 
their optical intensities, capsaicin induced the formation of a third group of neurons 
with higher optical intensities. These latter cells represented the capsaicin-responding 
neurons. The cut-off intensity was determined as the lower 95% confidence interval of 
the curve fitted to the group of neurons with the highest optical intensities. 
The reason for the presence of two groups in the control experiment is not known.  
Apparently, there is no correlation between the size of the neurons and their optical 
intensities (data not shown). 
(C) and (D) show similar distributions of hTRPV1-transfected HEK293 cells. 
 Note that, in control conditions (C), HEK293 cells formed only one group of 
cells regarding their optical intensities. Cobalt in these cells induced the 
formation of a second group of cells regarding their optical intensities. 
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5.2.6. Statistical analysis 
The average number of pERK1/2-expressing neurons per section in each 
spinal cord was established. Then, the average number of pERK1/2-expressing cells 
of animals subjected to the same treatment was calculated.  
 
The relative number of cobalt-labeled cells in each set of experiments in each 
culture was normalized to the highest relative number found in that set of experiments 
in order to make comparisons between primary sensory neurons and HEK cells easier. 
Normalized data obtained in the same condition were then averaged. 
 
Differences between relevant groups were assessed by one way or multiple 
analyses of variance as appropriate. The statistical significance of the differences was 
assessed by the Dunnett’s test. Differences were regarded as significant at p<0.05. 
Data are expressed as mean±SEM. n shows the number of cultures or animals which 
received the same treatment. 
 
 
5.2.7. CGRP assay: ELISA 
     CGRP release was assessed using ELISA (SPI-BIO, France), employing the 
method previously described by Ahluwalia and colleagues (2003).  All procedures 
were performed at room temperature.  Briefly, cells were washed once with release 
buffer (in mM: NaCl, 136; KCL, 536; MgCl2, 0.49; CaCl2, 1.27; Glucose, 5.5.; 
MgSO4, 0.4; KH2PO4, 0.44; NaH2PO4, 0.33;  HEPES,10; pH 7.4).  After washing, the 
cells were incubated in release buffer to which either 75%/25% N2/O2 or 75%/25% 
Xe/O2  mixtures had previously been introduced by bubbling the gases through the 
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buffers for 15 minutes with the plates covered by parafilm in order to inhibit the 
escape of the gases.  The cells were then placed in release buffer similarly treated, but 
which also contained the specified concentration of capsaicin (100 nM or 1 uM), or 
no capsaicin (as a control).  The cells were incubated in these buffers for 2 minutes, 
again using parafilm to cover the plates.  The buffers were removed, frozen 
immediately and then stored at -20 degrees C until the ELISA procedure was 
performed.     
 
      The CGRP content of the buffers was measured using the ELISA kit in 
accordance with the manufacturer’s instructions.  The absorption values of the 
acetylcholinesterase products were measured using a DYnex MRX-II 96 well plate 
reader (Dynex Technologies) using a 405 nm  filter, controlled and analysed using the 
Revelation 4.22 software package running on a PC.  Samples were measured in 
duplicate.  CGRP data were normalised to the total protein content of the appropriate 
coverslips. 
 
5.2.7.1    Protein content measurement   
     The protein content on each coverslip was measured in order to normalise the 
results of the CGRP release assay.  After removal of the release buffer used for CGRP 
ELISA, the cells were removed from the coverslips in a lysis buffer (Cell Lysis Buffer 
1x (Cell Signalling Technologies, Beverly, MA) with 1.7 mg/mL 
phenylmethylsulphonyl fluoride (Cell Signalling Technologies) and 3 mg/mL 
Dithiothreitol (Sigma) by scraping.  The cell lysate was frozen immediately, stored at 
–20 degrees C, and used subsequently for measurement of the protein content. 
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     Samples were first centrifuged at 4 degrees C, at 3000 rpm, for 10 minutes to 
separate the cells into a pellet.  The supernatant was then removed.  Protein standards 
were made using serial dilutions of Basic Standard Albumin into concentrations of 
(ug/mL) 1000, 500, 250, 125, 12.5, 1.25, fitted with a sigmoid curve.  The protein 
measurement was done on 96-well plates in triplicate using the Bio-Rad protein assay 
kit (Bio-Rad Labs, GmbH).  Absorption values were measured using the Dynex 
MRX-II (Dynex Technologies) plate reader with a 595 nm filter, using the 
Revelations 4.22 software package. 
 
5.2.7.2    Statistical analysis for CGRP assay  
      Averages of appropriate data were calculated and the differences between relevant 
data were analysed by ANOVA.  The significance of the differences was assessed 
using the Fisher post-hoc test.  Data were regarded as significantly different at p < 
0.05.  Data are expressed as mean  +/- standard error mean.  “n” refers to the number 
of cultures tested in each condition. 
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5.3. RESULTS 
 
5.3.1. Capsaicin-evoked phosphorylation of ERK1/2 in spinal dorsal horn 
neurons 
The immunostaining was readily recognisable in the dorsal horn of the spinal 
cord (Figure 2A-B). Based on their size and shape, all immunopositive cells were 
identifiable as neurons. The great majority of the immunolabelled neurons were 
distributed in the superficial layers of the dorsal horn. Immunostained neurons could 
only very rarely be seen in the deep dorsal horn or around the central canal. 
 
Injection of the vehicle into the hind-paw of rats resulted in negligible 
pERK1/2 expression in either the ipsilateral or the contralateral dorsal horn of the 
spinal cord, regardless of whether the animals had been treated with sodium 
pentobarbital or xenon (Figure 2C). Injection of capsaicin into the paws produced 
negligible pERK1/2 expression in the contralateral side of the spinal dorsal horn, too 
(Figure 2C). In contrast, injection of capsaicin into the paws resulted in a substantial 
number of pERK1/2-immunopositive cells in the ipsilateral spinal dorsal horn both in 
the sodium pentobarital-, and xenon-treated, rats (Figure 2C) In the sodium 
pentobarbital-anaesthetised rats, capsaicin injection resulted in pERK1/2 
immunolabelling in 12.4±0.4 neurons/section (n=3), which was significantly different 
from that found in the ipsilateral side of the vehicle-injected animals (Figure 2C). 
Xenon anaesthesia significantly reduced the capsaicin injection-evoked pERK1/2 
expression in the ipsilateral spinal dorsal horn (7.6±1.1 neurons/section; n=3; Figure 
2C). The reduction in the number of pERK1/2 expression neurons was about 40%. 
Collectively, these results suggested that xenon, in the dose which we employed, 
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reduced capsaicin-evoked activation of rat spinal dorsal horn neurons. In order to 
ascertain whether inhibition of TRPV1 was involved in, or contributed to, the 
reduction in neuronal activation in the spinal cord, next, we studied the effect of 
xenon on capsaicin-induced TRPV1 responses in rat primary sensory neurons and in 
hTRPV1-expressing HEK293 cells. 
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Figure 2. 
The effect of xenon on the activation of spinal cord neurons evoked by subcutaneous 
capsaicin injection was assessed by studying the expression of phosphorylated 
extracellular signal-regulated kinase 1/2 (pERK1/2) in the dorsal horn. Adult rats 
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were anaesthetised either by pentobarbital (Pento) or 75% xenon (Xe) and capsaicin 
was injected into the right hind paw. pERK1/2 expression was revealed by 
immunoflourescent staining.  
(A) A typical image of the ipsilateral spinal dorsal horn from a pentobarbital-
anaesthetised rat. Note that there are several pERK1/2-immunopositive neurons seen 
here in lamina I and outer lamina II. 
 (B) A typical image of the ipsilateral spinal dorsal horn from a xenon-anaesthetised 
rat. Note that the number of pERK1/2-immunoposive neurons is less than in the spinal 
cord of the pentobarbital-anaesthetised animals. Scale on (B) is 200µm.  
(C) The number of pERK1/2-immunolabelled neurons was counted in every second 
section of 10 adjacent sections prepared from the L4-L5 spinal cords. Then, the 
number of immunopositive cells per section was calculated. Note that xenon 
application resulted in a significant decrease in the average number of pERK1/2-
expressing neurons (n=3 in each data point). 
 
 
 
5.3.2. Capsaicin-evoked activation of TRPV1 in primary sensory neurons 
In the presence of the nitrogen/oxygen gas mixture, exposure of cultured 
dorsal root ganglion neurons to the capsaicin-free cobalt-uptake buffer resulted in 
labelling in a negligible proportion of neurons (Figure 3A, C). In contrast, exposure to 
the capsaicin-containing cobalt-uptake buffer in the same conditions resulted in a 
significant number of neurons showing cobalt-labelling (37.5±0.9% (n=3) of the total 
population at 1 µM capsaicin, Figure 3B, C). The proportion of labelled neurons by 
100nM capsaicin was significantly less than by 1µM. 
 
In the presence of the xenon/oxygen mixture, the cobalt-uptake buffer without 
capsaicin also produced only a negligible response (Figure 3C). While this value was 
lower than the proportion of labelled cells by the cobalt-uptake buffer alone in the 
presence of nitrogen/oxygen, the reduction was not significant. Capsaicin application 
resulted in a significant increase in the proportion of responding neurons (Figure 3C). 
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While that increase was less than that in the presence of nitrogen/oxygen at both 
concentrations, the reduction was significant only at 100nM capsaicin. The xenon-
evoked reduction at 100nM capsaicin was about 30% (Figure 3C). 
  
When primary sensory neurons were pre-incubated and incubated in the air-
tight chamber at 37ºC, xenon reduced the proportion of primary sensory neurons 
labelled by capsaicin-induced cobalt-entry by ~15% (with 15 minutes pre-incubation; 
n = 2), ~50% (with 30 minutes pre-incubation; n = 2) and 54.7±8.7% (with an hour 
pre-incubation; n=3; data are not shown). These findings indicated that increasing the 
exposure time to xenon in an air-tight chamber can increase the efficacy of the xenon-
evoked inhibitory effect on TRPV1.  
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Figure 3.  
 
Effect of xenon on capsaicin-evoked TRPV1 responses of rat cultured primary sensory 
neurons. 
 (A) Controls: a negligible number of neurons accumulated cobalt.  
(B) Incubation with Co2+ and capsaicin for 5 minutes:  a significant number of cells 
accumulated cobalt (dark cells indicated by the white arrows). Bar: 20µm.  
(C) Averaged normalised relative number of cultured primary sensory neurons 
showing cobalt accumulation in 3-5 cultures. White columns: cultures incubated with 
80% nitrogen and 20% oxygen. Black columns: cultures incubated with 80% xenon 
and 20% oxygen. Note that the proportion of capsaicin-responding neurons is 
reduced when the cells are pre-incubated in the buffer saturated with 80% xenon and 
20% oxygen. This reduction was significant only at 100nM capsaicin. 
 * indicates significant difference (p<0.05). 
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5.3.3. The effect of xenon on human TRPV1 
Based on the data obtained on cultured primary sensory neurons these experiments 
were done in an air tight chamber with 45 minutes pre-incubation. To confirm that the 
45 minute pre-incubation does not per se affect cobalt-labelling, first we compared 
the responses of the hTRPV1-expressing HEK293 cells with the usual twice 2 
minutes wash and the wash followed by a 45 minute pre-incubation in buffer A 
saturated with nitrogen/oxygen. In both conditions capsaicin (10nM-1µM), evoked a 
concentration-dependent increase in the number of labelled cells between 10 nM and 
300 nM (Figure 4). The relative number of cobalt-labelled cells at any capsaicin 
concentration was significantly higher than that produced by the cobalt-uptake buffer 
alone (Figure 4). We found the 300nM capsaicin application following only the usual 
wash produced labelling in about half of the cells in average (51.9±17.9%, n=3; 
Figure 4). The relative number of labelled cells at 1 µM capsaicin in both conditions 
was lower than at 300 nM, which was probably due to desensitisation of TRPV1 
(Figure 4).  
 
In the presence of xenon, capsaicin also produced a concentration-dependent 
increase in the number of cobalt-labelled cells between 10 nM and 300 nM (Figure 4). 
The 1 µM capsaicin-evoked labelling in this condition was also lower than that 
produced by 300 nM capsaicin. Comparison of the relative number of cells labelled 
by capsaicin-induced cobalt accumulation in the presence of nitrogen/oxygen and 
xenon/oxygen revealed that xenon reduced the capsaicin-evoked responses from 10 
nM to 300 nM. However, a significant difference in the reduction was found only at 
100 nM and 300 nM. On average, the xenon-induced reduction in the proportion of 
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cobalt-labelled cells was approximately 50% between 10nM and 300nM. The 
maximum reduction was found at 100 nM capsaicin, where the labelling was reduced 
by about 55%. Collectively, these results confirmed that the xenon-evoked reduction 
in the capsaicin injection-induced pERK1/2 expression in the spinal dorsal horn was 
contributed by xenon-evoked inhibition of TRPV1 activity on primary sensory 
neurons. 
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Figure 4. 
 
Effect of xenon on capsaicin-evoked responses of hTRPV1 expressed by HEK293 cells 
after transient transfection.  
(A) Controls: a negligible number of cells accumulated cobalt.  
(B) Incubation with Co2+ and capsaicin for 5 minutes, a significant number of cells 
accumulated cobalt (dark cells). Bar: 20µm.  
(C) Averaged normalised relative number of hTRPV1-expressing HEK293 cells 
showing cobalt accumulation in 3 cultures at each concentration. Empty bars: 
incubation with Co2+ and capsaicin for 5 minutes.  Gray bars: incubation for 45 min 
in 80% nitrogen-20% oxygen. Black bars: incubation for 45 min with 80% xenon-
20% oxygen.  Note that incubation of cells in the presence of xenon (black bars) 
resulted in reduction of the number of capsaicin-responding neurons. This reduction 
was significant only at 100nM and 300nM. 
 * indicates significant difference (p<0.05). 
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5.3.4. Results: capsaicin-evoked release of CGRP from DRG neurons in vitro 
 
5.3.4.1.   CGRP release from cells in buffer exposed to N2 /O2 mixture  
       Basal (non-stimulated) release of CGRP was 1.09 +/-0.20 pg/ug protein.  In the 
presence of 100 nM capsaicin, CGRP release was increased to 1.96 +/-0.50 pg/ug 
(n=3).  In the presence of 1 uM capsaicin, CGRP release was 1.32 +/- 0.38 (n=3), 
which was not significantly different from the control or from 100 nM capsaicin 
application. 
 
5.3.4.2.  CGRP release from cells in buffer exposed to Xe/O2  mixture 
     In the presence of xenon, basal CGRP release was increased but this increase was 
not significant (1.34 +/- 0.09 pg/ug) (n=3).   The presence of xenon failed to produce 
any significant changes in the extent of the CGRP release evoked by capsaicin when 
compared to the release evoked in the presence of the  N2 /O2  mixture.  At the lower 
concentration of capsaicin in the presence of xenon, CGRP release was 1.92 +/-0.44 
pg/ug.  At the higher concentration of capsaicin, CGRP release was 1.46 +/- 0.35 
pg/ug in the presence of xenon. 
 
     As expected, capsaicin application resulted in the release of CGRP in these 
preparations at both of the concentrations at which it was applied.  However, neither 
response was concentration dependent and, in fact, the release of CGRP evoked by 1 
uM concentration of capsaicin was less than that which resulted from exposure of the 
cells to 100 nM concentration of capsaicin, although this difference was not 
statistically significant.  
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Figure 5. 
CGRP release by cultured DRG neurons when challenged with 100nM and 1µM 
capsaicin, respectively, in the presence, and absence, of xenon. Note that xenon 
increased, though non-significantly, the basal release of CGRP in control conditions. 
Note also that only 100nM capsaicin induced a significant increase in CGRP release. 
Finally note also that xenon, when present, does not significantly affect CGRP 
release. 
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5.4. DISCUSSION 
 
5.4.1. Summary of results 
The present studies show that xenon, at the concentrations employed, 
significantly reduces capsaicin-induced activation of spinal cord neurons, and that this 
effect is mediated, at least in part, by reduced activation of TRPV1.   
 
Unlike volatile anaesthetics, xenon and nitrous oxide, at sub-anaesthetic 
concentrations, can reduce heat-induced pain (Yagi et al., 1995; Petersen-Felix et al., 
1998). In rats, xenon suppresses both the pain-related behavioural, and the spinal 
expression of the nociceptive marker, cFos, induced by formalin injection (Fukuda et 
al., 2002; Ma et al.). Our results demonstrate a significant inhibitory effect of xenon 
on the activity of TRPV1 in peripheral sensory afferents. We also demonstrate a 
similar inhibitory effect of xenon on the activation of spinal dorsal horn neurons 
evoked by peripheral capsaicin injection and consequential TRPV1 activation in 
nociceptive primary afferents.  At both capsaicin concentrations (100 nM and 1 uM), 
however, no effect of xenon on CGRP release was observed.  Surprisingly, the 
presence of xenon does not reduce CGRP release in this preparation.   Overall, 
however, these findings may well have important clinical implications for the control 
of severe inflammatory-type pain to which TRPV1 is a recognised contributor 
(Caterina et al., 2000;  Davis et al., 2000;  Charrua et al., 2007; Garcia-Martinez et al., 
2006; Tang et al., 2007).  
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5.4.2 Properties of xenon 
       The element xenon is one of the "noble gasses" and exists as single atoms in the 
atmosphere. Xenon does not readily form covalent bonds with other atoms under 
normal biological conditions because its outer electron shell is completely filled with 
electrons.  However, although traditionally characterised as an "inert" gas, it is now 
recognised that xenon can form certain compounds. Importantly, it is also capable of 
forming non-covalent bonds with atoms and molecules in many instances.  Under gas 
pressures ranging from 8 to 20 bar, xenon is able to bind to discrete sites in 
hydrophobic cavities, ligand-binding and substrate-binding pockets and into the pore 
of channel-like structures (Prange et al., 1998).   Even at moderate pressures, xenon 
binds to pre-existing atomic-sized cavities in the interior of certain globular protein 
molecules, such a sperm whale myoglobin and horse haemoglobin crystals, through 
weak van der Waals forces (Li.de la Sierra et al., 1997; Schoenborn et al., 1965). 
Since the interaction of xenon with proteins is the result these non-covalent, weak-
energy forces, the process of xenon binding is completely reversible (Tilton & Kuntz, 
1982; Tilton et al., 1984; Tilton et al, 1986; Tilton et al., 1988).  The binding of xenon 
to proteins is characterised by the large diversity of its binding sites.  Xenon binds to 
intra-molecular, as well as to inter-molecular, sites, to closed inaccessible cavities, as 
well as to exposed pockets and channel-pores.  Xenon may bind into void sites, or 
replace existing water molecules.  Thus, in contrast to the small, closed, hydrophobic 
cavities observed in the majority of proteins, the xenon binding sites in serine 
hydrolases are large solvent-accessible pockets that, in the case of elastase, 
collagenase and cutinase contain ordered water molecules which are displaced upon 
xenon binding (Prange et al., 1998). 
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       Xenon is known to be capable of exercising an inhibitory effect on ligand-gated 
ion channels, similar to TRPV1, including glutamatergic, serotonergic (Suzuki et al., 
2002) and nicotinic acetylcholine channels (Suzuki et al., 2003).  Glutamate receptor 
ion channels are of three types, described by their preferred ligands, namely:  NMDA, 
AMPA, and kainate glutamate channels.  Franks and colleagues showed that xenon 
can inhibit NMDA ion channels in cultured hippocampal neurons in a non-
competitive manner at 80 per cent xenon which is sufficient to maintain surgical 
anaesthesia (Franks et al., 1998).  All three types of glutamate channels are inhibited 
by xenon in cortical neurones (Dinse et al., 2005).   Xenon inhibits the human 
(alpha7)5 nACh receptor in a concentration-dependent manner, with this inhibition 
being non-competitive and independent of membrane potential (Suzuki et al., 2003).   
In contrast, xenon inhibits the 5-hydroxytryptamine 3 receptor, again independently of 
membrane potential, but the inhibition is competitive (Suzuki et al., 2002).   Finally, 
in this connection, it may be noted that xenon can activate, rather than inhibit, certain 
ion channels and is capable of activating two-pore-domain potassium channels (Gruss 
et al., 2004).  
 
     Notwithstanding the demonstration of a substantial effect of xenon in reducing 
TRPV1 ion channel activation in HEK 293 cells upon challenge with the potent 
agonist, capsaicin, we continued to entertain considerable doubt as to the extent to 
which xenon was delivered effectively to the HEK cells.  Therefore, in our subsequent 
experiments using DRG neurones, we considered it appropriate to attempt to improve 
the likelihood of effective delivery of the gas to the cells by bubbling it through the 
buffer in which the cells were maintained prior to their exposure to capsaicin. Having 
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regard to the results, in terms of TRPV1 activation, after this attempt at improving 
xenon delivery, our process of "bubbling" manifestly did not offer the answer to the 
problem which we perceived of improving delivery of xenon to the cells in vitro. 
 
5.4.3 CGRP assay 
        Xenon elicited a minor increase in the basal release of CGRP in the rat DRG 
cells preparation which was clearly occasioned by the action of xenon on unidentified 
receptors. The extent of this increase did not reach statistical significance in our 
experiments, but we believe that the phenomenon is real in the context of rat DRG 
neuronal preparations exposed to xenon.   However, we do not believe that it is of 
physiological significance in mediating a pain sensation.  Spontaneous release of 
neurotransmitter from neurones at rest is a recognised phenomenon which is not 
known to have a physiological effect in the transmission of information relating to 
pain stimuli.  Moreover, the transmission of information relating to pain stimuli 
manifestly requires a form of neurotransmitter release which is both organised and 
specific.  In any event, this effect of xenon was small in terms of the increase of 
neurotransmitter release elicited, and was not elicited when the neurones were 
subsequently challenged with capsaicin.  Therefore, it appears unlikely that it could 
constitute a significant adverse effect of the administration of xenon in vivo.  
Moreover, if xenon is indeed capable of mediating a pain sensation by activating 
receptors leading to neurostransmitter release, one would expect to find evidence of 
significant pain sensations attributable to xenon on the part of patients, who receive an 
anaesthetic dose of the gas, as they recover consciousness.     
 
 239 
     More surprising is our finding that xenon does not reduce the extent of CGRP 
release evoked by capsaicin.  Several reasons may be suggested for this finding.   
First, it may be that there is a disconnection between TRPV1 activity and CGRP 
release in rat DRG preparations.   In addition, or in the alternative, it may be that the 
maximal effect of xenon of reducing TRPV1 activity by approximately only 30 per 
cent in rat DRG neurones in vitro, using the gas-delivery method which we used, is 
insufficient to reduce CGRP release on challenge with capsaicin.   
 
5.4.4. Limitation of experimental design 
      It is considered that there must always remain considerable doubt as to the extent 
to which effective in vitro exposure of cells in solution to xenon is achieved.  This is 
because xenon atoms are uncharged with the result that there is no ionic flux which 
might attract these atoms through the channel pore.  The result is that delivery of 
xenon to, and through, the channel pore is dependent upon the concentration of atoms 
in the external solution and the resulting concentration gradient from without to 
within the cell which will tend to draw xenon atoms inward.   To this must be added 
the consideration, discussed above, that xenon can make binding sites for itself under 
pressure.  Since that pressure was not available in this case, and since even the 
presence of xenon atoms at TRPV1 ion channels was due to little more than mere 
accidental propinquity, the conclusion must be that it  is highly doubtful that xenon 
exhibited a maximal, or near maximal, effect of its potential to inhibit the activation 
of TRPV1.  In addition to this consideration, TRPV1 expression in the DRG neurones 
may have differed substantially from that in the transfected HEK cells and, moreover, 
one cannot know how the auxiliary proteins which interact with TRPV1 ion channels 
in the natural state, and which  are obviously absent in the transfected  cells, affected 
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the respective results.   Notwithstanding these reservations, our results demonstrate a 
significant effect of xenon on TRPV1 activity which may well have clinical 
implications for the control of severe inflammatory-type pain, such as that which is 
found most obviously in severe burn injuries, which is recognised as being mediated 
by TRPV1 (Davis et al., 2000). 
 
5.4.5 Mechanism of xenon’s actions 
       The further issue relates to the mechanism by which xenon may mediate its effect 
on TRPV1 and, here, there is evidence that xenon may achieve its effect by several 
mechanisms, rather than by a single mechanism.   
 
     First, xenon may act as a competitive antagonist at one, or more, of the binding 
sites for ligands of TRPV1.  Since TRPV1 possesses different binding sites for certain 
of its activators, xenon, given its known promiscuity in the matter of binding to other 
atoms or molecules, may well bind to one, or more, of these sites.   There is some 
evidence that xenon indeed acts as a competitive antagonist of the 5-
hydroxytryptamine 3 receptor, which is also a ligand-binding ion channel (Suzuki et 
al., 2002). 
 
     Second, there is substantial evidence that, in any event, xenon in fact acts as a 
"conduction blocker" of the TRPV1 channel pore.  This mechanism of action for 
xenon would be entirely consistent with the manner in which xenon mediates its 
effect on NMDA channels (Franks et al., 1998).  Thus, xenon atoms may occupy the 
TRPV1 channel pore thereby blocking, or reducing, the ingress of cobalt through the 
channel pore, notwithstanding ligand-binding by capsaicin which would otherwise 
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gate the channel to allow the cobalt ions into the cell.   In like manner, xenon may be 
expected to block, or reduce, the generation of membrane currents through that 
channel. This hypothesis is supported by a recent study by Oseguera and colleagues of 
the action of tetrabutylammonium (TBA) on HEK 293 cells transfected with rat 
TRPV1.   TBA is a member of a family of classic potassium channel blockers widely 
used for determining the localisation of the activation gate and the properties of the 
pore of several ion channels.  TBA was found to act as an ion channel conduction 
blocker in TRPV1 channels expressed in HEK 293 cells transfected with rat TRPV1.   
Pore-blocking by TBA of the TRPV1 ion channel is voltage-dependent and the 
properties of block are consistent with an open-state blocker, with the TBA molecule 
binding to multiple open states, each with different blocker affinities.  The kinetics of 
TRPV1 channel closure and burst-length analysis in the presence of blocker are 
consistent with a state-dependent blocking mechanism, with TBA interfering with 
closing of an activation gate (Oseguera et al., 2007).  Garcia-Martinez and co-workers 
(2006) investigated the effect of a synthetic compound, described as H-Arg-15-15C, 
in blocking TRPV1 activation at sub-micromolar concentrations.  H-Arg-15-15C acts 
as a non-competitive capsaicin antagonist with modest voltage-dependent blockade 
activity.  When assessed in rats, this compound is reported by these authors to: 
prevent the irritant activity of local administration of capsaicin and formalin; reverse 
the thermal hyperalgesia evoked by injection of complete Freund's adjuvant; and to 
attenuate carrageenan-induced paw inflammation -- without affecting normal 
nociception, and with little cross-reactivity with other receptors (Garcia Martinez et 
al., 2006).    However, this mechanism of xenon’s action at NMDA receptors is now 
believed to be less likely (Weight et al., 2008).   
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        The third possible mechanism by which xenon may inhibit the activity of TRPV1 
ion channels involves xenon binding to a pocket in the channel pore, or, indeed, to 
another binding site for xenon and thereby inducing a conformational change in the 
protein which results in a failure of “gating” in the ion channel.   The active site of 
enzymes can provide a specific binding cavity for a single xenon atom without 
inducing major changes in protein structure. Thus, the catalytic site of serine 
proteinases provides a specific binding cavity for xenon (Schiltz et al., 1995;  Prange 
et al., 1998).  Again, xenon occupies the haeme cavity of cytochrome P-450 
monooxygenases and competitively inhibits its catalytic activity (La Bella et al., 
1999). Colloc'h and colleagues (2007) recently employed x-ray crystallography 
techniques to study the binding characteristics of nitrous oxide and xenon, using urate 
oxidase and annexin V as structural models. Urate oxidase provides a model 
representative of a variety of intracellular globular proteins that possess large 
hydrophobic cavities, while annexin V is a protein that binds to biological membranes 
in a reversible calcium-dependent manner and possesses a hdyrophilic pore, believed 
to be the calcium conduction pathway, that lies at the interface of four homologous 
and structurally-related domains (Colloch et al., 1997;  Gerke et al., 2002).  Annexin 
V possesses structural characteristics and functional properties of ion selectivity and 
voltage-gating which allow it to be regarded as a prototype for the NMDA receptor 
(Berendes et al., 1992; Demange et al., 1993).   They identified the primary binding 
sites for xenon within these two soluble proteins as flexible gas cavities with no 
visible water (Colloc’h et al., 2007).   They postulate that occupation and expansion 
of large hydrophobic flexible gas cavities within intracellular or membrane proteins 
may lead to conformational rigidity, thereby disrupting protein and cell functions.  
Thus, they propose that the presence of a gas bound to a hydrophobic cavity within 
 243 
the transmembrane domain of the NMDA receptor channel may be capable of altering 
the flexibility of the pore, thereby limiting calcium exchange and disrupting NMDA 
receptor function.  This proposition would appear to be of no less validity in the 
context of the TRPV1 ion channel.  
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6.4. Discussion 
 
Figure 1 Microphotographs illustrating pERK1/2 labelling of  
neurons in the spinal dorsal horn 
 
Figure 2 Bar chart illustrating the average number of  
pERK1/2-labelled neurons in the ipsilateral and the 
contralateral spinal dorsal horn after various treatments 
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   6.1.  INTRODUCTION 
     Recent in vitro studies have shown that certain pungent gaseous anaesthetics, can 
activate, or increase the activation of, receptors on primary nociceptive afferents 
which have been implicated as mediators of hyperalgesia in inflammatory pain 
conditions.  These receptors are the transient receptor potential ankyrin, type 1 
(TRPA1) and the transient receptor potential vanilloid, type 1 (TRPV1).   TRPV1 is a 
ligand-gated, non-selective, cationic channel (Caterina et al., 1999; Heyman & Rang, 
1985; Marsh et al., 1987; Tominaga et al., 1998) which is known to play an important 
role in several types of heat-induced hyperalgesia.  Heat hyperalgesia secondary to 
inflammatory tissue injury fails to develop in TRPV1 null mice as in wild type mice 
in several models of thermal hyperalgesia, including that induced by carrigeenan, 
mustard oil, and complete Freund’s adjuvant (Caterina et al., 2000; Davis et al., 
2000), suggesting that TRPV1 is an essential component in the development of 
pathological thermal hyperalgesia in these models of peripheral inflammation 
(Pogatzki-Zahn et al., 2005).  The development of thermal hyperalgesia following 
inflammation involves an increased level of TRPV1 expression (Amaya et al., 2004;  
Kasama et al., 2007; McNaughton, 2005; Stein et al., 2006).   It also involves the 
sensitization of existing TRPV1 channels by inflammatory agents (Chuang et al., 
2001;Vellani et al., 2006; Zhang et al., 2008; Zhu & Oxford, 2007; Nagy et al., 2008; 
Nagy et al., 2009).   TRPA1 is a non-selective ligand-gated cation channel which is 
directly gated by Ca2+ (Doerner et al., 2007), and is found in a subset of nociceptive 
sensory neurons of dorsal root and trigeminal ganglia that co-express TRPV1 (Story 
et al., 2003; Jordt et al., 2004; Kobayashi et al., 2005).  Many of the exogenous 
activators of TRPA1 produce an inflammatory response when applied to the body; 
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but, more importantly, TRPA1 is activated by certain at least of the chemical agents 
generated by the inflammatory response (Jordt et al., 2004; Bautista et al., 2006; 
McNamara et al., 2007).  
  
        The pungent general anaesthetics isoflurane and desflurane robustly activate 
TRPA1, with isoflurane producing inward currents in voltage-clamped TRPA1-
expressing HEK293 cells and in cultured mouse dorsal root ganglion neurons (Matta 
et al. 2008).  Moreover, clinically relevant concentrations of isoflurane, sevoflurane, 
enflurane and desflurane have also been shown to sensitise TRPV1 to capsaicin and 
protons and to reduce the threshold for heat activation of this ion channel (Cornett et 
al., 2008).  Hence, the suggestion that, in the clinical context, volatile general 
anaesthetics may augment nociceptive signalling arising from surgical insults (Cornett 
et al., 2008).  In particular, the finding that sevoflurane may exert a sensitizing effect 
on TRPV1 (albeit an effect which is substantially less than that elicited by isoflurane) 
raises an issue of clinical importance, given its preferred status as a non-pungent 
inhalational anaesthetic.    
 
       Extracellular signal-regulated protein kinase 1/2 (ERK1/2) when activated by 
phosphorylation (pERK1/2) in spinal dorsal horn neurons is a recognised marker of 
spinal nociceptive processing (Ji et al, 1999). We have used activation of ERK1/2 in 
dorsal horn neurons of the spinal cord in rat to elicit the extent to which exposure of 
these animals to isoflurane and sevoflurane, in clinically relevant concentrations, 
results in nociceptive processing in the rat spinal cord.   We have also examined the 
extent to which these inhalational anaesthetics are sensitizers of TRPV1 by exposing 
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animals to clinically relevant concentrations of these gases and then injecting a hind-
paw with the archetypical TRPV1 agonist, capsaicin.   
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6.2.     METHODS 
 
6.2.1. Animals 
     All procedures were performed in accordance with the requirements of the UK 
Animals (Scientific Procedures) Act, 1986.  Altogether, 21 male Sprague Dawley rats 
(each ~ 100 gms in weight) were used in this study. The animals were kept at 12 
hours light-dark cycles at controlled temperature and humidity, with food and water 
ad libitum. 
 
6.2.2. Treatment groups 
      Animals were divided into five treatment groups.  Animals were randomly 
assigned to the several groups so each group had 4 animals except for the isoflurane 
group which contained 5 animals. In all cases, the animals were sacrificed by 
administration of a terminal dose of pentobarbital.  In previous experiments in this 
laboratory, we have confirmed that pentobarbital administered at such doses in those 
circumstances does not evoke any significant activation of ERK1/2 in spinal dorsal 
horn neurons. 
 
      Group 1 animals:  capsaicin (< 5 minutes). These animals were exposed to 
pentobarbital at a dose sufficient to render the animals unconscious (60 mg per kg, 
i.p.).  They were then immediately given a subcutaneous right hind-paw injection of 
capsaicin (1 mg/ml dissolved in 10% Tween 80; 25 uL).   At 3.5 to 4.5 minutes after 
capsaicin injection, the animals were sacrificed.  Activation of ERK1/2 in the 
contralateral spinal cord of these animals served as a control for the effect of capsaicin 
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on ERK1/2 activation in this group and for the effect of isoflurane and sevoflurane on 
ERK1/2 activation in the subsequent groups.    
 
      Group 2 animals:  isoflurane (1 hour).  These animals were exposed to isoflurane 
at a dose of 1.5 Mac which was sufficient to render the animals unconscious and were 
then maintained in that condition for a period of 1 hour, after which they were 
sacrificed. 
 
      Group 3 animals:  isoflurane (1hour) + capsaicin (< 5minutes).  These animals 
were exposed to isoflurane at a dose of 1.5 Mac which was sufficient to render the 
animals unconscious and were then maintained in that condition for a period of 1 
hour.  Then, these animals, still under isoflurane anaesthesia, were then given a 
subcutaneous right hind-paw injection of capsaicin (1 mg/ml dissolved in 10% Tween 
80; 25 ul).  At 3.5 to 4.5 minutes after capsaicin injection, the animals were sacrificed.    
 
    Group 4 animals: sevoflurane only.  These animals were exposed to sevoflurane at 
a dose of 1.5 Mac which was sufficient to render the animals unconscious and were 
then maintained in that condition for a period of 1 hour, after which they were 
sacrificed. 
 
    Group 5 animals:  sevoflurane (1 hour) + capsaicin (< 5 minutes).   These animals 
were exposed to sevoflurane at a dose 1.5 Mac which was sufficient to render the 
animals unconscious and were then maintained in that condition for a period of 1 
hour.  Then, these animals, still under sevoflurane anaesthesia, were then given a 
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subcutaneous right hind-paw injection of capsaicin (1 mg/ml dissolved in 10% Tween 
80; 25 ul). At  3.5 to 4.5 minutes after capsaicin injection, the animals were sacrificed.    
 
6.2.3. Perfusion 
      All animals were perfused transcardially with saline followed by 4% 
paraformaldehyde. The lumbar spinal cord was removed and placed into the same 
fixative and allowed to stand over-night. Tissues were then put into 15% sucrose until 
they sank. Then, the tissues were put into 30% sucrose until they sank.  The ventral 
horn of the L4-L5 segments were labelled by a shallow longitudinal cut on the left 
side. Cords were then mounted into OCT embedding medium (VWR, West Chester, 
Pa) and 20µm transverse sections were cut on a crysostat and thaw-mounted on 
Superfrost Plus microscope slides (VWR, West Chester, Pa). Sections were air dried 
overnight and stored at -20℃ until required. 
 
6.2.4. Immunohistochemistry 
     The sections were first washed in PBS and incubated in PBS containing 0.3% 
Triton X (PBST) for 10 minutes.  The endogenous peroxidase activity was quenched 
by incubating the sections in 0.3% H2O2. Sections were then placed in 10% normal 
donkey serum (NDS) for 25 minutes. The primary antibody was anti-phospho 
extracellular signal-regulated protein kinase 1/2 (pERK1/2) raised in rabbit against the 
residues surrounding T202/Y204 of pERK1/2 (1:2000, Neuromics). The sections 
were incubated in the primary antibody overnight.  Following washes in PBS, the 
sections were incubated with biotin-conjugated donkey anti-rabbit IgG (1:800; 
Jackson Immunoresearch) for 2 hours. The immunoreaction was visualised using the 
Vectastain Elite and IMPACT DAB kits (Vector). The slides were then dehydrated in 
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ethanol, cleaned in xylene and covered by depex polystyrene. All the washes and 
dilutions were performed at room temperature in PBST, with the addition of 0.3% 
NDS for the dilution of the primary antibody. 
 
6.2.5. Analysis of pERK1/2 immunolabelling 
      Spinal cord sections were analysed in a Leica light microscope using 
magnification of 400X (40X objective lens; 10X projector lens). Immunopositive 
neurons with clearly visible perikarya were manually counted on both the ipsi- and 
contra-lateral dorsal horn in every second of 10 adjacent sections.   
 
6.2.6. Statistical analysis 
      The average number of pERK1/2-expressing cells found in the dorsal horn on 
both sides in every section was calculated. Differences in the number of pERK1/2-
expressing neurons between the different experimental groups were analysed using 
one way ANOVA.  Whether differences found were significant was established using 
Fisher’s least significant difference test assuming that the data were normally 
distributed. Differences were regarded as significant at p<0.05.  “n” = number of 
animals from which sections were taken in each group. 
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6.3. RESULTS 
6.3.1. Group 1 animals:  capsaicin (< 5 minutes)   
      Animals given a right hind-paw injection of capsacin (under pentobarbital 
anaesthesia) with survival for 3.5 to 4.5 minutes after capsaicin injection exhibited 
ERK1/2 activation at the L4/L5 level as originally described by Ji and colleagues (Ji 
et al., 1999).   Labelling of neurons for pERK (18.7 +/- 6.2; n= 3) was found in an 
area on the lateral aspect of the medial superficial dorsal horn, with labelled neurons 
being found predominantly in laminae I and IIo of the superficial dorsal horn, while 
fewer labelled neurons were found in more ventral laminae. No pERK 
immunoreactivity was evoked in the dorsal horn contralateral to the capsaicin 
injection (Figures 1, 2 & 3). 
 
6.3.2.  Group 2 animals: isoflurane (1 hour)     
       Exposure to isoflurane for 1 hour potently activated ERK1/2 in the dorsal horn of 
both sides of the spinal cord at the L4/L5 level.  There was no significant difference 
between the number of neurons labelled on the respective sides of the spinal cord 
(12.5 +/- 3.2; 9.3 +/- 0.7; n = 3).  However, the location of the pERK1/2-labelled 
neurons induced by isoflurane differed from that found with the capsaicin-induced 
labelling, with the isoflurane-induced labelling being found on the more medial aspect 
of the medial dorsal horn on both sides of the spinal cord.  This difference in location 
was pronounced and it was patent that labelling induced by the gas involved neurons 
in a different part of the dorsal horn from the part where capsaicin induces pERK1/2 
labelling of neurons.  In addition, the vast majority of labelled neurons induced by 
administration of isoflurane were found in lamina 1 (Figures 1, 2 & 3).  
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6.3.3.  Group 3 animals: isoflurane (1 hour) + capsaicin (< 5 minutes)   
     Injection of capsaicin into the hind-paw of animals which had been maintained 
under isoflurane anaesthesia for 1 hour, completely abolished labelling of neurons on 
the contralateral side of the spinal cord.  A comparison of the number of neurons 
labelled on the ipsilateral side of the spinal cord by capsaicin alone (18.7 +/- 6.2; n= 
3) with the number of neurons labelled by capsaicin after treatment with isoflurane 
(9.8 +/- 1.8; n = 3) shows that prior treatment with this gas reduces the capacity of 
capsaicin injection to label neurons.  Moreover, the neurons found to be labelled after 
gas followed by capsaicin administration were distributed over two locations, namely, 
that part of the medial dorsal horn previously identified with capsaicin only–induced 
labelling, and that part of the same area previously identified with gas only-induced 
labelling (Figures 1, 2 & 3).  
 
6.3.4.  Group 4 animals: sevoflurane only   
        Exposure to sevoflurane for 1 hour potently activated ERK1/2 in the dorsal horn 
of both sides of the spinal cord at the L4/L5 level.  There was no significant 
difference between the number of neurons labelled on the respective sides of the 
spinal cord (7.6 +/- 2.5; 4.8 +/- 1.5; n = 3).  As with isoflurane, the location of the 
pERK1/2-labelled neurons induced by sevoflurane differed from that found with the 
capsaicin-induced labelling, with the sevoflurane-induced labelling being found on 
the more medial aspect of the medial dorsal horn on both sides of the spinal cord.  
Likewise, the vast majority of labelled neurons induced by administration of 
sevoflurane were found in lamina 1.  
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       Sevoflurane demonstrated the same pattern of p-ERK1/2 labelling on both the 
ipsilateral side and contralateral side of the spinal cord as did isoflurane.  However, on 
each side, fewer cells were labelled by sevoflurane than by isoflurane, although this 
difference was not statistically significant (Figures 1 and 2). 
   
  6.3.5.  Group 5 animals:  sevoflurane (1 hour) + capsaicin (< 5 minutes) 
       Injection of capsaicin into the hind-paw of animals which had been maintained 
under sevoflurane anaesthesia for 1 hour, completely abolished labelling of neurons 
on the contralateral side of the spinal cord.  A comparison of the number of neurons 
labelled on the ipsilateral side of the spinal cord by capsaicin alone (18.7 +/- 6.2; n= 
3) with the number of neurons labelled by capsaicin after treatment with sevoflurane 
(6.8 +/- 1.1; n = 4) shows that prior treatment with this gas reduced the capacity of 
capsaicin injection to label neurons.  As was also the case with isoflurane, the neurons 
found to be labelled after sevoflurane followed by capsaicin administration were 
distributed over two locations, namely, that part of the medial dorsal horn previously 
identified with capsaicin only–induced labelling, and that part of the same area 
previously identified with gas only-induced labelling (Figures 1 and 2).  
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Figure 1 
Microphotographs illustrating pERK1/2 labelling of neurons in the spinal dorsal 
horn. A: after capsaicin injection; B: after isoflurane anaesthesia for one hour; C: 
after isoflurane anaesthsia for one hour followed by capsaicin injection. Note the 
capsaicin injection-induced pERK1/2 expression in laminae 1 and IIo of the 
ipsilateral side of the spinal cord, and the absence of such expression on the 
contralateral side. Isoflurane anaesthesia results in pERK1/2-labelling on both sides, 
but in different area of the superficial medial dorsal horn. Note how capsaicin 
injection, after isoflurane anaesthesia, abolishes pERK1/2 expression on the 
contralateral side and how the capacity of capsaicin to induce pERK1/2 expression 
on the ipsilateral side is reduced. Bar indicates 100µm. 
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Figure 2. 
 
Bar chart illustrating the average number of pERK1/2-labelled neurons in the 
ipsilateral and the contralateral spinal dorsal horn after: capsaicin injection (caps); 
isoflurane anaesthesia for one hour (iso); isoflurane anaesthesia for one hour 
followed by capsaicin injection (iso caps); sevoflurane anaesthesia for one hour 
(sevo); and sevoflurane anaesthesia for hour followed by capsaicin injection (sevo 
caps). Asterisks indicate significant differences. 
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Figure 3. 
 
 
Diagram illustrating the combined distribution (over three sections) of pERK1/2-
immunopositive neurons in the spinal dorsal horn. The images generated reflect the 
position of pERK1/2-immunopositive neurons when combined from the three sections, 
(A) after capsaicin injection under pentobarbital anaesthesia; (B) after isoflurane 
anaesthesia alone; (C) capsaicin injection under isoflurane anaesthesia. The solid 
line indicates the border between lamina I and the white matter. 
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6.4. Discussion 
      Activation of spinal ERK1/2 is a recognised marker of spinal nociceptive 
processing.  Ji and colleagues (1999) showed that peripheral capsaicin injection into a 
hind-paw of rat activates ERK1/2 by phosphorylation (pERK1/2) in dorsal horn spinal 
cord neurons and induces pain-related behaviour in the animal.26   We have shown 
that isoflurane or sevoflurane, when administered to rats at 1.5 MAC, each result in 
potent activation of ERK1/2 in the dorsal horn of both sides of the spinal cord at the 
L4/L5 level.  However, the location of the pERK1/2-labelled neurons induced by each 
of these gasses differs from that found with capsaicin-induced labelling, with the gas-
induced labelling being found on the more medial aspect of the medial dorsal horn on 
both sides of the spinal cord.  This difference in location is pronounced, allowing for 
no doubt that labelling induced by the gas involved neurons in a different part of the 
dorsal horn from that part where capsaicin induces pERK1/2 labelling of neurons, 
which is of proven association with nociceptive processing in the dorsal horn.  
Therefore, it is not possible to assert that the ERK1/2 activation induced by isoflurane 
and sevoflurane, respectively, is a marker of spinal nociceptive processing.   
Moreover, TRPA1 is expressed in a sub-population of neurons expressing TRPV1 
[19,21].  Hence, if administration of either of these gases were to result in activation 
of primary afferents via activation of TRPAI or TRPV1, then one would necessarily 
expect to find the resulting neuronal labelling within the area of the medial dorsal 
horn occupied by those cells within which ERK1/2 is activated by administration of 
capsaicin alone.   
 
      We have also shown that the effect of capsaicin injection after 1 hour exposure to 
isoflurane or sevoflurane is to abolish neuronal labelling (attributable to gas 
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administration) on the contralateral side of the spinal cord.   At the same time, the 
number of neurons attributable to capsaicin-induced labelling is significantly reduced 
from that found where capsaicin is administered on its own.  A comparison of the 
number of neurons labelled on the ipsilateral side of the spinal cord by capsaicin alone 
with the number of neurons labelled by capsaicin after treatment with either gas 
shows that prior treatment with either of these gases  reduces the capacity of capsaicin 
injection to result in pERK1/2 labelling of neurons.  This effect of the gasses in 
reducing labelling for capsaicin administration is even more pronounced when one 
has regard only to the number of pERK1/2 labelled neurons found in the area of the 
dorsal horn identified with capsaicin only–induced labelling.  
 
        There is no evidence that ERK1/2 activation of spinal dorsal horn neurons by 
isoflurane or sevoflurane is in any way attributable to the excitation of primary 
afferent neurons resulting from ion channel activation by these gases.  Neither TRPV1 
nor TRPA1 activation of primary afferents can be involved since neither gas induces  
pERK1/2 labelling in that area of the medial dorsal horn of the spinal cord where 
capsaicin induces cell labelling [19,21].  On the other hand, the fact that these gases 
are systemically active allows for the possibility that descending inhibitory inputs, 
additional to those which normally obtain, are brought to bear by higher order brain 
areas which potently reduce nociceptive processing in the spinal cord.  These same 
inputs may potently reduce nociceptive processing in the spinal dorsal horn during 
surgery, thereby reducing the pain which would otherwise be induced by surgery.   
Certainly, our results suggest that, under general anaesthesia with either isoflurane, or 
sevoflurane, patients are unlikely to be subjected to ongoing excitatory inputs  from 
primary afferents which result in nociceptive processing in the spinal cord during the 
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course of surgery.  On the contrary, surgical patients appear likely to benefit from an 
analgesic effect induced by these gases during the course of surgery.  
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CHAPTER 7 
 
SUMMARY OF RESULTS AND CONCLUSIONS 
 
Contents 
7.1. The role of TRPV1 in burn injury 
7.2. Whether xenon may mediate an analgesic action through an effect on TRPV1 
7.3. Whether isoflurane and sevoflurane occasion pain-inducing spinal  
nociceptive processing 
 
7.1. THE ROLE OF TRPV1 IN BURN INJURY 
 
 
        Activation of ERK1/2 in the spinal dorsal horn is a recognised marker for spinal 
nociceptive processing. At 5 minutes after severe scalding injury to WT mouse hind-
paw, a substantial number of phosphorylated ERK1/2 (pERK1/2) immunopositive 
neurons were found in the ipsilateral dorsal horn. At 1 hour post-injury, the number of 
pERK1/2-labelled neurons remained substantially the same. However, at 3 hours post-
injury, a further increase in the number of labelled neurons was found on the 
ipsilateral side, while a remarkable increase in the number of labelled neurons on the 
contralateral side resulted in there being no significant difference between the extent 
of the labelling on both sides. By 6 hours post-injury, the number of labelled neurons 
was reduced on both sides without there being significant difference between the two 
sides. A similar pattern of severe scalding injury-induced activation of ERK1/2 in 
spinal dorsal horn neurons over the same time-course was found in TRPV1 KO mice, 
 263 
except that the extent to which ERK1/2 was activated in the ipsilateral dorsal horn at 
5 minutes post-injury was significantly greater in WT animals when compared to 
TRPV1 null animals. This difference in activation of ERK1/2 in spinal dorsal horn 
neurons was abolished within 1 hour after injury, demonstrating for the first time that 
TRPV1 is not essential for the maintenance of ongoing spinal nociceptive processing 
in inflammatory pain conditions in mouse resulting from at least certain types of 
severe burn injury.  The facts that neuronal staining for activated ERK1/2 not only 
persisted, but also that the number of neurons expressing activated ERK1/2 increased 
with the passage of time are significant novel findings of this study which have 
important implications.  After an acute noxious stimulus (provided by hind-paw 
injection of capsaicin), ERK1/2 activation reaches a peak within 2-5 min and then 
quickly subsides, such that it is barely detectable or absent by 2 hours after the 
stimulus (Ji et al., 1999).  The findings of this study that activated ERK1/2 is: (i) still 
present in neurons at the 3 hour and 6 hour time-points post-burn injury; and (ii) that 
it is found in even more neurons at those later time-points than at the earlier time-
points measured, strongly suggest that the ERK1/2 activation found at 3 hours and 6 
hours post-injury, respectively, is not merely residual from the initial noxious heat 
stimulus, but rather that it has been caused by the ongoing inflammatory process 
itself.  This is a key novel finding of this study.  The data obtained contain evidence 
of a dissociation within the physiological process of the burn injury of these two 
distinct "noxious insults" comprising: first, the initial external heat stimulus of the 
burn injury, which causes direct damage to the tissue accompanied by heat-induced 
activation of heat-sensitive receptors which result in excitation of nociceptive primary 
afferents; and, second, the burn injury-induced massive inflammatory response 
whereby inflammatory mediators occasion an ongoing activation of their receptors on 
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those nociceptors to maintain, and, indeed, increase, nociceptive signaling in those 
neurons.  The further finding that, at 3 hours after scalding-type burn injury, in both 
TRPV1-null and wild-type mice, the contralateral side of the spinal cord now 
exhibited a substantial number of pERK1/2-immunopositive neurons remains 
intriguing, notwithstanding that the phenomenon of hyperalgesia developing in the 
hind-paw contralateral to a heat injury has long been noted (Coderre and Melzack, 
1991; Polgar et al., 1998). One may speculate that this labelling is caused, or 
contributed to, by an action of descending fibres on these contralateral dorsal horn 
neurons since the concept of supraspinal pronociceptive modulation of pain is now 
well recognised (Lima et al., 2002; Tavares and Lima, 2007). In addition, or in the 
alternative, this labelling may result from cross-communication between opposite 
dorsal horn neurons (Coderre and Melzack, 1991; Shenker et al., 2003). In any event, 
the activation of ERK1/2 on both sides of the dorsal horn discloses a process in which 
spinal neurons are driving inflammatory nociceptive activity after the excitatory effect 
of peripheral inflammagens has abated in primary sensory afferents. 
 
 
7.2. WHETHER XENON MAY MEDIATE AN ANALGESIC ACTION  
THROUGH AN EFFECT ON TRPV1 
 
Xenon (75%) reduced the number of primary sensory neurons responding to 
the TRPV1 agonist, capsaicin (100 nM-1 µM) by ~25% to ~50%. Xenon reduced the 
number of heterologously-expressed hTRPV1 activated by 300 nM capsaicin by 
~50%. Xenon (80%) reduced by ~40% the number of phosphorylated ERK1/2-
expressing neurons in rat spinal dorsal horn resulting from hind-paw capsaicin 
injection. The key original finding is that xenon substantially reduces the activity of 
TRPV1 in response to noxious stimulation by the specific TRPV1 agonist, capsaicin, 
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suggesting a possible role for xenon as an adjunct analgesic where hTRPV1 is an 
active contributor to the excitation of primary afferents which initiates the pain 
sensation.   Next, to investigate whether the xenon-induced inhibition of TRPV1 in rat 
DRG neurons reduces nociceptive processing, the effect of xenon in reducing the 
release of calcitonin gene-related peptide (CGRP) from those neurons was examined.  
Exposure to xenon failed to effect a reduction of capsaicin-evoked CGRP release 
from cultured primary sensory neurons when stimulated by capsaicin.  This latter 
novel finding suggests that xenon acts on several molecular targets on nociceptive 
primary sensory neurons, and that xenon’s action on one, or more, of those targets 
serves to offset the inhibitory, pro-analgesic, effect of xenon on TRPV1.  It is 
concluded that xenon may not produce any analgesic effect through peripheral 
nociceptors. 
 
 
7.3. WHETHER ISOFLURANE AND SEVOFLURANE OCCASION 
 PAIN-INDUCING NOCICEPTIVE SPINAL PROCESSING 
 
       To investigate this suggestion, intraplantar capsaicin injection-induced 
phosphorylation of extracellular signal-regulated kinase 1/2 (pERK1/2) in spinal 
dorsal horn neurons (which is a recognised marker of spinal nociceptive processing) 
in rat was studied during isoflurane or sevoflurane anaesthesia after 60 min under 
anaesthesia. Control animals were anaesthetised with pentobarbital (which of itself 
does not activate ERK1/2 in spinal dorsal horn neurons). Unilateral intraplantar 
capsaicin injection in control animals evoked pERK1/2 in a group of neurons in 
lamina I and lamina II of the ipsilateral spinal dorsal horn in a somatotopically 
appropriate area. In contrast, both anaesthetic gases (given for 60 min and without 
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subsequent capsaicin injection) induced ERK1/2 activation in a different group of 
mainly lamina I neurons bilaterally. The total number of spinal dorsal horn neurons 
labelled on the ipsilateral side following capsaicin injection into the isoflurane-, or 
sevoflurane-, anaesthetised animals was significantly less than that produced by 
capsaicin alone. Further, capsaicin injection into isoflurane-, or sevoflurane-, 
anaesthetised animals reduced pERK1/2 induced by the gases alone on both sides. 
These key original findings are inconsistent with the suggestion that isoflurane-, or 
sevoflurane-, induced sensitisation of TRPV1 by capsaicin, or other agonist, is 
translated into induction of spinal nociceptive processing and consequential pain 
sensation. 
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